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Zusammenfassung 
Eine Entzündung ist eine komplexe und facettenreiche Antwort des Immunsystems gegen Infektionen, 
welche die Beseitigung des Infektionserregers und die Wiederherstellung der Gewebefunktion zum 
Ziel hat. Neutrophile Granulozyten sind die erste zelluläre Abwehrlinie des Immunsystems. Sie sind die 
am häufigsten vorkommende Gruppe weißer Blutzellen und mit ihren antimikrobiellen Mechanismen 
und ihrer Fähigkeit, weitere Immunzellen zu rekrutieren, nehmen sie eine Schlüsselposition bei der 
Bekämpfung von Pathogenen ein. Neutrophile produzieren „Neutrophil Extracellular Traps“ (NETs), ein 
mit antimikrobiellen Molekülen bestücktes Netzwerk aus Chromatinfasern, das während eines 
Zelltodprogramms namens „NETosis“ von den sterbenden Neutrophilen ausgestoßen wird. Ihre 
netzartige Struktur erlaubt es ihnen, eine weitere Verbreitung des Infektionserregers zu verhindern; 
zudem erzeugen sie eine hohe lokale Konzentration an toxischen Molekülen, die Mikroorganismen 
töten können. Unter normalen Bedingungen werden NETs von Nukleasen zerkleinert und anschließend 
von Makrophagen entfernt. Wenn dieser Aufräummechanismus gestört ist, aktivieren NETs das 
Immunsystem und führen zur Produktion von Autoantikörpern oder entzündungsfördernden 
Zytokinen. NETs werden mit einer wachsenden Liste von inflammatorischen und 
Autoimmunerkrankungen in Verbindung gebracht, wie z.B. Sepsis, systemischen Lupus erythematodes 
oder rheumatoider Arthritis. Wie genau dabei NETs durch das Immunsystem erkannt werden, ist noch 
nicht bekannt. 
In der vorliegenden Arbeit zeige ich, dass NETs durch den zytosolischen DNA Sensor „cyclic GMP-AMP 
synthase“ (cGAS) detektiert werden können und dass dadurch die Expression von Typ I Interferonen 
(TIIFN) induziert wird. Zu Beginn demonstriere ich, dass NETs durch rekombinantes cGAS erkannt 
werden und dass mit isolierten NETs stimulierte Immunzellen cGAS-abhängig TIIFN produzieren. Des 
Weiteren zeige ich, dass Neutrophile, die NETosis begehen, in Nachbarzellen ebenfalls cGAS-anhängig 
TIIFN induzieren können. Dafür müssen die NETs mittels Phagozytose aufgenommen werden. 
Abschließend konnte ich diese Ergebnisse in einem in vivo Mausmodel für systemische NET-Produktion 
bestätigen. Wildtyp-Mäuse, die nach Injektion von Concanavalin A systemisch NETs produzieren, 
regulieren die Transkripte von interferonstimulierten Genen hoch. cGAS-/- Mäuse oder auch Cybb-/- 
Mäuse, welche nicht zur NET-Bildung fähig sind, zeigten diese Regulierung nicht. Die vorliegende Arbeit 
zeigt einen Mechanismus, wie NETs durch das Immunsystem erkannt werden und dadurch sowohl zur 
Entstehung als auch zur Progression von Krankheiten beitragen kann. Sie ermöglicht dementsprechend 
die Entwicklung neuer Interventionsstrategien, welche zur Heilung oder Linderung einer Vielzahl von 
Erkrankungen beitragen können. 
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Summary 
Inflammation is a complex multilayered response of the human immune system against infection, 
aiming to remove the microbial agent and to restore tissue homeostasis. The first line of cellular 
defense of the immune system are neutrophils. They are the most abundant white blood cell, which 
exert an array of antimicrobial effector functions and attract other immune cells by releasing “alarmin” 
signals upon pathogen recognition. The combination of these two characteristics makes them crucial 
for an effective immune response, because they both contain the infection and activate other immune 
cells, resulting in effective pathogen clearance. Neutrophils release neutrophil extracellular traps 
(NETs), a composite of chromatin and antimicrobial molecules, into the extracellular space during a 
form of regulated cell death called NETosis. NETs are released in response to a variety of microbial 
stimuli like bacteria, fungi and parasites, but also by host-derived factors. Their net-like structure 
prevent further dissemination of the invader and establishes a high local concentration of toxic 
molecules that mediate pathogen killing. Under healthy conditions, NETs are degraded by nucleases 
in circulation and cleared by macrophages. If this clearance is disturbed, NETs provide a platform for 
undesired immune activation and contribute to the production of autoantibodies and pro-
inflammatory cytokines. NETs are implicated in a growing list of inflammatory and autoimmune 
diseases, like sepsis, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The exact 
mechanism how NETs are recognized by the immune system is not fully understood.  
In this study, I demonstrate that the cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) senses 
NETs and induces the production of type I interferons (TIIFN). I first showed that NETs are recognized 
by recombinant cGAS and that cells treated with isolated NETs produce TIIFN in a cGAS dependent 
mechanism. Secondly, I demonstrate that neutrophils undergoing NETosis are taken up by neighboring 
immune cells and induce cGAS-dependent TIIFN expression. Lastly, I confirmed our in vitro results in a 
mouse model of systemic NET induction. Wildtype mice injected with Concanavalin A significantly 
upregulate the expression of interferon stimulated genes, while cGAS-/- mice and Cybb-/- mice, which 
are incapable of producing NETs, fail to induce this response.  
 
Taken together, this study shows a novel mechanism for sensing of neutrophil cell death and 
demonstrates how NETs contribute to the development and progression of a growing list of diseases. 
This provides a starting point for drug development, potentially bringing mitigation to affected 
patients. 
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1 Introduction 
1.1 Inflammation and the inflammatory cascade 
The immune system is a multilayered network of cellular and soluble factors that evolved to recognize 
and eradicate invading pathogenic microbes, while, at the same time, preserving self-structures. The 
ongoing development and arms race of pathogens and the immune system is one of the essential 
driving factors of evolution. The fact that basic immunological concepts like the recognition of invasion 
followed by a directed response are conserved in evolution from prokaryotes to plants, invertebrates, 
and mammals, points out their fundamental importance for life as such 1. 
The mammalian immune response consists of an innate and an adaptive arm. The innate system is 
based on a definite set of germ-line encoded receptors that allow fast recognition of a large variety of 
different pathogens. The adaptive immune system, on the other, hand evolves highly specific receptors 
to each new challenge that are codified as immunological memory and can be activated during 
repeated infections. Both arms are required for the recognition and effective resolution of an infection 
during a process called inflammation.  
Inflammation encompasses a complex response of the host to a disturbed tissue homeostasis that 
needs tight regulation, both temporally and spatially 2. Controlled inflammation is beneficial for the 
host, because it eradicates the invader, clears the damage and reestablishes tissue homeostasis. 
Uncontrolled inflammation on the other hand can become chronic and results in tissue damage and 
consequently in disease 3. 
Four key components define the process of inflammation: inducer, sensor, mediator and effector. 
Inflammation can be induced by the recognition of endogenous and exogenous stimuli that signalize 
infection or tissue damage. Exogenous signals of microbial origin are summarized as microbial 
associated molecular patterns (MAMPs) that represent conserved structures that microbes require for 
their survival. Examples are lipopolysaccharide (LPS) of gram-negative bacteria and flagellin, a protein 
of the mobility apparatus of bacteria. Endogenous stimuli of inflammation are host-derived molecules 
that are not “visible” for the immune system under homeostatic conditions. Their presence indicates 
uncontrolled cell death in response to infection or injury, which is why they are called danger 
associated molecular patterns (DAMPs). Examples of DAMPs are uric acid crystals, high-mobility group 
box 1 (HMGB1), as well as RNA and DNA. In living cells, DNA is concealed in the nucleus and hidden 
from immune recognition, but it becomes highly immunogenic if it is released into the extracellular 
space by necrotic cell death 4,5. The importance for the recognition of nucleic acids by the immune 
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system is supported by the fact that DNA recognition is conserved during evolution from plants to 
mammals 6. 
The immune system has a plethora of germ-line encoded sensors to recognize infection or tissue 
damage. Receptors of the innate system are summarized as pattern recognition receptors (PRR) and 
divided into four subfamilies: (1) Toll-like receptors (TLRs) are membrane bound receptors that 
recognize a large variety of MAMPs and DAMPs, increasing their spectrum of recognition by forming 
homo- and heterodimers. (2) C-type lectin receptor (CLRs) recognize carbohydrates presented on the 
surface of microbes, such as zymosan, and play a crucial role in the recognition of pathogenic fungi. (3) 
NOD-like receptors (NLRs) are cytosolic sensors that detect a broad variety of ligands, including crystals 
and MAMPs of intracellular pathogens. Lastly, (4) nucleic acid sensors like retinoic acid inducible gene 
I (RIG-I), melanoma differentiation antigen 5 (MDA5), absent in melanoma 2 (AIM2) and cGAS detect 
cytoplasmic DNA or RNA of viral or bacterial origin 7–10. 
Activation of these receptors by ligand binding induces different intracellular signaling cascades like 
the NFκB pathway or interferon regulatory factors. This results in the production of inflammatory 
mediators, most importantly pro-inflammatory cytokines and chemokines. Their expression marks the 
locus of infection and induces recruitment of the effectors of inflammation, which are innate and 
adaptive immune cells. Innate immune cells involve granulocytes, monocytes, macrophages and 
dendritic cells. They are the first line of defense that quickly responds and prevents dissemination of 
the invader. The adaptive immune response consists mostly of B- and T-cells and requires more time 
to allow the production of high affinity receptors for the pathogen, namely antibodies and T-cell 
receptors. It also establishes a long-term memory that allows a quicker and stronger response if the 
same invader infects the host again. The cells of innate and adaptive immunity work in a cooperative 
way and together orchestrate an effective immune response to eradicate invading microbes 2,11. 
Once the infection is cleared the resolution of inflammation starts. Neutrophils undergo apoptosis and 
macrophages clear them by phagocytosis. This induces a switch in macrophages towards an anti-
inflammatory phenotype. They release anti-inflammatory cytokines like transforming growth factor β 
(TGF-β) and IL10 that signalize the return to tissue homeostasis 12. 
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1.2 Neutrophils – the foot soldiers of innate immunity 
Neutrophilic granulocytes, short neutrophils, are the most frequent type of innate immune cells and 
arrive as a first line of defense at the side of infection. They exert a plethora of antimicrobial functions, 
which makes them a key player in the rapid recognition and clearance of invading pathogens. The 
human immune system is dependent on functional neutrophils. Patients carrying a mutation in the 
Neutrophil Elastase gene (ELANE) develop severe congenital neutropenia, also known as Kostmann’s 
syndrome, and show that neutrophil insufficiencies predispose to a variety of different infectious 
diseases, such as mouth ulcers, otitis, pharyngitis and pneumonia 13.  
1.2.1 Activation of neutrophils 
Neutrophils represent up to 70 % of the white blood cell compartment. They are characterized by a 
high number of granules in their cytoplasm and a multi-segmented nucleus, which is why they are also 
referred to as polymorphonuclear cells (PMN) 14. Neutrophils are relatively short lived and dying 
neutrophils are cleared in the spleen, the liver and the bone marrow 15. To replenish the pool, the bone 
marrow produces approx. 1,5x1011 neutrophils per day from a myoblast precursor population and 
releases them as fully differentiated cells into the blood stream where they patrol for signs of 
infections 16. In order to do so, neutrophils are equipped with an array of innate PRRs, like TLRs, CLRs 
and NLRs. Furthermore, they express Fc-receptors (FcR) and Complement receptors to recognize 
opsonized microbes 17. With the help of chemokine and cytokine receptors, neutrophils can follow a 
chemotactic gradient towards the site of infection, where tissue-resident antigen-presenting cells 
(APCs) or endothelial cells recognized MAMPs and secreted chemo- and cytokines. In parallel to 
chemokine secretion, endothelial cells upregulate P- and L-selectin on their surface that faces the 
blood vessel lumen. The neutrophil approaches the activated endothelial cells and binds the selectins 
with their respective ligands, resulting in a rolling and finally a firm adhesion to the endothelium at the 
infection site. The neutrophil transmigrates through the endothelial layer in the infected tissue where 
it releases further chemokines to attract additional neutrophils, monocytes and macrophages. More 
importantly, they can employ a battery of antimicrobial effector functions in order to kill microbes and 
contain the infection (Fig. 1.1) 14. 
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Figure 1.1 Activation of neutrophils during infections  
Activated endothelial cells upregulate selectins that are recognized by neutrophils patrolling the blood stream. Upon selectin 
binding (a), neutrophils roll over the endothelium (b) and tightly adhere close to the side of infection (c). After extravasation 
through the endothelial layer, neutrophils secrete cytokines to recruit further immune cells and exert different effector 
functions to eliminate the infection. (Figure taken from Amulic et al., 2012) 
 
1.2.2 Neutrophil effector functions 
Communication with other immune cells by cytokines and chemokines 
Neutrophils are important producers of chemokines and cytokines that are required to coordinate an 
efficient antimicrobial response during infections. Although neutrophils are not the most potent 
cytokine producers, their high abundance and early arrival at the inflammatory site assigns them an 
important position in the inflammatory cascade. The major chemokine they produce is IL-8 (CXCL8) 18. 
Interestingly neutrophils themselves respond to IL8 by upregulation of adhesive molecules and 
chemotaxis, resulting in an increased neutrophil recruitment. Furthermore IL8 primes neutrophils to 
undergo a stronger reactive oxygen species (ROS) burst and enhanced phagocytosis 19. Another 
chemokine that they produce is MIP1α, a chemokine that recruits monocytes and macrophages to the 
inflammatory site.  
Neutrophils also produce pro-inflammatory cytokines like IL1β, IL6 and TNF 20. These factors regulate 
the innate immune response during the acute phase of inflammation on both a local and a systemic 
level. They induce the attraction of further immune cells or license immune cell functions e.g. by 
inducing phagocytosis in macrophages. Systemically, these cytokines induce fever, trigger the release 
Introduction 
5 
 
of antimicrobial acute phase proteins from the liver and upregulate the expression of endothelial 
surface receptors, enabling immune cells to extravasate to the inflammatory site 21. 
Production of ROS 
During a process called the oxidative burst, neutrophils produce high amount of short-lived oxygen-
based molecules summarized as ROS, using an enzyme complex called NADPH-oxidase 22. This complex 
catalyzes molecular oxygen to superoxide, a highly reactive molecule that myeloperoxidase (MPO) 
further processes to hypochlorous acid or hydrogen peroxide 23. Different ROS species are potent 
antimicrobials that kill microbes by oxidizing and thereby damaging DNA, lipids and proteins 24. Due to 
missing specificity, ROS released by neutrophils also affect host structures and lead to tissue damage25.  
Patients suffering from Chronic Granulomatous Disease (CGD) demonstrate the importance of ROS for 
the innate immune defense. Due to a mutation in NADPH-oxidase the cells of these patients cannot 
produce sufficient amounts of ROS, resulting in an increased susceptibility to bacterial and fungal 
infections 26. 
Release of antimicrobial molecules by degranulation 
Neutrophils are equipped with a large array of pre-synthetized antimicrobial molecules with different 
bactericidal mechanisms. Cationic peptides comprising α-defensins, LL37 and bactericidal/ 
permeability increasing protein (BPI) interfere with the bacterial membrane integrity, a mechanism 
they have in common with the neutrophil proteases lysozyme, Proteinase3 (PR3), Neutrophil Elastase 
(NE), Cathepsin G (CG) and Azurocidin. Another class of antimicrobials present in neutrophils are metal 
chelator proteins like Lactoferrin and Calprotectin that inhibit bacterial growth by complexing essential 
ions like iron, manganese or zinc 27.  
To prevent self-damage the antimicrobials are packed into specific organelles called granules that are 
stored in the cytoplasm. There are three major types of granules, characterized by their protein 
content and their mobilization potential. Primary granules (also known as azurophilic) are the first type 
of granule produced during neutrophil development. They contain MPO, defensins, BPI and the 
proteases NE, CG and PR3 and are thereby the most important carriers of the antimicrobial activity. 
The secondary or specific granules are formed after the primary granules and contain Lactoferrin, LL37 
and lysozyme. The third class, the tertiary granules are deposits for the metalloproteases Gelatinase 
and Leukolysin 28. During activation, the neutrophil mobilizes the granules consecutively, starting with 
the azurophilic granules, followed by specific and tertiary granules. They either fuse with the 
phagosome (discussed below) or with the plasma membrane, releasing their cargo into the 
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extracellular space. This process, called degranulation, establishes an antimicrobial environment in the 
surrounding of the neutrophil, resulting in bacterial killing and containment of the infection 29.  
Uptake and killing of microbes by phagocytosis 
Neutrophils clear microbes by engulfing and digesting them by a mechanism called phagocytosis. 
Phagocytosis is a receptor-mediated process, during which the neutrophil forms a membrane 
invagination that surrounds the microbe, forming a separated compartment known as the phagosome. 
Neutrophils induce phagocytosis upon recognition of microbes either directly by sensing their PAMPs 
by PRRs or indirectly by binding antibody-opsonized microbes with their FcR. Different than in 
macrophages, neutrophil phagosomes establish their bactericidal environment by fusion with granules 
and the assembly of the NADPH oxidase on the phagosomal membrane, resulting in a cocktail of 
antimicrobial molecules and ROS that together eradicate enclosed microbes 30–32.  
1.2.3 Neutrophil extracellular traps  
An additional effector mechanism is the release of NETs into the extracellular space 33. NETs are 
defined by a chromatin backbone that is decorated with histones and a variety of antimicrobial 
molecules, such as NE, PR3, CG, MPO, LL37 and defensins 34. They originate from a programmed form 
of necrotic cell death named NETosis 35, which is evolutionary conserved from plants to mammals 36.  
Inducers of NET formation 
The production of NETs is reported for a variety of microbial stimuli, such as bacterial components and 
entire bacteria, fungi, viruses and protozoa 33,37–43. It is reported that neutrophils are capable of 
recognizing the size of microbes and either phagocytose them if possible or selectively release NETs in 
response to large opponents 44. In addition to microbial inducers, a variety of self-molecules cause NET 
formation. Neutrophils treated with complement factors, autoantibodies, ureate crystal or activated 
platelets undergo NETosis 45–48. To reduce the complexity during experimental procedures, 
standardized inducers like the mitogens Phorbol-Myristate-Acetate (PMA), Concanavalin A (ConA) and 
phytohaemagglutinin as well as the calcium ionophore A23187 or the fungal toxin Nigericin are used 
38. Interestingly, NET formation results from an aborted reentry into the cell cycle, since it shares 
similarities with the onset of mitosis, like the activation of CDK6, upregulation of Ki-67 or breakdown 
of the nuclear envelope 49. 
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Mechanisms of NET formation 
The mechanism leading to NETosis is dependent on the stimulus. Whereas stimuli like PMA, ConA and 
Candida albicans require ROS production for NET formation, other stimuli like A21387 and Nigericin 
activate NETs by a ROS independent pathway. Interestingly, CGD patients, which are not able to 
produce ROS due to mutations in NAPDH oxidase, are also not able to produce NETs in response to 
ROS-dependent stimuli. This is reflected by an increased rate of fungal infections by C. albicans or 
Aspergillus nidulans 26, that can be cured by a gene therapy approach that restores ROS-dependent 
NET production 50. 
The ROS-dependent pathway leading to NET formation is the most accurately described mechanism. 
PMA activates protein kinase C, resulting in an intracellular Ca2+ release and the activation of the Raf-
MEK-ERK pathway, finally triggering NADPH oxidase that produces ROS at granular membranes 35,51. 
Subsequently, ROS activate a multi-protein complex called the azurosome that, among other proteins, 
contains MPO. MPO converts ROS to halic acid that permeabilizes the granular membrane and allows 
the liberation of NE and other proteases 52. NE processes Gasdermin D (GSDMD) into its active form, 
which induces additional NE release from the granules by a feed-forward mechanism 53. NE 
transmigrates into the nucleus via the GSDMD pores where it processes histones and induces 
chromatin decondensation, nuclear delobulation and expansion 39. During this process, the rising Ca2+ 
levels activate protein arginine deaminases (PAD) that citrullinate histones inducing further chromatin 
decondensation 38. Finally, the nuclear envelope disintegrates, the exposed chromatin is decorated 
with liberated granular content and expelled into the extracellular space. In contrast to this suicidal 
NETosis, it is described that neutrophils can survive the ejection of NET material in response to 
Staphylococcus aureus, a process named vital NETosis 54. 
NETs trap and kill microbes 
NETs indirectly limit infections by trapping bacteria 33,55 or fungi 42 and prevent further dissemination 
in the host. More importantly, NETs provide a highly inhospitable environment by establishing high 
local concentrations of bactericidal agents like histones or antimicrobial peptides, and even the DNA 
is reported to be antimicrobial 56. NETs kill bacteria like Escherichia coli and Salmonella flexneri 33,35,38 
and fungi like C. albicans 42. Also Leishmania amazonensis, the parasite causing Leishmaniasis, is killed 
by NETs in vitro 57. Interestingly, there are different adaptation strategies of microbes to NETs. 
Different pathogens have developed virulence factors that allow the escape from NET-mediated killing, 
e.g. Streptococcus pneumoniae which expresses an endonuclease that degrades NETs 55. Other 
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pathogens like Haemophilus influenzae and S. aureus deliberately induce NETs, to shield them from 
immune cell recognition 58,59. 
Neutrophil extracellular traps in disease 
The formation of NETs has not only beneficial outcomes for the host. Although the liberation of high 
concentrations of antimicrobial molecules like histones and ROS is an effective way to fight infections, 
these molecules are unspecific and can be cytotoxic to host tissues. Especially in circulation, NETs 
induce endothelial damage and provide a framework for thrombotic events. Thus, it is not surprising 
that NETs are implicated as negative contributors in a growing list of diseases. So far, NETs have a 
proposed role in cancer 60, diabetes 61, sepsis 62, thrombosis 63, arteriosclerosis 64 and an array of 
autoimmune diseases.  
1.3 Neutrophil extracellular traps in autoimmunity 
Autoimmune diseases are characterized by a dysfunction of the immune system that results in a loss 
of tolerance towards self-structures, leading to an uncontrolled formation of autoantibodies or auto-
reactive cytotoxic T-cells. Effects of autoimmune diseases can be local or systemic, depending on the 
target that the immune system erroneously recognizes. Since innate and adaptive immune system are 
tightly connected, false regulation of innate effector functions can severely influence adaptive 
immunity and vice versa. NETs are implicated in a number of autoimmune diseases, like SLE, vasculitis, 
gout, RA and psoriasis 65. Although these diseases differ in symptoms and pathogenesis, they share 
some remarkable characteristics when it comes to NETs. The pathogenesis of these diseases produces 
specific molecules that prime neutrophils or directly induce NETosis, like MSU crystals in gout or 
immune complexes in SLE. Increased appearance of spontaneous NET formation is described for some 
of the diseases, whereas others show increased levels of NET-associated proteins like NE or MPO in 
plasma or synovial fluids 66,67. These observations show that NETs play a role in autoimmune diseases 
although it is not entirely understood if they are a symptom or a driver of pathogenesis.  
1.3.1 SLE as an example of a NET–associated diseases 
SLE is a multifactorial autoimmune disease that is characterized by systemic inflammation of 
connective tissue, the formation of autoantibodies and a type I interferon (TIIFN) signature. The 
average incidence of SLE is approx. 0,1 %, depending very much on sex and ethnicity. Women of child 
bearing age display the highest incidence of SLE development and people of Hispanic and African 
ethnicity show a higher incidence than Caucasians 68. Genetic risk factors for the development of SLE 
are e.g. mutations in the nucleases DNAse-1 and DNase1-like 3 69,70. SLE progresses in flairs and patients 
Introduction 
9 
 
go through phases of exacerbation and remission. SLE patients present with a large variety of 
symptoms that advance over time 71. During the early phase of disease, patients suffer from fatigue, 
fever and loss of appetite. Patients also often develop a characteristic skin rash in the face, known as 
butterfly rash. As the disease progresses patients experience joint and muscle pain and a variety of 
organs get affected 72. Most prominently, patients develop lupus nephritis, resulting in an impairment 
and finally destruction of the kidneys. Other organs affected are the lung, the heart and skin 71,73.  
Autoantibodies and their contribution to SLE pathology 
In SLE these auto-antibodies recognize a large variety of antigens 74 like dsDNA 75 and chromatin 76. 
Interestingly, patients also develop antibodies targeting NET-related proteins like histones, MPO, PR3 
and NE 77–81. By binding their respective antigen, they form immune complexes that cause vascular 
damage leading to glomerulonephritis 82,83. Additionally, they can indirectly exacerbate the disease by 
further activating innate immune cells. SLE neutrophils stimulated with immune complexes produce 
NETs 84,85 and plasmacytoid dendritic cells (pDCs) respond by producing TIIFN 81,84,86,87, thus 
contributing to the second hallmark of SLE: the TIIFN signature. 
The TIIFN signature in autoinflammatory diseases 
TIIFN are a group of pro-inflammatory cytokines that bind the IFN α/β-receptor (IFNAR) and are 
expressed as mediators of an antiviral response. They are induced upon activation of viral nucleic acid 
sensors like RIG-I or cGAS. The most prominent subclass of TIIFN is IFNα, representing 13 subtypes, 
and IFNβ. Binding of IFNAR by TIIFN induces signaling via different STAT proteins, finally inducing a 
plethora of interferon stimulated genes (ISGs) that establish an antiviral defense state 88. TIIFN play a 
crucial role in the development of SLE 89,90. Transcriptome analysis of pediatric and adult SLE patients 
revealed a global upregulation of TIIFN and ISGs, when compared to healthy donors or patients with 
RA 91,92. By expressing this signature, SLE is part of a group of diseases that all show TIIFN 
overexpression, the type I interferonopathies. The receptors leading to TIIFN production in SLE are not 
clearly identified yet. 
1.3.2 Neutrophil extracellular traps in SLE 
NET components like DNA, nucleosomes, MPO and NE are found in the circulation of SLE patients 93–
95. The fact that 40-60 % of SLE patients are neutropenic, suggests that these circulating molecules can 
be attributed to increased neutrophil cell death 96. Normal SLE neutrophils are prone to undergo 
apoptosis 84,97, but are not predisposed to spontaneous NET formation 98. However, when stimulated, 
they form more NETs, most likely due to TIIFN priming 84. Furthermore, autoantibodies against LL37 81 
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and ribonuclear particles 84 can induce NETs. Interestingly, SLE patients present with a subtype of 
neutrophil-like cells termed low density granulocytes (LDGs). They migrate together with the 
peripheral blood mononuclear cells (PBMCs) on a density gradient, instead of with the normal density 
neutrophils (NDGs) 91,99. They serve as a marker for juvenile SLE and their occurrence correlates with 
vasculitis and skin involvement in SLE patients 67,100. Compared to NDGs, LDGs have a more pro-
inflammatory phenotype. They spontaneously undergo NETosis, produce elevated levels of pro-
inflammatory cytokines (IL6, IL8, TNF and TIIFN) and contribute to disease pathogenesis by causing 
endothelial damage 67,98. Neutrophils undergoing NETosis were detected in skin and the nephritis 
associated glomeruli of SLE patients 98,101,102. 
Inefficient NET clearance due to DNAse1 and macrophage insufficiencies 
In healthy individuals, NETs are cleared by a combination of soluble factors and phagocytes. In a first 
step, DNases degrade NETs into smaller fragments 101 and subsequently, NET remnants are removed 
by macrophages in an immunologically silent way 103. In SLE, the clearance of dead cells by 
macrophages is impaired 97,104. Additionally, there are different mechanisms impairing the functionality 
of DNAse1, an endonuclease that is secreted from the liver and the main degrading enzymes of NETs 
101. Mutations in DNAse1 and DNAse1L3 cause familial forms of SLE with high autoantibody titers 
against nuclear antigens and high prevalence of lupus nephritis 69,70, a phenotype that is recapitulated 
in mice 105,106. Insufficiencies in DNAse1 activity correlate with diseases severity and contribute to the 
occurrence of lupus nephritis 98,101,107. Interestingly, also the mutation of an intracellular cytoplasmic 
DNAse known as TREX1 results in interferon-driven autoimmunity and SLE 108,109. 
1.3.3 NETs as inflammatory stimulus in SLE 
The prolonged half-life of NETs in circulation caused by insufficient degradation by DNAse1 and 
clearance by macrophages provides a platform for undesired autoimmune activation. NETs activate 
different immune sensors of the innate immune system and induce the production of pro-
inflammatory cytokines that drive disease progression. NET proteins activate the NLRP3 
inflammasome and induce IL1β and IL18. IL18 induces NETosis, potentially resulting in an inflammatory 
feed forward loop 110–112. Furthermore, NETs induce expression of IL6 and IL8 in human epithelial 
cells113. 
NETs also serve as a stimulus for the induction of TIIFN. Most studies describe pDCs as the main 
producers of NET-induced TIIFN production, but also monocytes can fulfil this function 114. NETs need 
to be phagocytosed to stimulate intracellular DNA sensors. Their uptake is supported by NET bound 
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proteins such as LL37 and HMGB1 81,87. Notably, different groups report that oxidized mitochondrial 
DNA serves as stimulus TIIFN production, not only the genomic DNA component of NETs 81,84,85,115.  
Although different papers suggest TLR9 as a potential NET receptor that induces TIIFN expression, its 
role is not completely clear. Surprisingly, TLR9 seems to be protective in SLE, since TLR9-/- mice present 
with a exacerbated renal phenotype and increased autoantibody production 116,117. Notably, oxidized 
DNA and DNA-LL37 complexes induce TIIFN induction in a stimulator of interferon genes (STING) 
dependent manner, both in isolated human monocytes, pDCs and in an in vivo mouse model, indicating 
that the cGAS-STING pathway might be involved in NET recognition 85,114. 
1.4 The cGAS STING pathway 
DNA is not only a carrier of the genetic information, but also a potent stimulator of innate immune 
system. It can originate from viruses, bacteria or from dying cells that release DNA as a DAMP into the 
extracellular space. A battery of nucleic acid sensing receptor facilitates the recognition of DNA, which 
upon activation induce the production of TIIFN. Only recently, the cytosolic DNA sensor cGAS was 
discovered 118. 
1.4.1 The cytosolic DNA sensor cGAS 
cGAS is a cytoplasmic receptor that recognizes DNA of different origin. It senses the genomes of viruses 
like cytomegalovirus, herpes simplex viruse-1, vaccinia virus, adenovirus, hepatitis B virus and Kaposi-
Sarcoma-Herpesvirus 119–125. cGAS also recognizes reversely transcribed cDNA of HIV-1 and HIV-2, when 
the capsid membrane of the viruses is damaged by host factors 118,126. It is important to note that many 
of these viruses developed mechanisms to escape cGAS recognition to prevent immune recognition. 
cGAS is also capable of recognizing bacterial DNA of Mycobacterium tuberculosis and Francisella 
tularensis 127,128. Apart from external pathogen-derived DNA, cGAS also senses self-DNA like 
mitochondrial DNA, DNA damage side products or chromatin fragments 129–131. In principal, cGAS 
recognizes dsDNA larger than 40 base pairs (bp) in a sequence independent manner 132,133. 
The cGAS-STING signaling cascade 
cGAS is a protein of approx. 59 kDa and contains two DNA binding domains and a 
nucleotidyltransferase domain 134. Ligand binding induces the formation of a 2:2 complex of cGAS and 
DNA, resulting in a conformational change activating the nucleotidyltransferase domain, that is 
autoinhibited in the inactivated state 135,136. This conformational change enables the catalysis of 
guanosintriphosphate (GTP) and adenosintriphosphate (ATP) to cyclic guanosine monophosphate–
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adenosine monophosphate (cGAMP), a cyclic dinucleotide connected by two phosphodiester bonds 
that serves as a second messenger 137. The ER-bound immune adapter molecule STING recognizes 
cGAMP and translocates to the Golgi-apparatus 138,139. Upon translocation, STING recruits the kinase 
TANK binding protein 1 (TBK1) that phosphorylates the transcription factor Interferon regulatory factor 
3 (IRF3), resulting in its dimerization and translocation into the nucleus 140. There IRF3 binds to 
Interferon-stimulation response elements (ISRE) and induces the expression of TIIFN to upregulate the 
antiviral response 141. 
 
Figure 1.2 The cGAS-STING pathway  
After viral entry, the viral DNA is recognized in the cytoplasm by a dimer of cGAS molecules, resulting in the production of 
the cyclic dinucleotide cGAMP. cGAMP activates the ER-bound signaling adapter STING, leading to the phosphorylation and 
translocation of the transcription factor IRF3. TIIFN are secreted and activate the IFNAR receptor of neighboring cells, inducing 
an antiviral state by upregulation of an array of ISGs. 
 
1.4.2 The cGAS-STING pathway in autoinflammation 
cGAS is not only able to recognize foreign DNA introduced by viruses and bacteria, but also self-DNA. 
It recognizes mitochondrial DNA 142 and transcripts of endogenous retroelements 143 and was shown 
to induce STING dependent immune activation 85. Furthermore it was demonstrated that DNA damage 
induces cGAS activation 129. 
Under steady conditions, excess DNA is cleared by nucleases. As described above, DNAse1 degrades 
DNA in the circulation. DNAse2 is located in lysosomes and degrades DNA of particles that are taken 
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up by endocytotic pathways. Another intracellular DNAse is TREX1, also known as DNAse3. It is 
localized in the cytoplasm and shuttles to the nucleus upon oxidative stress. TREX1 clears excess DNA 
originating from endogenous retroelements or DNA damage repair- and replication intermediates 144. 
In cases where this DNA homeostasis is impaired, the cGAS-STING pathway induces severe 
autoinflammatory syndromes. Mice depleted of TREX1 suffer from a systemic organ inflammation and 
die untimely. A knockout of cGAS rescues this phenotype by reducing tissue inflammation and protects 
from premature lethality 145. A similar phenotype can be observed for DNAse2-/- mice. The knockout is 
embryonic lethal and liver-resident macrophages produce high amounts of TIIFN in a STING dependent 
manner due to an accumulation of undigested DNA. This phenotype is rescued by cGAS 145 and IFNAR 
deletion 146,147. Also in human patients, impairment of intracellular DNAses leads to the induction of 
autoinflammatory diseases. TREX1 insufficiency is associated with the Aircardi Goutière syndrome 148 
and SLE 108, while mutations in DNAse2 are connected to an arthritis-like syndrome 149,150. The close 
similarity to the murine phenotypes suggests an involvement of the cGAS-STING pathway in these 
diseases, although this has not been directly shown yet. Interestingly, gain-of-function mutations in 
STING lead to autoinflammatory diseases that share similarities with SLE 151. 
1.5 Aim of the study 
NETs can be beneficial to the host because they prevent spreading and kill pathogens. NET production 
is accompanied by the release of cytotoxic and immune-stimulatory molecules and therefore requires 
a tight regulation and efficient clearing system once the infection clears. Auto-inflammatory diseases, 
like SLE, not only show an overproduction of NETs, but also insufficient NET clearing due to limited 
uptake by phagocytes or non-functional DNAses. Especially the lack of functional intra- and 
extracellular DNAses, either caused by mutation or by blocking of accessibility, causes NET 
accumulation and prolonged exposure to the immune system.  
cGAS, a innate sensor of microbial DNA, recognizes DNA independently of its sequence and senses self-
DNA. The aim of this study was to investigate whether NETs induce expression of TIIFN by activating 
cGAS, to understand the role of NETs as an inflammatory stimulus. To reach this aim I took three 
consecutive steps. First, I investigated if isolated NETs activate cGAS in human and murine cells in vitro. 
Second, I tested if neutrophils undergoing NETosis induce cGAS in neighboring cells to produce TIIFN 
in vitro. Thirdly, I confirmed my findings in a mouse model of systemic NET induction. 
Taken together, the aim of this thesis was to investigate a new mechanism of NET induced immune 
activation and thereby explore new intervention strategies for NET-associated diseases. 
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2 Results 
2.1 NETs activate recombinant cGAS 
NETs were initially described as a new antimicrobial defense mechanism against invading pathogens. 
There is an increasing body of literature suggesting that an insufficient clearance of NETs provides the 
basis for autoimmune activation in a plethora of diseases. The exact mechanism how NETs drive 
autoimmune activation is not well characterized. Here, I investigate the role of the cytosolic DNA 
sensor cGAS as a potential receptor of NETs. 
2.1.1 Isolation of NETs 
To generate NETs, I isolated human neutrophils from peripheral blood of healthy donors 35. I 
determined the purity of the preparation by FACS and identified neutrophils as CD15+CD66b+ (Fig. 
2.1A). The average purity was 97 %. After inducing NETosis by stimulation with 100 nM PMA for 3 h 33, 
I verified NET formation by immune fluorescence where NETs stained positive for DNA, NE and a 
histone/DNA complex (Fig. 2.1B).  
To isolate NETs, I stimulated neutrophils for 4 h with PMA (100 nM), washed them with PBS and 
detached them from the plate by scraping. Since the harvested NETs formed large aggregates, I 
sonicated or digested them with DNAse1 to generate smaller fragments for further experiments (see 
paragraph 2.1.2, Fig. 2.2B). I analyzed the protein content by mass spectrometry. As expected, I 
detected NET-associated proteins that were identified before like NE, MPO, Cathepsin G and different 
histone variants (Fig. 2.1C) 34. The full proteome is listed in appendix A.  
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Figure 2.1 Characterization of Neutrophil extracellular traps 
A) Gating strategy to determine the purity and viability of isolated human neutrophils that were identified as DAPI-
CD15+CD66b+ by FACS. B) NET formation of unstimulated or PMA (100 nM) treated neutrophils was analyzed by 
immunofluorescence staining with DAPI (blue), anti-NE- (green) and anti-DNA-histone-complex staining (red). C) Excerpt of 
NET associated proteins identified by mass spectrometry. 
 
2.1.2 Isolated NETs activated recombinant human and murine cGAS 
Upon activation with DNA, cGAS produces the second messenger cGAMP that activates the 
downstream signaling adaptor STING 152,153. To show that NETs are a substrate for cGAS, I sonicated 
them and incubated them with recombinant cGAS in the presence of radioactively labeled ATP. 
Plasmid DNA served as a positive control. This resulted in the production of the second messenger 
cGAMP which I detected by thin-layer chromatography, showing that NETs are recognized by cGAS 
(Fig. 2.2A). 
   
Uniprot ID Protein names Gene name
P12814 Alpha-actinin-1 ACTN1
O43707 Alpha-actinin-4 ACTN4
P20160 Azurocidin AZU1
P08311 Cathepsin G CTSG
P59665 Neutrophil defensin 1 DEFA1
P08246 Neutrophil elastase ELANE
P07305 Histone H1.0 H1F0
P16403 Histone H1.2 HIST1H1C
P10412 Histone H1.4 HIST1H1E
P16401 Histone H1.5 HIST1H1B
Q92522 Histone H1x H1FX
P20671 Histone H2A type 1-D HIST1H2AD
Q71UI9 Histone H2A.V H2AFV
P33778 Histone H2B type 1-B HIST1H2BB
P62807 Histone H2B type 1-C HIST1H2BC
Q16695 Histone H3.1t HIST3H3
P62805 Histone H4 HIST1H4A 
P61626 Lysozyme C LYZ
P22894 Neutrophil collagenase MMP8
P35579 Myosin-9 MYH9
P05164 Myeloperoxidase MPO
P05109 Protein S100-A8 S100A8
P06702 Protein S100-A9 S100A9
P31949 Protein S100-A11 S100A11
P80511 Protein S100-A12 S100A12
P37837 Transaldolase TALDO
P02788 Lactotransferrin LTF
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Figure 2.2 Recombinant cGAS recognizes isolated human NETs  
A) Stimulation of murine recombinant cGAS with plasmid DNA or sonicated NETs in the presence of radioactively labeled ATP 
for the indicate time. cGAMP production was visualized by thin-layer chromatography. B) DNAse1 digested NETs were 
separated by agarose gel electrophoresis and C) used for stimulation of human recombinant cGAS. The indicated time reflects 
the time of digestion with DNAse1, only the 10 min time point of incubation of NETs with cGAS and ATP is shown. D) NETs 
were separated into DNA and proteins or digested with DNAse1 or Proteinase K. Resulting fractions were analyzed using 
agarose-gel electrophoresis and subsequently used to stimulate recombinant cGAS for the indicated time (E). 
I digested NETs with DNAse1 for different times and analyzed the resulting fragment sizes by agarose 
gel electrophoresis (Fig. 2.2B). Due to their high charge, undigested NETs form large aggregates that 
barely migrate into the gel. NET digestion with DNAse 1 results in smaller fragments of heterogeneous 
sizes. After 20 min, NET fragments reached nucleosome size of approx. 150 bp (Fig. 2.2B). I stimulated 
recombinant cGAS with the resulting fragments (Fig. 2.2C). Undigested NETs are poor stimulators of 
cGAS, probably due to their high charge-dependent aggregation status, leaving only few available cGAS 
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binding sites. NETs digested with DNAse1 for up to 20min activated cGAS, whereas NET fragments of 
nucleosome size (150 bp) did not activate cGAS anymore. This is consistent with previous publications 
suggesting that cGAS requires a minimum length of 36 bp of free DNA for activation 137, which is not 
present in nucleosomes because the remaining DNA is wrapped around the histone core and thereby 
inaccessible for cGAS. To proof that the DNA of NETs activates cGAS, I extracted the nucleic acid from 
NETs by phenol chloroform extraction as well as digested them for 1h with either DNAse1 or Proteinase 
K. In parallel, I isolated NET-bound proteins. DNA was absent in the protein extract and in NETs 
extensively treated with DNAse1-treated samples, whereas DNA was detectable in NETs treated with 
Proteinase K (Fig. 2.2D). As expected, the isolated DNA or proteinase-digested NETs induced cGAMP 
production by recombinant cGAS, whereas NET proteins and DNAse1-digested NETs failed to activate 
a response (Fig. 2.2E). In summary, these results demonstrate that the DNA of NETs is a potent 
activator of recombinant cGAS. 
2.2 Isolated NETs activate human and murine immune cells in vitro 
After showing that NETs are a substrate for cGAS I investigated if they are recognized by cGAS in living 
cells in vitro.  
2.2.1 Generation and characterization targeted CRISPR knockouts in human THP1 cells and 
murine immortalized Balb/c macrophages 
To test the activation of cGAS by NETs in vitro, I generated an number of gene specific knockout 
mutants (summarized in 4.1.4) using the clustered regulary interspeaced short palindromic repeats 
(CRISPR)/Cas9 technology 154,155. As target cells I chose the human monocytic cell line THP1 or murine 
immortalized Balb/c macrophages. In total, I targeted seven human and eight murine genes with two 
independent guide RNAs (gRNAs) each. For each gRNA I generated single cell clones by limited dilution 
cloning, sequenced 32 clones per construct by next generation sequencing and analyzed the mutations 
using the Outknocker tool 156. Outknocker compares the retrieved sequences to the genomic reference 
locus and creates a pie chart containing a piece for every uniquely identified indel detected, while the 
pie chart size corresponds to the number of reads for that locus. Examples of the graphical output are 
shown for human and murine cGAS and STING (gene name hTMEM173) in Fig. 2.3. Using Outknocker 
I verified out of frame mutations in all targeted genes, resulting in a total of 168 modified single clones. 
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Figure 2.3 Generation of genetic knockouts in the human THP-1 cell line and immortalized Balb/c macrophages using CRISPR 
Representative Outknocker analysis for knockouts generated by CRISPR/Cas9 in human THP1 or murine immortalized Balb/C 
macrophages targeting cGAS or STING (TMEM173). The pie chart represents a clone, its size representing the numbers of 
processed reads and its fractions uniquely detected indels in comparison to the reference sequence. 
 
2.2.2 Detection of TIIFN expression in human and murine cells 
The activation of cGAS by DNA ligands ultimately results in the production of TIIFN 134. To use TIIFN 
production as a functional readout for NET recognition by cGAS, I established systems to measure TIIFN 
in both human and murine primary cells.  
Human PBMCs expressed both hIFNA1 and hIFNB in response to stimulation with the TLR4 agonist LPS, 
the TLR3 agonist polyinosinic:polycytidylic acid (p(I:C), the TLR9 agonist ODN2216 and lipofectamine 
transfection with synthetic dsDNA-sequence poly(deoxyadenylic-deoxythymidylic) acid (pdAdT) (Fig. 
2.4A). Interestingly, p(I:C) and pdAdT induced stronger hIFNB expression than hIFNA1. To confirm 
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protein production, I used a reporter cell line that specifically produces a secreted phosphatase upon 
stimulation with human TIIFN, but not with IFNγ (Fig. 2.4B), that can be quantified by color-shift of the 
phosphatase substrate. 
 
Figure 2.4 Measurement of TIIFN expression in the human and murine system 
A) Expression of IFNA1 and IFNB by PBMCs stimulated with LPS (500 ng/ml), p(I:C) (1 µg/ml), ODN2216 (5 µM) or transfected 
with pdAdT (2 µg/ml) was analyzed by qPCR. B) HEK Blue IFNα/β reporter cells were stimulated with serial dilution of human 
recombinant universal IFNα, IFNβ or IFNγ. Reporter cell activity was quantified by Quanti-Blue assay (OD655 nm). C) Murine 
Wildtype BMM were stimulated with p(I:C) (1 µg/ml) or transfected with pdAdT (2 µg/ml). TIIFN in the supernatant were 
assessed using reporter cells expressing luciferase under the control of IFNAR. All results are presented as mean±SD (n=3). 
 
To validate the murine system, I stimulated primary Wildtype BMM with p(I:C) or transfected them 
with pdAdT. I detected TIIFN production using a reporter cell line expressing luciferase upon TIIFN 
recognition (Fig. 2.4C) 157. 
Taken together these results show that I are able to measure TIIFN production in both murine and 
human cells. 
2.2.3 Isolated NETs induce TIIFN production in human immune cells in vitro 
I analyzed the TIIFN response of different cell types towards isolated NETs. Shortly after neutrophils 
arrive at the side of inflammation, monocytes migrate into the inflammatory side and differentiate 
into macrophages 158. Due to their high phagocytic potential and their role in the resolution of 
inflammation, macrophages are promising candidates for the uptake of NETs. Interestingly, an earlier 
publication described the induction of TIIFN by macrophages transfected with NETs, showing that they 
are able to respond to NET material 103. 
I stimulated human PBMCs, monocyte-derived macrophages (MDM), as well as the monocytic cell line 
THP1 before and after differentiation into macrophage-like cells and measured their TIIFN response. 
Of note, NETs that were frozen and stored did not induce TIIFN production in any of the cell types 
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when added on cells. However, when I transfected those NETs as described by Ferrera & Fadeel (2013), 
TIIFN production is initiated. Freshly isolated NETs on the other hand induced a response in MDM (Fig. 
2.5A), but not in the other primary cells or the THP1 cells. The inhibition of NE by two different 
inhibitors resulted in a reduced TIIFN production of macrophages, indicating that NE is required in that 
process (Fig. 2.5B). Importantly, the NE inhibitors did not reduce activation of macrophages by 
transfected pdAdT, suggesting that the NE effect is NET specific (Fig. 2.5C). Utilization of a pan-
Cathepsin (K777) or a pan-caspase (zVAD-FMK) inhibitor had no influence on macrophage activation 
(Fig. 2.5B and C).  
It is described that mitochondrial DNA (mtDNA) in NETs is interferogenic 85,115. To assess the 
contribution of mtDNA during NET induced macrophage activation I isolated mtDNA from HEK cells 
and stimulated macrophages in comparison to fresh NETs. mtDNA did not induce TIIFN production in 
my hands. (Fig. 2.5D). 
In the next step, I aimed to verify that the NET induced TIIFN production is cGAS dependent. Since 
genetic manipulation of primary MDM is not feasible and THP1 cells do not respond to NETs alone (Fig. 
2.5A), I transfected THP1 CRISPR clones with NETs and analyzed TIIFN induction. Wildtype, scrambled 
(scr) and two clones targeting Neutrophil Elastase (NE), which served as control, produced TIIFN upon 
stimulation, whereas clones carrying mutations for cGAS, STING or IRF3 failed to do so. Furthermore, 
I tested knockouts of other DNA sensors. Clones carrying mutations deficient for the DNA sensors DAI 
159, Gamma-interferon-inducible protein 16 (IFI16) 133 or TLR9 160 produced TIIFN levels comparable to 
the control clones (Fig. 2.5E), indicating that NETs are specifically recognized by cGAS. 
NET stimulation induces other signs of cGAS activation. cGAS activation results in phosphorylation of 
the transcription factor IRF3 134,138, that regulates the expression of TIIFN. I showed IRF3 
phosphorylation after transfection of human primary monocytes with NETs (Fig. 2.5F), indicating cGAS 
activation. 
Complement factors, autoantibodies or DNA binding proteins 84,161,162 in the serum of SLE patients 
facilitate the uptake of NETs in immune cells. To test if these factors convey NETs into target cells and 
induce cGAS activation I stimulated human PBMCs with NETs in the presence of serum from eight SLE 
patients or healthy controls. The sera alone were not able to induce PBMC activation, whereas all SLE 
sera were able to induce TIIFN induction in the presence of NETs, while only a subgroup of the control 
sera was able to do so (responders) and the other was not (non-responders) (Fig. 2.5G). 
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Figure 2.5 Isolated NETs induce TIIFN production in human cells by activating cGAS in vitro  
A) TIIFN production of MDMs, PBMC, THP1 cells and PMA-differentiated THP1 cells after stimulation with NETs (n=3). B/C) 
TIIFN production of MDM treated with either with fresh NETs (B) or pdAdT (C) in the presence of NE inhibitors. D) TIIFN 
production of MDMs treated with mtDNA. (n=3) E) THP1 CRISPR clones transfected with NETs. TIIFN production was 
normalized to pdAdT transfection (n=3). F) Representative FACS analysis of IRF3 phosphorylation in human monocytes after 
stimulation with NETs. G) Summary of stimulation of PBMCs with NETs and sera of different donors normalized to 
unstimulated cells. (n=3) H) ELISA for ANA-antibodies and I) complement factor C1q in the sera of SLE patients and healthy 
control donors. A, B, C, D, E, G) TIIFN production was quantified by Interferon-reporter cell assay, values represent mean±SD. 
Data were analyzed by Kruskal-Wallis test α=0,05 followed by Dunn’s multiple comparison test α=0,05. *p<0,05, 
***p<0,001,****p<0,0001. 
 
To determine the factor that separates the responder and the non-responder healthy control sera in 
their ability to induce TIIFN production together with NETs, I measured the presence of anti neutrophil 
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cytoplasmic antibodies and complement factor C1q. I did not detect a difference in the two analyzed 
factors between the two groups (Fig. 2.5H and I).  
Taken together these results show that isolated NETs induce TIIFN production in human cells in vitro 
by activating the cGAS-STING pathway. Notably, NETs do not need transfection to activate the cytosolic 
DNA sensor. 
2.2.4 Isolated NETs induce TIIFN expression in murine immune cells in vitro 
To verify the finding made with human cells I analyzed if NETs also induce TIIFN production in murine 
cells. I stimulated murine BMM with increasing concentrations of sonicated NETs with DOTAP or NETs 
that had been treated with DNAse1 for different time periods. I measured a dose-dependent 
production of TIIFN after stimulation, as well as a decreasing response the longer the NETs were 
digested with DNAse1 (Fig. 2.6A).  
Next, I tested the hypothesis that the NET-induced TIIFN production is cGAS-dependent. I treated 
immortalized Balb/c BMM carrying knockouts in different target genes with isolated NETs and DOTAP. 
Scrambled control cells or cells with a knockout of NE that I used as a negative control produced TIIFN 
as expected. Also, a clone carrying a mutation in TLR9 produced comparable amounts of TIIFN. 
Importantly, clones with a knockout of cGAS or STING produced significantly less cytokines upon 
stimulation with NETs (Fig. 2.6B). Finally, I tested knockouts of two isoforms of DNAse2. The DNAse2 
knockout is embryonic lethal in mice due to an accumulation of endogenous nuclear DNA, a phenotype 
that can be rescued by STING depletion 147,163. The link between DNAse2 deficiency and STING 
activation led us to investigate the role of DNAse2 in NET recognition. Clones deficient for DNAse2 did 
not produce significantly different amounts of TIIFN than control cells (Fig. 2.6B).  
To further consolidate the role of cGAS in NET recognition I compared primary BMM of Wildtype and 
cGAS-/- mice. Upon stimulation, I detected TIIFN production by Wildtype BMM, while cGAS-/- failed to 
induce a TIIFN response to NETs (Fig. 2.6C). Interestingly, cGAS-/- BMM did not respond to pdAdT 
stimulation either, although pdAdT is thought to be recognized by a variety of DNA sensors and also 
indirectly by the RNA sensor RIG-I.  
To analyze general functionality of cGAS-/- BMM, I tested NLRP3 and AIM2 inflammasome activation. 
Interestingly, other groups reported that cGAS has a role in DNA inflammasome activation 164,165. I 
primed Wildtype, cGAS-/-, AIM2-/-, MYD88-/- and CASP1/11-/- BMM with LPS and further stimulated them 
with Nigericin (activator of NLRP3), pdAdT (activator of AIM2) or NETs. All cells of different genotypes 
except cGAS-/- produced TIIFN upon NET stimulation (Fig. 2.6D). Notably, AIM2-/-, MYD88-/- and  
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Figure 2.6 Isolated NETs induce TIIFN expression in murine primary cells  
A) TIIFN production by primary BMM stimulated with increasing amounts of NETs (100 µg/ml -1 µg/ml) with DOTAP or NETs 
digested with DNAse1 for different periods (1-20 min) and DOTAP (n=3). B) Stimulation of immortalized Balb/c BMM CRISPR 
clones with NETs and DOTAP, interferon production values are normalized to the cell count. The data were analyzed by 
Kruskal-Wallis test (α=0,05) followed by Dunn’s multiple comparison test (α=0,05), *p<0,05, **p<0,01. (n=4) C) Comparison 
of interferon production of primary BMM from Wildtype and cGAS-/- mice stimulated with NETs. The data were analyzed by 
Mann-Whitney test (α=0,05), **p<0,01, ***p<0,001, (n=4). D) Primary BMM of different genotypes were primed with LPS 
(500 ng/ml) or left unprimed and subsequently stimulated with NETs, Nigericin (15 µM) or pdAdT (2 µg/ml). TIIFN andIL1β 
production was measured. (n=3) A-D) TIIFN production was measured by luciferase reporter cell assay, IL1β and IFNβ were 
quantified by ELISA. Values are presented as mean±SD. 
CASP1/11-/- BMM produced higher amounts of TIIFN than Wildtype BMM. As expected, Wildtype, 
cGAS-/- and AIM2-/- BMM produced IL1β after NLRP3 activation with LPS and Nigericin, while MyD88-/- 
and CASP1/11-/- did not respond. Upon LPS priming and stimulation with the DNA stimuli pdAdT and 
NETs, only Wildtype and cGAS-/- cells produced IL1β, while AIM2-/-, MyD88-/- and CASP1/11-/- cells were 
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not activated (Fig. 2.6E). Here, cGAS-/- produced more IL1β than Wildtype. These data show that cGAS 
depletion does not affect inflammasome activation and that cGAS-/- BMM are functional in responding 
to inflammasome stimuli. 
 
2.3 Neutrophil undergoing NETosis activate human immune cells in vitro 
I demonstrated that recombinant cGAS recognizes isolated NETs and that these are able to induce 
TIIFN in human and murine primary cells by activating the cGAS-STING axis. In the next section, I 
analyze the ability of neutrophils undergoing NETosis to induce TIIFN expression in human primary 
target cells directly. 
2.3.1 Co-cultivation of NET-forming neutrophils with human immune cells induces TIIFN 
I co-cultivated human PBMCs and neutrophils in the presence of NET-inducing stimuli and analyzed 
TIIFN expression. PBMCs co-cultivated with PMA-stimulated neutrophils (Fig. 2.7A) upregulate the 
expression of the TIIFN IFNα and IFNβ, when compared to unstimulated PBMCs. I observed the same 
result when I coincubated PBMCs with ConA activated neutrophils (Fig. 2.7B). Since IFNα and IFNβ 
expression significantly correlate with each other (Fig. 2.7C), I further on only present IFNα expression. 
PBMCs consist of T-, B-, NK-cells, monocytes and dendritic cells 166, hence I investigated which cell type 
is responsible for TIIFN production upon NET recognition. Experimental evidence shows that 
monocytes 114 and plasmacytoid dendritic cells (pDCs) 81,87 are promising candidates for NET 
recognition. To test this, I isolated monocytes and pDCs and co-cultivated them with neutrophils 
undergoing NETosis. Both monocytes and pDCs expressed TIIFN when stimulated with PMA stimulated 
neutrophils (Fig. 2.7D and E).  
I analyzed the supernatants of co-cultures to show that neutrophils undergoing NETosis do not only 
induce TIIFN expression but also secretion. I detected significant release of bioactive TIIFN by a 
reporter cell assay. Furthermore I were able to detect IFNα and the interferon surrogate marker 
CXCL10 167 by ELISA (Fig. 2.7F-H).  
Taken together, these results show that neutrophils undergoing NETosis induce TIIFN production in 
neighboring target cells. 
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Figure 2.7 Induction of TIIFN in PBMCs by neutrophils undergoing NETosis in vitro  
Co-cultivation of human PBMCs with neutrophils in the presence of A) PMA (n=24) or B) ConA (n=5). Data were analyzed by 
Kruskal-Wallis test (α=0,05) followed by Dunn’s multiple comparison test (α=0,05), ****p<0,0001. C) Correlation of IFNA1 
and IFNB expression, analyzed using Spearman r test (α=0,05), *p<0,05. D) TIIFN expression after co-cultivation of PMA-
stimulated neutrophils with D) monocytes (n=5) or E) pDCs (n=3). F-H) Measurement of cytokine production in co-cultivation 
supernatants using F) a interferon reporter cell assay (n=5) or G) ELISA for human IFNα (n=11) and H) human CXCL10 (n=4). 
Data were analyzed by Mann-Whitney test (α=0,05), *p<0,05, **p<0,01. Values represent the mean±SD. A-E) TIIFN expression 
was measured by qPCR. 
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2.3.2 The induction of TIIFN by neutrophils is cGAS-dependent 
To show that TIIFN expression in human PBMCs activated by neutrophils undergoing NETosis is 
dependent on cGAS, I repeated the co-cultivation in the presence of pharmacological inhibitors. The 
inhibition of cGAS by RU.521 168 resulted in a significantly decreased TIIFN expression when PBMCs 
were co-cultivated with neutrophils and PMA. This result was supported by the observation that the 
inhibition of the downstream signaling molecules STING by CCCP and TBK1 by Amlexanox show the 
same effect (Fig. 2.8A). To prove that the observed effect is not due to reduced NET formation I 
stimulated neutrophils with PMA in the presence of the above mentioned inhibitors. The inhibitors did 
not influence NET formation (Fig. 2.8B), indicating that they reduce TIIFN expression by inhibiting their 
corresponding target molecule. Furthermore, I co-cultivated PMA-differentiated THP1 CRISPR clones 
with primary neutrophils undergoing NETosis. Clones with knockouts in cGAS and STING expressed 
significantly less TIIFN when compared to scrambled. A clone carrying a mutation IRF3 showed a 
markedly, but not significant, reduction (Fig. 2.8C). NETs and complexes of self-DNA and antimicrobial 
peptides were shown to induce TIIFN by a TLR9-dependent mechanism before 81,84,87. To investigate if 
TLR9 is involved in my model I co-cultivated PBMCs with neutrophils undergoing NETosis in the 
presence of Bafilomycin A1, a potent inhibitor of lysosomal TLRs 169,170. I did not detect a difference in 
TIIFN expression between co-cultivations with or without Bafilomycin A1 (Fig. 2.8C), indicating that 
TLR9 is not involved in NET recognition in my experimental setting. 
These results show that PBMCs recognize NETs by the cGAS-STING-pathways. 
 
Figure 2.8 TIIFN induction by neutrophils is cGAS-dependent  
A) Co-cultivation of human PBMCs with neutrophils and PMA in the presence of RU.521 (10 µM) (n=7), CCCP (10 µM) (n=4) 
or Amlexanox (10 µg/ml) (n=4). hIFNA1 expression was quantified by qPCR, values were normalized to co-cultivation without 
inhibitors B) Human neutrophils stimulated with 100 nM PMA in the presence of indicated inhibitors. NET formation was 
assessed by immunofluorescence staining. C) Co-cultivation of PMA-differentiated THP1 CRISPR clones with neutrophils and 
100 nM PMA. (n=5) D) Co-cultivation of human PBMCs and neutrophils in the presence of 100 nM PMA and Bafilomycin (1 
µM) (n=4). Induction of TIIFN was quantified by qPCR. Results are presented as mean±SD. The results were analyzed using 
Kruskal-Wallis test (α=0,05) followed by Dunn’s multiple comparison test (α=0,05), *p<0,05, **p<0,01. 
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2.3.3 DNAse1 enhances the TIIFN expression in PBMCs co-cultivated with NET-forming 
neutrophils 
In the circulation of the human body NETs are degraded by the exonuclease DNAse1 101,171. To 
determine the effect of DNAse1 on TIIFN induction by neutrophils undergoing NETosis, I co-cultivated 
PBMCs with neutrophils and PMA in the presence of the enzyme. DNAse1 treatment increased the 
production of TIIFN by PBMCs after co-cultivation with neutrophils undergoing NETosis (Fig. 2.9). 
 
Figure 2.9 Presence of DNAse1 increases TIIFN expression in co-cultivation system  
Co-cultivation of PBMCs and PMA stimulated PMN in the presence of DNAse1 (5U/ml). hIFNA1 expression was quantified by 
qPCR. Data represent mean ± SD. (n=4) 
 
2.3.4 Neutrophil mediated TIIFN expression in PBMCs is dependent on NET-formation 
So far, I showed that neutrophils undergoing NETosis are able to induce TIIFN production in PBMCs. 
During the process of NETosis the cell undergoes necrosis-like disintegration, membrane rupture and 
releases a large variety of molecules into the extracellular space 35. To ensure that NETs themselves 
induce the observed TIIFN expression, I co-cultivated PBMCs with neutrophils in the presence of fMLP 
to induce degranulation. The release of granular content did not induce TIIFN expression (Fig. 2.10A). 
Furthermore, I did not detect TIIFN induction when I stimulated PBMCs with the supernatant of 
cultured neutrophils in combination with PMA (Fig. 2.10A). 
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Figure 2.10 Neutrophils induce cGAS-dependent TIIFN expression by releasing NETs  
A) PBMCs stimulated with different control stimuli (n=4). Data were normalized to PBMCs coincubated with PMN and PMA 
(100 nM). B) PBMCs were coincubated with PMN from either CGD patient or PMN from a healthy donor in the presence of 
PMA (100 nM). Data were normalized to the co-cultivation of healthy donor PBMCs and healthy neutrophils (n=3). C) Co-
cultivation of PBMCs and PMN in the presence of PMA and an NE-inhibitor (20 µM). Data were normalized to the co-
cultivation without inhibitor and analyzed by Mann-Whitney test (α=0,05), **p<0,01. D) ROS production of PMN stimulated 
with PMA (100 nM) in the presence of NE-inhibitor (20 µM) was measured by luminol assay (representative result of n=3). E) 
During co-cultivation PBMCs and PMA stimulated PMN were separated by 0,4 µm pore-sized membrane in a transwell system 
(n=4). Expression of hIFNA1 was analyzed by qPCR in all experiments. All results represent the mean±SD.  
During activation with PMA, neutrophils undergo a potent ROS burst. ROS function not only as 
antimicrobial agent, but also as signaling molecules 172. Patients suffering from CGD present with 
mutations in NADPH oxidase. Their neutrophils fail to induce a ROS burst and are not capable of 
producing ROS-dependent NETs. Neutrophils of these patients were not able to induce TIIFN 
expression in PBMCs of healthy donors when stimulated with PMA (Fig. 2.10B), indicating that a ROS-
dependent process is required for TIIFN induction, which is likely NET formation. To further address 
the question whether TIIFN induction occurred due to the oxidative burst or due to NET release, Ialso 
inhibited NET formation using a pharmacological inhibitor of neutrophil elastase (NEi). Although NEi-
treated neutrophils are still able to produce ROS (Fig. 2.10C), they induced significantly reduced levels 
of TIIFN in PBMCs (Fig. 2.10D). Lastly, I performed the co-cultivation in a transwell system, separating 
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the PBMCs and the neutrophil by a 0,4 µm membrane. When the cells were separated, PMA-
stimulated neutrophils were not able to induce TIIFN expression in PBMCs (Fig. 2.10E).  
Taken together these results demonstrate not only that the induction of TIIFN is dependent on NETs, 
but also that the cells require direct contact for the activation and that the observed TIIFN induction is 
not mediated by soluble factors.  
2.3.5 TIIFN induction requires phagocytosis of NETs by PBMCs 
To induce cGAS activation, NETs most likely need to get into the cell and reach the cytoplasm. Since 
macrophages phagocytose isolated NETs 147, I investigated if this is also observed under my co-
cultivation conditions.  
With a live cell imaging approach, I observed macrophages that encountered PMA-activated 
neutrophils and ingested a fraction of them as soon as they disintegrated and released their DNA into 
the extracellular space (Fig. 2.11A). To validate that NETs were taken up, I stained the macrophages 
for NET markers and observed colocalisation of DNA, DNA-histone complexes and NE in the 
macrophage cytoplasm, indicating that they had internalized NETs (Fig. 2.11B, upper panel). When I 
added the phagocytosis inhibitor Cytochalasin B (CytoB) to the co-cultivation, I could not observe 
uptake of NET material (Fig. 2.11B, lower panel). The cells were treated with 20 U DNAse1 during the 
last 15 min of the incubation to ensure that NETs do not stick to the cell surface and detected NET 
signal is intracellular. 
Next I investigated the necessity of phagocytosis for TIIFN induction. Cells treated with the 
phagocytosis inhibitors CytoB or Nystatin expressed significantly less TIIFN when challenged with PMA 
stimulated neutrophils (Fig. 2.11C). The ability of neutrophils to undergo NETosis was not affected by 
the inhibitors (Fig. 2.11D), demonstrating that the observed effect is due to phagocytosis inhibition. 
Taken together these results demonstrate that NETs need to be taken up by phagocytosis in order to 
induce a TIIFN response.  
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Figure 2.11 TIIFN induction requires NET internalization by phagocytosis 
A) Fixed images of a video of a human MDM phagocytosing a PMN stimulated in the presence of 100 nM PMA. All cells are 
labeled with Hoechst (cyan), PMN are marked with cell tracker (pink). Scale bars represent 50 µm. B) Co-cultivation of MDM 
with PMN and PMA (100 nM) in the presence of Cytochalasin B. Cell were stained with Hoechst (blue), PL23 (red) and NE 
(green). Scale bars represent 20 µm. C) Co-cultivation of PBMCs with PMN and PMA in the presence of the phagocytosis 
inhibitors Nystatin (10 µg/ml) and Cytochalasin B (5 µg/ml). The expression of hIFNA1 was quantified by qPCR and normalized 
to the co-cultivation without inhibitors. The data were analyzed with the Kruskal-Wallis test (α=0,05) followed by Dunn’s 
multiple comparison test (α=0,05) **p<0,01 (n=5). D) NET formation of PMA stimulated PMN (100 nM) after 4 h, quantified 
by immunofluorescence staining (n=3). Data are presented as mean±SD.  
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2.3.6 Phagocytosed NETs escape from the phagosome into the cytoplasm 
I demonstrated that NETs are internalized by phagocytosis. To activate cGAS they need to escape from 
the phagosome to get into the cytoplasm. I co-cultivated PMA stimulated neutrophils and 
macrophages in the presence of lysotracker, a dye staining acidified phagosomes. After fixation, cells 
were stained with Hoechst and for NE to visualize NETs. In PMA-treated macrophages no NE or 
cytosolic DNA signal was observed, while the lysotracker signal was faint (Fig. 2.12, upper panel). NE 
was detected in neutrophils in the control condition, but not in macrophages (Fig. 2.12, middle panel). 
When macrophages were co-cultivated with neutrophils in the presence of PMA, I observed NE and 
DNA positive NETs in the cytoplasm that mostly colocalized with a strong lysotracker signal (Fig. 2.12, 
lower panels). These data show that NETs mostly end up in phagosomes. However, there are also NE 
and DNA positive areas that are negative for lysotracker indicating that NETs escaped from the 
phagosome into the cytoplasm where they would be able to activate cGAS.  
 
Figure 2.12 NETs escape from the phagosome into the cytoplasm 
MDM were coincubated with PMN and 100 nM PMA for 4 h. Samples were stained with Hoechst (blue), NE (green) and 
lysotracker (red). White arrows mark NE-positive lysotracker-negative areas. Scale bars represent 50 µm, for the zoom in 20 
µm. 
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2.4 Neutrophil extracellular traps induce TIIFN in vivo by a cGAS-dependent mechanism 
In the previous sections I demonstrated that NETs are taken up by phagocytosis into target cells and 
induce a TIIFN response by activating the cGAS-STING-pathway. In the next section, I will show that 
cGAS-dependent recognition of NETs also plays a role in vivo.  
2.4.1 Characterization of cGAS-/- neutrophils 
Phenotypes of cGAS-/- mice are so far only described in the context of viral and bacterial infections, but 
not in the context of neutrophil biology. First, I analyzed neutrophils of cGAS-/- mice to ensure their 
functionality and exclude that observed phenotypes are due to neutrophil insufficiencies.  
cGAS-/- mice present similar amounts of circulating neutrophils as Wildtype mice (Fig. 2.13A). For 
functional characterization, I included Cybb-/- mice as a control. Like CGD-patients, Cybb-/- mice carry a 
mutation in a subunit of NADPH-oxidase. Due to a resulting inability to mount a ROS burst, they cannot 
produce NETs in response to ROS-dependent stimuli. When I isolated neutrophils from the peritoneal 
cavity of animals after casein injection, I found that the recruitment of neutrophils was the same in 
Wildtype, Cybb-and cGAS-deficient mice. Peritoneal neutrophils of Wildtype and cGAS-/- animals 
produced a similar ROS burst after PMA stimulation (Fig. 2.13B) and made comparable amounts of 
NETs upon stimulation with PMA and ConA (Fig. 2.13C). As expected, Cybb-/- neutrophils produce 
neither ROS nor NETs after PMA stimulation.  
I therefore conclude that the response of cGAS-/- neutrophils to both PMA and ConA is comparable to 
that of Wildtype neutrophils. 
 
Figure 2.13 cGAS-/- mice have normal neutrophil functions  
A) Quantification of whole blood neutrophils by FACS. Neutrophils were defined as CD3-, CD45+, Ly6G/C high (Gr1) and CD115-
. B) ROS production of neutrophils after stimulation with 100 nM PMA measured by chemiluminescence assay (representative 
of n=3). C) NET formation of Wildtype and cGAS-/- neutrophils stimulated with 100 nM PMA for 16 h (n=3). Results are 
represented mean±SD, B) shows mean values, error bars are not included for visibility. 
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2.4.2 Systemic NET induction in vivo 
There are only limited models available to investigate NETosis in vivo. One option is the i.p. injection 
with LPS 173. Since LPS administration can induce TIIFN production in itself, this system was not 
applicable for us. A recent report described the induction of NETs by the plant lectin ConA 174. I.v. 
administration of ConA is an established model for acute immune-mediated hepatitis that leads to 
liver destruction 175, and I consider it a promising model to investigate NET formation in vivo. I injected 
mice with 15 mg/kg ConA i.v. and measured markers of liver damage in the serum to ensure that the 
system works in my hands. Both alanine-aminotransferase (ALT) and asparatate-aminotransferase 
(AST) are elevated in mice after 12 h ConA administration and I did not observe a difference between 
Wildtype, cGAS-/- and Cybb-/- mice (Fig. 2.14A and B). Although the variation between the animals was 
very high, all ConA injected mice present AST/ALT levels that are above diagnostic threshold. In 
parallel, I assessed NET production by sandwich ELISA for NE and DNA. Wildtype and cGAS-/- produce 
comparable amounts of NETs. Cybb-/- mice, which I used as a negative control, did not produce NETs 
after ConA challenge (Fig. 2.14C). As a further readout for ConA induced cell death I quantified 
nucleosome in the sera of ConA injected mice by ELISA. No difference between Wildtype, cGAS-/- and 
Cybb-/- mice was observed.  
 
Figure 2.14 Systemic NET induction by i.v. ConA administration  
The liver damage markers AST (A) and ALT (B) were measured in serum of mice 12 h after injection with 15 mg/kg ConA (n=5) 
C) Quantification of NET induction by sandwich ELISA for NE and DNA in sera of ConA injected mice (n=10). D) Quantification 
of nucleosomes in the sera of ConA injected mice by ELISA (n=5). 
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2.4.3 Injection of ConA induce cGAS-dependent ISG expression in vivo 
To test the effect of systemic NET induction in vivo I injected mice with the NET inducer ConA. The 
TIIFN IFNA2 and IFNB were not detectable by qPCR in white blood cells, so I measured ISGs that I used 
as surrogate markers for TIIFN expression and signaling. Wildtype mice significantly upregulated the 
expression of the ISGs CXCL10, MX1, IFIT1, IFIT2, IFIH1 and OAS1A 12 h after ConA challenge. In 
comparison to Wildtype mice, cGAS-/- animals expressed significantly lower amounts of all of the 
above-mentioned ISGs after ConA stimulation (Fig. 2.15), indicating that the cGAS-STING pathway is 
involved in ISG upregulation in response to ConA.  
 
Figure 2.15 ConA injection results in cGAS-dependent upregulation of ISGs 
Expression of ISGs in Wildtype and cGAS-/- mice 12 h after i.v. injection of ConA (15 mg/kg). Expression levels were quantified 
by qPCR, data represent mean±SD (n=9). Data were analyzed by Mann-Whitney test, α=0,05, *p<0,05, **p<0,01, 
****p<0,0001. 
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2.4.4 Reduced ISG upregulation in cGAS-/- mice is a global phenomenon after ConA stimulation 
In the previous experiment, I compared the expression of six well-described ISGs after ConA 
stimulation between Wildtype and cGAS-/- mice. To further analyze the response to ConA in a broader 
and unbiased way, I subjected the same samples to a microarray analysis to assess global differences  
 
Figure 2.16 Increased global upregulation of ISGs in Wildtype mice when compared to cGAS-/- mice after ConA injection 
A) Scatterplot comparing log fold change PBS vs. ConA (15 mg/kg, 12 h) between Wildtype and cGAS-/- mice. Annotated genes 
are examples of ISGs. B) GO-term analysis of genes significantly upregulated in Wildtype over cGAS-/-.  
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between the two mouse strains. By comparing the fold changes of significantly regulated genes 
between PBS- and ConA injected mice between genotypes, I detected a number of genes that were 
stronger upregulated in Wildtype mice than in cGAS-/- animals (Fig. 2.15A). A gene-ontology analysis of 
these significantly stronger regulated genes revealed an significant enrichment for the terms “viral 
sensing & immunity” (LI.M111.0), “antiviral IFN signature” (LI.M75) and “type I interferon response” 
(LI.M127) (Fig. 2.15B). These results show that not only the six previously selected ISGs are effected by 
cGAS depletion, but that TIIFN regulated genes show a weaker induction in cGAS-/- mice than in 
Wildtype mice on a global scale.  
 
2.4.5 Neutrophil depletion has a limited effect on ISG expression in Wildtype mice after ConA 
injection 
To test if ConA-induced upregulation of ISGs is dependent on NETs I depleted neutrophils by treating 
mice with a Ly6G-specific depletion antibody (1A8) or the corresponding isotype control (2A3) 176. I 
verified neutrophil depletion 24 h after antibody injection before ConA injection using whole blood 
FACS analysis and identified neutrophils as CD3-, CD45+, Ly6G/Chigh(Gr1) and CD115- (Fig. 2.17A). The 
neutrophil counts in depleted animals were reduced but not completely abolished (Fig. 2.17B). I 
measured NETs and nucleosomes in the sera of the antibody-depleted mice by ELISA and did not 
observe a difference between mice treated with the depleting antibody or the isotype control (Fig. 
2.17C and D). This results can be explained by an emergency release of neutrophils from the bone 
marrow induced by ConA administration. The effect on the ISG response after ConA injection was 
variable between the different ISGs. The expression of IFIT2 was significantly reduced (Fig. 2.17H) in 
Ly6G-depleted animals in comparison to isotype treated animals and CXCL10 and IFIH1 were at least 
partially reduced (Fig. 2.17E and I). No effect could be observed for the ISGs MX1, IFIT1 and OAS1A 
(Fig. 2.17F, G and J). 
These results indicate that neutrophils only partially contribute to ISG induction, although the data 
need to be interpreted carefully with regard to the incomplete neutrophil deletion. 
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Figure 2.17 Neutrophils contribute to cGAS-dependent ISG upregulation after ConA injection  
A) Gating strategy for identification of neutrophils in full blood as CD3-, CD45+, Ly6G/C high(Gr1) and CD115-.B) Quantification 
of neutrophils 24h after antibody administration by FACS. C) ISG expression in Ly6G-depleted (1A8) or isotype-treated (2A3) 
Wildtype mice injected with PBS or ConA (15 mg/kg) for 12 h. ISGs were quantified in white blood cells by qPCR (n=10). Data 
were analyzed by Mann-Whitney test, α=0,05, *p<0,05, values represent the p-value. Data are presented as mean±SD. 
Results 
38 
 
3.4.6 NET formation induces ISG expression in vivo 
Since neutrophil depletion was incomplete, I tested the contribution of NET formation to the induction 
of ISGs genetically. As shown before, Cybb-/- mice are not capable of producing NETs in response to 
ROS-inducing stimuli such as PMA or ConA. Upon ConA injection Cybb-/- mice expressed significantly 
lower amounts of transcripts for the ISGs IFIT2, IFIH1 and OAS1A as Wildtype animals and two other 
ISGS, MX1 and IFIT1, showed the same trend (Fig. 2.18).  
These data strongly suggest that NET formation also plays a role in ISG induction in vivo. 
 
Figure 2.18 NETs induce ISG upregulation in ConA injected mice  
Expression levels of ISGs in white blood cells of Wildtype and Cybb-/- mice 12 h after injection with either PBS or ConA (15 
mg/kg) (n=10). Data are plotted as mean±SD and analyzed by Mann-Whitney test, α=0,05, *p<0,05 **p<0,01 ***p<0,001 
****p<0,0001, values represent the p-value. 
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2.5 NET induced TIIFN expression is dependent on Cathepsins in vitro but not in vivo 
In the previous sections I demonstrated that NETs can escape the phagosome and enter the cytoplasm 
where they activate cGAS and induce TIIFN, both in vitro and in vivo. In this section, I want to 
investigate the molecular mechanism for this phagosome escape. A study from 2015 shows that silica 
particles are liberated from the phagosome by a combination of Cathepsins 177. Cathepsins are a family 
of endoproteases that consists of 15 different enzymes with different catalytical mechanisms. 
Azurophilic granules of neutrophils contain Cathepsin G, a serine protease that digests phagocytosed 
pathogens 178. Other neutrophil-expressed Cathepsins, Cathepsin B, C and S, are cysteine proteases 
and fulfill a variety of functions in the cell.  
To test the role of Cathepsins in NET-induced TIIFN expression I co-cultivated human PBMCs with PMA-
stimulated neutrophils in the presence of the pan-Cathepsin inhibitor K777 179 and observed a 
significantly reduced expression of TIIFN in cells treated with the inhibitor (Fig. 2.19A). I performed a 
NET formation assay in the presence of K777 and observed no difference in comparison to the 
untreated control (Fig. 2.19B). This result indicates that the measured effect on TIIFN expression is due 
to Cathepsin inhibition and not due to inhibited NET formation. 
To show that Cathepsins also play a role in vivo, I tested mice carrying a triple knockout for the 
Cathepsins B, C and S (BCS TKO mice). BCS TKO mice presented comparable amounts of neutrophils in 
blood when compared to Wildtype mice (Fig. 2.19C). BCS TKO mice injected with ConA showed a 
increased levels of liver damage compared to Wildtype mice, which I assessed by measurement of the 
liver enzymes ALT and AST in serum (Fig. 2.19D and E). Furthermore, sera of ConA injected BCS mice 
contained equal amounts of NETs and nucleosomes (Fig. 2.19F and G). I subsequently assessed ISG 
expression in white blood cells of ConA injected mice. None of the measured ISGs showed as significant 
difference when comparing Wildtype and BCS TKO mice (Fig. 2.19H-M). 
The observation that Cathepsins are required for the NET-induced TIIFN expression in vitro could not 
be validated in vivo. To finally determine their role in NET release from the phagosome, further 
experiments are required. 
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Figure 2.19 BCS TKO mice produce reduced ISGs after stimulation with ConA 
A) Co-cultivation of PBMCs with PMA-stimulated neutrophils in the presence of the pan-Cathepsin-Inhibitor K777 (10 µM). 
IFNA1 expression was quantified by qPCR, results are normalized to the co-cultivation without inhibitor (n=5). B) NET 
formation of PMN stimulated with 100 nM PMA in the presence of K777 was quantified by immunofluorescence staining 
(n=3). C) Quantification of whole blood neutrophils by FACS. Neutrophils were defined as CD3-, CD45+, Ly6G/C high (Gr1) and 
CD115-. D/E) Quantification of liver damage after 12 h of ConA measured by ALT/AST concentrations in serum. F/G) 
Concentration of NETs and nucleosomes in sera of ConA injected mice after 12 h. H-M) ISG expression levels in Wildtype and 
BCS TKO mice injected with either PBS or ConA (12 h, 15 mg/kg) were quantified by qPCR (n=12). Data are plotted as mean±SD 
and analyzed by Mann-Whitney test, α=0,05, *p<0,05 **p<0,01 ***p<0,001 ****p<0,0001, numerical values depict actual p-
values. 
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3 Discussion 
Neutrophils play a central role in the defense against invading pathogens, both by exerting a variety of 
antimicrobial effector functions and by recruiting additional immune cells to the locus of infection. 
One of the most important neutrophil effector functions is the release of NETs into the extracellular 
space, a composite of chromatin and antimicrobial molecules that can trap and kill invading microbes. 
Under healthy conditions, nucleases cleave NETs and macrophages dispose remnants by phagocytosis. 
If this clearance system is impaired, NETs remain in the circulation and induce the production of pro-
inflammatory cytokines by activating immune cells. These cytokines can promote disease progression 
and deteriorate the outcome of the affected patients. How exactly NETs induce cytokine expression is 
not completely understood. In this thesis, I show that NETs induce TIIFN expression in human and 
murine immune cells in vitro by activating the cytosolic DNA sensor cGAS. I recapitulated this finding 
in an in vivo mouse model of systemic NET induction, showing its physiological relevance. This finding 
does not only represent an interesting insight into a self-activating mechanism of the immune system 
under pathological conditions, but also provides a possibility for new intervention strategies for a 
growing list of NET-associated diseases. 
 
Figure 3.1 Recognition of NETs by the cGAS STING pathway 
Neutrophils produce NETs that are digested by DNAse1 and phagocytosed by target cells. After liberation from the 
phagosome, NETs are recognized by cGAS, resulting in the production of the second messenger cGAMP and the activation of 
the signaling adaptor STING. STING and TBK1 induce the phosphorylation of the transcription factor IRF3 that translocates to 
the nucleus and induces TIIFN expression.  
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3.1 Recognition of NETs by cGAS – a new perspective in understanding disease 
development 
3.1.1 cGAS as a receptor of NETs 
cGAS is a cytosolic DNA sensor that evolved to recognize viral genomes and bacterial DNA. Due to its 
sequence-independent sensing mechanism, cGAS also recognizes self-DNA. In fact, cGAS senses 
mitochondrial DNA, DNA damage side products, endogenously amplified retroelements and chromatin 
fragments in vivo 130,180,181. Notably, these self-ligands originate from cell intrinsic events and 
accumulate due to defects in the clearance system. In this thesis, I present NETs as a naturally occurring 
substrate of cGAS. To my knowledge, NETs are the first endogenous extracellular DNA-containing 
stimulus that activates cGAS in immune cells.  
For in vitro experiments, most publications fall back to plasmid or artificially generated DNA species 
182,183. Although these experimental systems are required to further elucidate the function and 
mechanism of cGAS, they are artificial in the sense that the DNA is not protein-bound as it occurs in 
nature. Furthermore, entry into the cell requires transfection. NETs, on the other hand, have a 
distinguished position among self-molecules as an extracellular source of protein-DNA complexes that 
activate the immune system. NETs represent naturally occurring DNA bound to different molecules 
like histones, nucleosomes, HMGB1 and others, individually described as DAMPs. Interestingly these 
molecules are intrinsically immunostimulatory and can activate different PRRs 184. Furthermore, NETs 
carry different antimicrobials like NE and LL37, which might facilitate the release of NET material from 
the phagosome into the cytoplasm. By combining these two characteristics, NETs specifically provide 
all requirements to be a potent activator of cGAS, by combining the substrate of the enzyme and 
accessory molecules facilitating the release from the phagosome into the cytoplasm. 
3.1.2 DNAse insufficiencies – the crossroads where NETs and cGAS meet 
Malfunctions in DNAses are associated with diseases like the Aicardi-Goutière syndrome, SLE or 
familial chilblain lupus 108,109,148,185. These examples point out the importance of DNA clearance to avoid 
immunopathology. During the interplay between NETs and cGAS, both partners require functional 
nucleases to avoid unwanted immune cell activation. The recognition of self-DNA by cGAS is mostly 
described in the context of impaired DNA clearance due to missing intracellular nuclease activity in the 
lysosome or the cytoplasm. The two most important intracellular nucleases are the lysosomal DNAse2 
and the cytoplasmic TREX1. TREX1-/- mice suffer from a systemic inflammation, while DNAse2-/- mice 
die in utero. Both phenotypes are caused by accumulation of self-DNA leading to uncontrolled TIIFN 
production and can be rescued by depletion of cGAS or IFNAR 144,147. These reports show that cGAS can 
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be activated by self-DNA in the context of nuclease insufficiency. The clearance of genetic material by 
DNAse1 in blood on the other hand is described to be important to avoid undesired immune activation 
101,186. This genetic material can originate from NET formation, but there are also other potential 
sources, like damaged necrotic endothelium 98. In SLE, insufficient DNAse1 activity is caused by a 
variety of factors, e.g. mutations, binding of autoantibodies or inhibition by other molecules. 
Interestingly, also mutations of TREX1 and DNAse2 are associated with SLE development. To 
summarize, the insufficient clearance of NETs by extracellular DNAse1 can result in prolonged 
exposure that might lead to uptake of NETs and the activation of cGAS. 
The experimental conditions chosen for the cocultivation experiment (Fig 2.7) resemble the situation 
in patients with SLE. While the intracellular DNAses are functional, DNAse1 does not degrade NETs in 
the extracellular space. Notably, NETs induce cGAS dependent TIIFN expression with the intracellular 
DNAses are functional. Hakkim et al. show that NETs are stable for up to 90 h in vitro in the absence of 
DNAse1 101, resulting in prolonged exposure of NETs to the target cells. The half-life of NETs in 
circulation or tissues is not known. I repeated the cocultivation in the presence of DNAse1, expecting 
an abrogation of TIIFN expression due to NET degradation. Surprisingly, I observed the opposite effect 
(Fig. 2.9). One possible explanation is that a certain size of NETs favors their uptake by target cells. 
Alternatively, cGAS could recognize NET fragments of a certain size or accessibility better than large 
compact structures. My data support the second explanation, because I observed that recombinant 
cGAS poorly responds to large NET structures, but shows strong activation when NETs are processed 
by DNAse1(Fig. 2.2). This observation does not rule out the first explanation, both mechanisms might 
apply in parallel. 
3.1.3 TIIFN in NET-associated diseases 
An extending list of diseases is either indirectly or directly associated with NETs. These “NETopathies” 
do not only include autoimmune and auto-inflammatory diseases like gout, RA , vasculitis, psoriasis 
and SLE, but also metabolic disorders like diabetes, lung diseases like cystic fibrosis and COPD, and 
cancer 187. However, care must be taken when evaluating the impact of NETs on a disease, because 
some publication infer NET-involvement simply from measuring NET components in circulation. Since 
the detection of NETs in serum and tissue samples remains difficult, further research might add more 
diseases to that list. To complicate matters further, NET-bound proteins have a high intrinsic affinity 
to bind DNA. Antimicrobial molecules like LL37 could be released by neutrophils during degranulation 
and bind DNA from another source, resulting in NET-like structures that are not neutrophil derived.  
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A majority of the listed diseases are not only associated with NETs, but also with TIIFN. SLE, as the most 
prominent example, shows a global upregulation of ISGs, resulting in a characteristic TIIFN signature 
91,92. This signature can also be found in in a subset of patients suffering from RA, which show a 
particularly poor outcome 188. In skin lesions of psoriasis patients ISGs like IFI27, IFI56 and MX1 are 
upregulated and form a psoriasis TIIFN signature 189,190. 
TIIFN are not only inhibitors of viral amplification. As activators of the immune system they can actively 
drive disease progression of autoimmune and autoinflammatory diseases. They influence the immune 
system on three levels. i) They directly induce the secretion of pro-inflammatory cytokines from other 
immune cells. ii) They intensify the immune functions of other immune cells, like antigen presentation 
by professional APCs, the release of pro-inflammatory cytokines by macrophages or autoantibody 
formation by plasma cells. Interestingly, up to 19 % of cancer patients treated with TIIFN produce 
autoantibodies 191,192. iii) They shape the microenvironment by inducing chemokine release resulting 
in increased immune cell recruitment or influence the differentiation of immune cells, e.g. by driving 
monocytes towards a DC-phenotype 193,194.  
Taken together, TIIFN are not only a marker of pathologic immune activation in autoimmune diseases, 
but actively contribute to development and the progression of these diseases. 
3.1.4 NETs as a stimulus for TIIFN production 
The fact that NETs serve as a stimulus for TIIFN production has far-reaching consequences. It 
substantiates the notion that NET formation is not only a symptom of a generally activated immune 
status in patients, but also becomes a driving factor in the pathogenesis and the progression of 
diseases. In a non-autoimmune setting on the other hand, NET induced TIIFN production might also 
have a positive effect, because it induces the upregulation of innate and adaptive defense mechanism, 
which could help the fight invading pathogens and prevent further dissemination in the host. Although 
it was reported before that NETs induce TIIFN production in other immune cells 84,85, a deeper 
understanding of how NETs are recognized by the immune system is needed.  
Since NET formation is a process that is specific to neutrophils, I was able to induce NETs with PMA, 
while the target cells like PBMCs and macrophages remained unaffected. This makes it intrinsically 
difficult to compare NET formation to other forms of cell death, because the target cells would also 
respond e.g. to inducers of apoptosis like cis-platin or ultraviolet light. This is an experimental 
drawback of this work that could not be circumvented. 
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Two different publications from 2016 show that the mtDNA that is present in NETs is the main inducer 
of TIIFN production and that the genomic DNA in NETs is less interferogenic 85,115. In my experiments, 
isolated mtDNA alone does not induce TIIFN production in human primary cells (Fig. 2.5). This 
discrepancy might occur because the mtDNA used in the publications was artificially oxidized 
subsequent to the isolation and transfected into the target cells to induce TIIFN production. Whether 
mtDNA expelled during NET formation plays a role in TIIFN induction cannot be concluded from the 
experiments performed in this thesis, but merits further investigation. 
A proposed candidate for NET recognition is TLR9. Although TLR9 was not required for NET recognition 
in my experimental setting (Fig. 2.5; Fig. 2.8), different groups report TLR9-dependent TIIFN production 
by pDCs that were stimulated with NETs or complexes of DNA and the antimicrobial peptide LL37 in 
vitro 81,84,87. The results of a TLR9-/- in different mouse models of SLE are controversial. A TLR9 knockout 
in the lupus-prone MRL.FASlpr background results in a exacerbated lupus phenotype 116,117, an 
observation that was recapitulated in a model of pristine-induced lupus 195. On the other hand, reports 
show that a blocking of TLR9 by chemical antagonists leads to an ameliorated phenotype in MRL.FASlpr 
mice and that TLR9 knockout is beneficial in pristine induced lupus 196,197. The conflicting data could 
indicate the involvement of an alternative receptor that recognizes NETs.  
In this thesis, I show that cGAS is a NET receptor and thereby it could contribute to disease. In fact, 
changes in cGAS expression is associated with the prime example of a NET-associated diseases, which 
is SLE. PBMCs of SLE express higher levels of cGAS when compared to healthy donors, positively 
correlating with the expression of the ISGs MX1, CXCL10 and protein kinase R. cGAMP, the second 
messenger produced by cGAS, was detected in the PBMCs of a subset of SLE patients by mass 
spectrometry, whereas healthy controls and PBMCs of RA patients remained negative 198. The finding 
that oxidized DNA, as it is also present in NETs, can induce TIIFN production in a STING-dependent 
manner, supports the observation that cGAS is a receptor of NETs 85. Furthermore, stimulation of 
monocytes with DNA-LL37 complexes results in STING-dependent TIIFN production, supporting the 
observations made in this thesis 114. Interestingly, Chamilos et al. (2012) report that pDCs are sensitive 
for TLR9 inhibition by Bafilomycin A1 when stimulated with DNA-LL37 complexes, whereas monocytes 
are not affected. This finding suggests that different cell types might utilize different receptors for NET 
recognition. 
By inducing TIIFN, NETs do not only contribute to general activation of the immune system, but they 
also induce further stimulation of other neutrophils. Human neutrophils primed with TIIFN are 
reported to produce NETs upon stimulation with autoantibodies 84. This could result in an ongoing 
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inflammatory circuit that could be accountable for the disease flares observed in SLE (Fig.3.2). 
Moreover, NET formation could link the two molecular hallmarks of SLE, which are the production of 
autoantibodies and the TIIFN signature. In this model, neutrophils would undergo NETosis, either 
spontaneously as reported for SLE LDGs or after stimulation with immune complexes 67,84. The resulting 
NETs, which are not degraded due to DNAse1 insufficiency, remain in circulation and activate the two 
arms of the immune system in parallel. Innate APCs recognize NETs by cGAS and produce TIIFN that 
further activate the immune system and prime neutrophils to undergo NETosis. In parallel, the 
adaptive immune system produces autoantibodies recognizing NET proteins, further stimulated by 
TIIFN. By binding their antigen, they form immune complexes that in turn activate neutrophils to 
undergo NETosis, so that the cycle starts again. 
 
Figure 3.2 NET formation as the driving force in inflammatory diseases  
Primed neutrophil undergo spontaneous NET formation in autoinflammatory diseases. Due to defective clearance 
mechanisms, NETs are taken up by APCs and activate cGAS-mediated TIIFN production. TIIFN simultaneously prime 
neutrophils for further NET formation, as well as B cells to produce increased amount of autoantibodies. Autoantibodies form 
immune complexes by binding their antigen, which cause both endothelial tissue damage and neutrophil activation. 
 
3.1.4 cGAS as a therapeutic target in NET-associated diseases 
Due to their involvement in a multitude of diseases, NETs and NET-mediated effects are a promising 
therapeutic target. In NET-associated autoimmune diseases TIIFN are the target in a variety of clinical 
studies applying monoclonal antibodies. Sifalimumab and Rontalizumab, both IFNα-depleting 
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antibodies, were tested in a phase 2 clinical trials and significantly reduced the TIIFN signature in 40-
50 % of the SLE patients 199,200. Furthermore, blocking of the IFNAR receptor using the monoclonal 
antibody Anifrolumab significantly reduced disease activity in a clinical phase 2 trial 201,202. The 
usefulness of this clinical TIIFN reduction is further consolidated by the observation that a subgroup of 
SLE patients spontaneously develop anti-IFNα-antibodies. Their appearance correlates with reduced 
ISG expression and an diminished disease activity, resulting in an improved outcome 203. 
Even more useful than a retroactive targeting of inflammatory mediators would be the development 
of treatment approaches aiming to avoid the formation of these. I show that cGAS is a promising 
candidate for this kind of intervention, because it is the initial receptor of a potentially self-amplifying 
system of TIIFN and NET formation. Different inhibitors are under development 204 and targeting of 
cGAS by a small molecule inhibitor resulted in reduced TIIFN expression in macrophages of a 
interferonopathy mouse model of Aicardi-Goutières syndrome 168.  
Interestingly, another treatment option frequently applied in the NET-associated diseases SLE are 
antimalarials, especially hydroxychloroquine (HCQ) 205. HCQ administration reduces flares, organ 
damage and thrombotic events. Furthermore, the overall survival of SLE patients is increased by HCQ 
treatment 206. Additionally, it allows a reduced steroid administration 207. Initially discovered as an 
antimalarial drug that prevents the blood stage progression of Plasmodium falciparum, its mode of 
action in autoimmune diseases is not completely understood. Potential mechanism are the inhibition 
of autophagy that results in a reduced production of pro-inflammatory cytokines like IL1β, IL6 and TNF 
208 or the inhibition of TLR9 signaling 209. Importantly, antimalarials like quinacrine, HCQ and 9-amino-
6-chloro-2-methoxyacridine were recently shown to inhibit cGAS activation by blocking its interaction 
with DNA 210,211. Also patients suffering from RA, a disease associated with both NETs and cGAS 
contributing to disease progression, are treated with antimalarials 212,213. Although cGAS inhibition by 
antimalarials might not be an exclusive mechanism, the fact that NET-associated diseases are already 
treated with cGAS inhibitors supports the importance of the findings reported in this thesis.  
The concept of interfering with NET recognition to reduce TIIFN might also be applicable in Malaria 
itself. Malaria is a disease caused by infection with the parasite P. falciparum. During its life cycle 
malaria parasites infect red blood cells and lyse them simultaneously resulting in periodically 
reoccurring fever. Disease progression is driven by an array of pro-inflammatory cytokines that are 
induced by the parasite itself or the release of bioactive molecules like hemozoin. Among these 
cytokines are TNF, IL1α, IL1β and TIIFN 214. TIIFN play an important role in Malaria pathogenesis. 
Different studies indicate that TIIFN are required to contain the parasite but also in contributing to 
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vascular damage, indicating that a tight regulation of TIIFN is required 215. Plasmodium-induced TIIFN 
production can be induced by a variety of different PRRs, such as TLR9 and TLR4. Also cGAS is reported 
to sense parasite derived DNA in Malaria infection 216. In the light of the discovery made in this thesis, 
cGAS could also contribute by another mechanism to TIIFN-driven Malaria pathogenesis. There are 
different indications that NETs might play a role in Malaria pathogenesis. Indeed, an accumulation of 
NET-associated proteins is described for pediatric patients suffering from cerebral Malaria, a severe 
variant of Malaria affecting the brain. Another report directly shows NETs in blood smears of pediatric 
Malaria patients 217,218. According to my results, these NETs could also be recognized by cGAS and 
induce increased production of TIIFN, thereby contributing to an inflammatory feed-forward loop as 
described above for SLE. Notably, TIIFN primed neutrophils are shown to contribute to vascular 
damage in Malaria, one of the major risk factors in Malaria pathogenesis 219.  
3.2 Escape of NETs from the phagosome into the cytoplasm 
cGAS and NETs have to get in contact to induce TIIFN production. One possibility is that cGAS migrates 
to the phagosome and recognizes NETs there. cGAS is only known as a cytoplasmic protein and to date, 
no translocation of cGAS to the phagosome is described. Alternatively, NETs could escape from the 
phagosome to activate cGAS in the cytosol. There are different potential mechanisms how NETs could 
pass the membrane. 
Inflammasomes are multi-protein complexes that recognize a variety of ligands. The NLRP3 
inflammasome senses large crystalline structures, like silica or mono-sodium ureate crystals. These 
structures are internalized by macrophages by phagocytosis and also need to escape into the 
cytoplasm to activate the cytosolic receptor NLRP3. In 2015 Orlowski et al. demonstrated that 
Cathepsins, intracellular serine proteases, facilitate the liberation of crystals from the phagosome and 
mediate NLRP3 activation. Since NETs are also large structures, I reasoned that a similar mechanism 
might apply during their release. Initially, in vitro cocultivation of PMA-stimulated neutrophils and 
PBMCs in the presence of the pan-Cathepsin inhibitor K777 substantiated this assumption, because 
only reduced amounts of TIIFN were expressed (Fig. 2.19A). This phenotype was not reproduced in my 
in vivo mouse model when I tested mice carrying a triple knockout for the Cathepsins B, C and S (Fig. 
2.19). This discrepancy could be caused by missing specificity of K777. Alternatively, K777 could inhibit 
a Cathepsin other than B, C or S. To finally solve this questions, an in vitro system for the activity of 
different Cathepsins in the presence of K777 would need to be established.  
As described above, NETs are a very potent immune-stimulators, because they combine different 
DAMPs in one complex. Some of these molecules have the ability to alter membrane characteristics 
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and thereby allow escape of NETs from the phagosomes. NETs contain histones that are bound to the 
DNA as nucleosomes. Histones can be liberated from DNA when the surrounding milieu is acidic, like 
in the phagosomes of macrophages. This results in free highly charged histones that can bind the 
phosphodiester bonds of membrane phospholipids, inducing changes in membrane permeability. This 
could lead to the disruption of membranes and liberation of contained material, as shown for the lysis 
of endothelial cells by histones  220,221. 
An antimicrobial protein that has similar characteristics to histones and is present in NETs is LL37. 
Similar to histones it has a high positive charge and could be released from NETs in an acidic 
environment like the phagosome. LL37 was shown to destabilize membranes by formation of 
membrane pores 222. In complex with DNA, as it would occur in NETs, LL37 was described to induce 
TIIFN expression in pDCs 81, suggesting that it might support NET uptake. 
Another NET-bound protein that is of interest in this context is high-mobility group box-1 (HMGB1). 
HMGB1 is a chromatin remodeling enzyme that has two DNA binding motifs. Apart from that, it is a 
potent alarmin that is actively released by monocytes and macrophages, but also passively during lytic 
cell death 223. HMGB1 was shown to be present on NETs and is  involved in NET-mediated TIIFN 
induction in pDCs 84. HMGB1 can bind to the receptor of advanced glycation end-products (RAGE) and 
induce dynamin-dependent endocytosis. In this context, HMGB1 was shown to damage lysosomal 
membranes and confer liberation of intra-lysosomal content 224. Although DNA import by RAGE alone 
is possible, HMGB1-RAGE interaction was shown to be required for lysosomal damage and the 
establishment of a potent TIIFN response towards DNA and RNA 225,226. Only recently HMGB1 was 
reported to enhance cGAS activation by forming DNA-protein ladders that allow enhanced binding of 
cGAS 227. 
The potential mechanisms suggested above have in common that NET-bound factors interfere with 
membranes and thereby could facilitate the release of NETs from phagosomes. Alternatively, cytosolic 
factors of the target cells that have taken up the NETs might contribute to the transport of NETs into 
the cytoplasm.  
SID1 transmembrane family member 2 (SIDT2) is a transmembrane protein localized at the membrane 
of lysosomes. It shuttles dsRNA from the lysosome to the cytoplasm, where it is recognized by PRRs 
like mitochondrial antiviral signaling protein (MAVS) and RIG-I, in order to allow a fast recognition of 
extracellular viral material 228. Interestingly, SIDT2 was shown to be able to transport DNA and work in 
a bidirectional fashion 229. By actively exporting DNA from the lysosome into the cytoplasm, SIDT2 or 
related protein could contribute to the recognition of NET-fragments by cGAS.  
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Another possible mechanism that could allow the transport of NET components into the cytoplasm is 
the sampling machinery for the cross presentation of foreign antigens on major histocompatibility 
complex I (MHC-I) molecules. For the purpose of antigen presentation, molecules from the inside of 
the phagosome need to be exported by a channel into the cytoplasm 230. Although the exact 
mechanism is still elusive, it is known that phagosomal content needs to be processed by the 
Endoplasmic reticulum-associated degradation (ERAD) in the cytoplasm  to be further loaded on MHC-
I 231. During this process, NETs could have contact with cGAS. 
3.3 ConA injection as a new in vivo model of systemic NET formation 
The field of NET research lacks reliable in vivo systems to investigate the effect of NETs on other blood 
cells or endo- and epithelial cells. To date, most in vivo NET mouse models are based on injection of 
microbial components or infection of the animals. It is reported that a model of LPS-induced sepsis 
results in NET formation in the liver and induces thrombosis 173. Also infections of mice with S. flexneri, 
S. aureus or C. albicans induce NET formation in vivo 33,174,186. These models, however, have the 
constraint that NETs were only described at local sides of infection, like the lung in the case of C. 
albicans or the liver in case of S. aureus. In addition, injection of PAMPs or infections causes expression 
of inflammatory cytokines like TIIFN by activating various PRRs independently of the desired NET 
production. Investigating the contribution of a single receptor or signaling molecule might therefor be 
difficult. In order to investigate the effect of NET formation as it occurs in SLE for example, these 
models are less applicable. To circumvent this problem and mimic systemic NET formation, Lood et al. 
injected oxidized DNA, a component of NETs, i.v. together with DOTAP, a transfection reagent 85. 
Although this approach is more closely related to pathological situations like in SLE, the co-injection of 
a transfection reagent might influence the outcome of the experiment. 
In this thesis, I apply the model of ConA-induced autoimmune hepatitis as a systemic model of NET 
formation. ConA administration leads to the antigen-independent activation of cytotoxic T cells and 
hepatic Kupffer-cells, which release high amounts of TNF that is toxic for the endothelial layer and the 
hepatocytes residing below 175. Only recently, ConA was shown to induce NETs in vitro 174. Here I report 
for the first time that ConA also induces NET formation in vivo (Fig. 2.14). This model has different 
advantages. Successful ConA injection can be verified by quantifying the liver enzymes AST and ALT, 
which serve as surrogate markers for liver damage. Since the resulting NET induction is systemic, an 
ELISA can be used to quantify NETs in serum and compare NET concentrations between different 
genotypes (Fig. 2.14). As presented in this study, systemic NET induction has an effect on the global 
expression of ISGs (Fig. 2.16), while, at least to my knowledge, no background TIIFN expression is 
reported in the literature. This notion is supported by my human cocultivation experiment of PBMCs 
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and neutrophils in the presence of ConA, where ConA treatment alone does not induce TIIFN, while 
neutrophils and ConA together induce TIIFN expression in PBMCs (Fig. 2.7). The experiments can be 
performed very rapidly compared to infection models. The system also has some drawbacks. The 
efficiency of ConA injection is variable between different animals (Fig. 2.14). Although ALT/AST values 
deviate between the different animals, all animals injected show significant ALT/AST release compared 
to uninjected animals. This variability is observed in multiple experiments and may result in differential 
levels of NET production that ultimately leads to different levels of ISG expression. The reason for this 
variability is not clear. Since the mice in one group are of the same background, sex and age, the 
experimental variability has to be attributed to the ConA injection procedure. Another drawback is 
that ConA induces massive liver damage and hepatocyte death, which results in the release of DAMPs 
like nucleosomes into the extracellular space. Although the NET ELISA allows accurate quantification 
of NETs and also a distinction between NETs and other DAMPs (Fig. 2.14D and E), it is hard to estimate 
the bias introduced by DAMPs from other dying cells or neutrophils undergoing degranulation. 
The depletion of neutrophils did not result in an effect on ISG expression in this model (Fig. 2.17E-J). 
Although the FACS analysis showed that the antibody-mediated depletion was successful in blood (Fig. 
2.17B), depleted mice still displayed NETs in their serum after ConA administration (Fig. 2.17C). This 
indicates that either there were enough remaining neutrophils to produce sufficient amount of NETs 
for cGAS activation or that the pool of depleted neutrophils is replenished during the experiment. In 
fact, during inflammatory conditions, like a systemic bacterial infection, the bone marrow is able to 
rapidly release tremendous amounts of neutrophils during a process called emergency granulopoiesis. 
This process is described both in humans and mice 232, and might very well be activated by ConA, either 
directly by its function as a mitogen or indirectly by causing hepatocyte death related cytokine 
production.  
Interestingly, not all ISGs are regulated the same way when I compared different genotypes. Although 
the ISGs have in common that they are expressed upon IFNAR activation, they can also be induced by 
other signaling pathways independently of IFNAR engagement. CXCL10, for example, is the only ISG 
that is not downregulated in ConA stimulated Cybb-/- mice, when compared to Wildtype (Fig. 2.18 A). 
Apart from being activated by TIIFN signaling, CXCL10 is also upregulated by NFκB signaling (nuclear 
factor 'kappa-light-chain-enhancer' of activated B-cells), a transcription factor induced by a variety of 
other pathways, including TNF signaling. This could provide the explanation for the missing phenotype 
in Cybb-/- mice, because the TNF induced by the liver damage could upregulate CXCL10 independently 
of TIIFN 233.  
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Taken together, the applied ConA model combined with the NET ELISA allows a quantifiable systemic 
NET induction and opens the opportunity to investigate the effects of NETs on other immune cells.  
3.4 Interaction of cGAS with other receptors 
A group of innate DNA sensors execute the recognition of dsDNA in the cytoplasm that comprises, 
among others, cGAS, IFI16 and AIM2. Although each of them is a DNA sensor per se, they do not work 
as separated entities, but rather interact and regulate each other 234.   
IFI16, a DNA sensor structurally related to AIM2, has a high binding affinity towards dsDNA. Two 
publications describe IFI16 as a co-factor required for potent cGAS activation in both human 
macrophages and keratinocytes 183,235. The papers suggest that IFI16 is both important for cGAS binding 
to DNA but also for activation of STING by cGAMP. My results, achieved by stimulation of PMA-
differentiated THP-1 cells as in Almine et al., do not support this observation (Fig. 2.5E). In my hands, 
IFI16-/- clones and cells of the positive control produced comparable amounts of TIIFN. This might be 
due to the different stimulus that is applied. While the Cytomegalovirus infection used in the 
publication transfers only a small amount of DNA into the target cells, the NET treatment used in my 
study might introduce larger amounts of DNA, and a supporting co-factor for enhanced DNA binding 
is no longer required. There is no direct ortholog of IFI16 in mice, but a mouse with depleted PYHIN-
encoding genes (a domain also found in IFI16) does not show alterations in DNA sensing 236, supporting 
my observation that IFI16 is dispensable for cGAS activation. 
Another DNA receptor undergoing mutual regulation with cGAS is AIM2. In primary murine BMM I 
observed increased TIIFN production following NET stimulation after silencing of the AIM2 
inflammasome pathway. This occurred independently of whether the priming (MyD88-/-), the DNA 
sensor (AIM2-/-) or the executing caspases (CASP1/11-/-) were affected (Fig. 2.6D). This result indicates 
that AIM2 is a negative regulator of cGAS activation, a result supported by recent literature. Banerjee 
et al. describe that AIM2 activation results in GSDMD pore formation and a subsequent K+ efflux from 
the cell that has an inhibitory effect on cGAS activation 237. Another publication reports an 
overproduction of IFNβ in a M. tuberculosis infection model in an AIM2-/-  background. They show that 
apoptosis-associated speck-like protein (ASC) interferes with the interaction of TBK1 and STING, 
downstream of cGAS 238. Lastly, AIM2 activation induces caspase1 dependent cleavage of cGAS, 
resulting in decreased TIIFN production 239. In addition to the mechanisms mentioned above, blocking 
of pyroptosis by inflammasome inhibition generally results in a prolonged life-span and allows 
increased production of TIIFN. 
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I also observed increased AIM2-mediated IL1β production in cGAS-/- BMM when compared to 
Wildtype, while NLRP3 activation remained unchanged (Fig. 2.6E). This indicates that cGAS is a negative 
regulator of AIM2, a notion that is in opposition with the recent literature. Different papers show that 
activation of the cGAS-STING pathway has a priming effect on inflammasome activation. This occurs 
either directly by driving IFNβ production, which is an external priming signal for inflammasome 
activation or by producing cGAMP, which induces IL1β production by a AIM2-dependent mechanism 
240.  
Taken together, these findings indicate that cGAS activation by NETs is not an isolated immunological 
signaling event, but rather incorporates into a complex signaling network of different receptors and 
pathways. 
3.5 Conclusion and Outlook 
The results presented in this thesis contribute to answering the central question of how a specific form 
of neutrophil cell death can contribute to the development and progression of autoinflammatory 
diseases. It closes the gap between the undesired production of NETs and the expression of TIIFN, a 
group of pro-inflammatory cytokines that are involved in a plethora of different diseases by showing 
that NETs are recognized by the cytosolic DNA sensor cGAS, which controls TIIFN expression. My data 
describe a hitherto unknown process by which cGAS is activated in the cytoplasm of an intact 
phagocytic cell that has feasted upon NETs. In doing so, I am the first to present NETs as a self-ligand 
of an extracellular source that is able to activate cGAS leading to the production of TIIFN. These findings 
have implications for a growing list of NET-associated diseases, because it helps on the one hand to 
understand their etiology and on the other hand it opens a window for the development of new 
treatment strategies, which hopefully will bring improvement to the affected patients.  
A possible next step would be to investigate the role of cGAS activation by NETs in murine models for 
SLE like the DNAse1L3-/- mouse, which spontaneously develops a lupus-like phenotype. To test the 
effect of cGAS in this model, the mice could be treated with pharmacological inhibitors of cGAS like 
RU.521 or they can be crossed onto a cGAS-/- background. Furthermore, I would address the question 
how NETs escape from the phagosome, by inhibiting the HMGB1-RAGE pathway or SIDT2 with small 
molecule inhibitors. 
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4 Material and Methods 
4.1 Material 
4.1.1 Eukaryotic and prokaryotic Cells 
Eukaryotic cells – cell lines 
Name Origin Medium and culture conditions 
HEK-Blue™ IFN-
α/β Cells 
(Invivogen) 
 
human, embryonic kidney cell line 
carrying SV40-large T antigen 
DMEM basic medium, 37°C, 5 % CO2 
 split every 3 days at ratio 1:5 
HEK293T human, embryonic kidney cell line 
carrying SV40-large T antigen 
 
DMEM basic medium, 37°C, 5 % CO2 
 split every 3 days at ratio 1:5 
THP-1 human, monocytic leukemia RPMI basic medium, 37°C, 7 % CO2 
 split every 3 days at ratio 1:5 
 
L929 ISRE luc murine, fibroblast DMEM basic medium, 37°C, 5 % CO2 
 split every 3 days at ratio 1:5 
 
Immortalized 
Balb/C 
Macrophages 
Murine, macrophage DMEM basic medium, 37°C, 5 % CO2 
 split every 3 days at ratio 1:5 
 
Eukaryotic cells – primary cells 
Genotype Origin Medium and culture conditions 
Wildtype murine, primary cells 
from bone marrow 
DMEM with 10 % FCS, Q, P/S and 20 % L-cell 
supernatant containing mMCSF 
 
AIM2-/- murine, primary cells 
from bone marrow 
DMEM with 10 % FCS, Q, P/S and 20 % L-cell 
supernatant containing mMCSF 
CASP1/11-/- murine, primary cells 
from bone marrow 
DMEM with 10 % FCS, Q, P/S and 20 % L-cell 
supernatant containing mMCSF 
cGAS-/- murine, primary cells 
from bone marrow 
DMEM with 10 % FCS, Q, P/S and 20 % L-cell 
supernatant containing mMCSF 
MyD88-/- murine, primary cells 
from bone marrow 
DMEM with 10 % FCS, Q, P/S and 20 % L-cell 
supernatant containing mMCSF 
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Prokaryotic cells 
Name Genotype Application Source 
E. coli 
DH5α 
F-φ80lacZΔM15 Δ(lacZYAargF)U169 
recA1 end A1hsdR17 (rk-,mk-) 
phoAsupE44 thi-1 gyrA96 relA1 λ- 
Chemically competent bacteria 
for plasmid amplification 
Invitrogen 
(Carlsbad, CA, 
USA) 
 
4.1.2 Mouse strains 
 
Strain Short name Description Source 
C57BL/6 
 
Wildtype Wildtype mice in C57BL/6 
background 
 
The Jackson Laboratory 
Mb21d1tm1a(EUCOMM)Hmgu cGAS-/- Strain carrying a knockout of the 
cytosolic DNA sensor cGAS 
Kindly provided by Veit 
Hornung, Genzentrum 
München, Germany 
 
B6.129S6-Cybb 
tm1Din /J 
Cybb-/- KO Strain carrying a knockout in the 
Cybb subdomain of NADPH 
oxidase 
 
The Jackson Laboratory 
B6.129X-Ctsbtm1Vil 
Ctsctm1Ley Ctsstm1Cha/J 
CtsBCS TKO Strain carrying a tripple knockout 
for the Cathepsins B, C and S. 
Kindly provided by Kenneth 
Rock, University of 
Massachusetts, USA 
 
4.1.3 Media 
 
Name Ingredients 
DMEM basic DMEM with 10 % (v/v) FCS, 2 mM L-glutamine, 100 U/ml Penicillin, 100 
µg/ml streptomycin 
 
RPMI basic RPMI with 10 % (v/v) FCS, 2 mM L-glutamine, 100 U/ml Penicillin, 100 µg/ml 
streptomycin 
 
RPMI neutrophil medium RPMI w/o phenol red, 0,2 % HSA, 5 mM HEPES 
 
DMEM BMM DMEM with 10 % (v/v) FCS, 2 mM L-glutamine, 100 U/ml Penicillin, 100 
µg/ml Streptomycinand 20% L-cell supernatant containing mMCSF 
 
freezing medium 90 % FCS and 10 % DMSO 
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4.1.4 CRISPR gRNA 
Target gene number of guide gRNA sequence (no PAM) 5’3’ 
hcGAS 1 GGCCATGCAGAGAGCTTCCG 
hcGAS 2 CTGCCCCCAAGGCTTCCGCA 
hDAI 1 CCTTGAACAAAGAATCCTGC 
hDAI 2 AGGAATGCCAAGCACCCAAG 
hIFI16 1 GACCAGCCCTATCAAGAAAG 
hIFI16 2 CAAGCAGCACTGTCAAAACT 
hIRF3 1 GGGCAGGATCCGTGGCTTTG 
hIRF3 2 TGGTGTCGCAGCTGGACCTG 
hNE 1 ACTCGCGTGTCTTTTCCTCG 
hNE 2 TGCGCCCAACTTCGTCATGT 
hSTING 1 CACTCCAGCCTGCATCCATC 
hSTING 2 CTCCAGCCTGCATCCATCCA 
hTLR9 1 CCGGACTGCCACACTTCACC 
hTLR9 2 GCTCCGAAGCTCCGCTGATG 
mcGAS 1 AGATCCGCGTAGAAGGACGA 
mcGAS 2 GCGAGGGTCCAGGAAGGAAC 
mNE 1 AGAGATTGTTGGTGGCCGGC 
mNE 2 TGACCTGCGGCGACAGGAGC 
mSTING 1 GATGATCCTTTGGGTGGCAA 
mSTING 2 CTCCAAATATGTAGCCCTCA 
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4.1.5 Oligonucleotides 
Primer for qPCR 
species gene orientation sequence 5'3' 
human hIFNA1 fwd TGGAAGCCTGTGTGAT 
  rev ATGATTTCTGCTCTGACA 
 hIFNB fwd GTCAGAGTGGAAATCCTAAG 
  rev CTGTAAGTCTGTTAATGAAG 
 hB2M fwd CTCCGTGGCCTTAGCTGTG 
  rev TTTGGAGTACGCTGGATAGCCT 
     
mouse mCXCL10 fwd CCAAGTGCTGCCGTCATTTT 
  rev CTCAACACGTGGGCAGGATA 
 mGAPDH fwd AACTTTGGCATTGTGGAAG 
  rev ACACATTGGGGGTAGGAAC 
 mIFIH1 fwd ATGGACGCAGATGTTCGTGG 
  rev TCCCTTCTCGAAGCAAGTGTC 
 mIFIT1 fwd TGCTGAGATGGACTGTGAGG 
  rev CTCCACTTTCAGAGCCTTCG 
 mIFIT2 fwd GGAGAGCAATCTGCGACAG 
  rev GCTGCCTCATTTAGACCTCTG 
 mMX1 fwd GATCCGACTTCACTTCCAGATGG 
  rev CATCTCAGTGGTAGTCAACCC 
 mOAS1A fwd GCCTGATCCCAGAATCTATGC 
  rev GAGCAACTCTAGGGCGTACTG 
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Primer for Outknocker 
 
To validate the efficiency of the knock out, the target locus was amplified with the primers indicated 
below, which were fused to the following adapter sequences: 
 
Adapter for Fwd-primer: ACACTCTTTCCCTACACGACGctcttccgatct-primer 
Adapter for Rev-primer: TGACTGGAGTTCAGACGTGTGctcttccgatct-primer 
 
 
Target guide fwd primer 5'3' rev primer 5'3' 
hcGAS 1 TGTGCCCGCCAGTAGTGCTTGGT TTTTCTGCCGGGATCCCGACTTC 
hcGAS 2 GCTGCTGCTGGCTCTTCCTCTTG GGCGCTCTTTTTCTGCCGGGATC 
hDAI 1 TTGCCCTTTCCTCTGCCCTGGAC TGTGAGGGAGACTTTCAACTCCT 
hDAI 2 TGGGGACCTGGGAGACTCAGTTC CAAGGCCAGCTCTGCAGGACCCT 
hIFI16 1 GAACCCTCAAGCAGGAACTGAGA GGACTTGAAGCCTGCTCCTCTTC 
hIFI16 2 CTGCTTCAGCTGTCGGAGATCGT AGAAATAACTGCCTGCTGGAGAG 
hIRF3 1 AAAATATGGGTGAAGGACCTGTG GAAATCCTCCTGCTGTGCATCCT 
hIRF3 2 AGGAGGTCTGGGTGCGGAAACTC CGTCGCACGCACCTGGAAGATTC 
hNE 1 GTGCCAGGGGAGAGGAAGTGGAG AGGATGAGGGACCCACACTGGTG 
hNE 2 CAGGCTCCTTGGCAGGCACTCAG GCCTGAGGGCGAAGGTGCTCGAG 
hSTING 1 TGGGAGTGGCTGGGCACCAGGGA TGGAGCACCAGGTACCGGAGAGT 
hSTING 2 GAGTGGCTGGGCACCAGGGAAAG TAGGTGGAGCACCAGGTACCGGA 
hTLR9 1 CAAGACAGTGGACCACTCCTGGT TGATGCAGCATGGGCACACCCAG 
hTLR9 2 CTTCCGCTCACTCGATGAGACCA TGAAGTTGAGGGTGCTGCAGTTG 
mcGAS 1 GCGGATACTGACCGGCTACGTTC TCCGTGGTGTCCCCGTCACGCTC 
mcGAS 2 AGGCCATCCTGGATCCGGAGCTG CCGACTCCCGTTTCTGCATTCTG 
mNE 1 GGCTAGGTCCCTTGTCTTTTCTC ACTCACAGGCCGTTCACACAGTG 
mNE 2 GCCCTCAATGTCCATGCGGGTCA TTGCACGAGGCTCAGGTTCCTGA 
mSTING 1 CAGAAGCATAGCTGTGGATTTCT GTTACCTGGACTGGACATGGCAC 
mSTING 2 CTAGTCAGGACCTTAGGCCCTGA CAGCAGAGGTTTTTCAACAGTAG 
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For the subsequent sequencing analysis, a second PCR step was performed. The used primers 
contained the binding sites for the sequencing chamber and Illumina barcode indices. The combination 
of a barcoded fwd- and rev-primer allowed to trace back in which well which clone was frozen, once 
the sequencing results were received. 
 
primer sequence 
Illumina 
Barcode 
Index 
Barcode fwd 1 AATGATACGGCGACCACCGAGATCTACACTATAGCCTACACTCTTTCCCTACACGACGCT D501 
Barcode fwd 2 AATGATACGGCGACCACCGAGATCTACACATAGAGGCACACTCTTTCCCTACACGACGCT D502 
Barcode fwd 3 AATGATACGGCGACCACCGAGATCTACACCCTATCCTACACTCTTTCCCTACACGACGCT D503 
Barcode fwd 4 AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTACACGACGCT D504 
Barcode fwd 5 AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACACTCTTTCCCTACACGACGCT D505 
Barcode fwd 6 AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCCTACACGACGCT D506 
Barcode fwd 7 AATGATACGGCGACCACCGAGATCTACACCAGGACGTACACTCTTTCCCTACACGACGCT D507 
Barcode fwd 8 AATGATACGGCGACCACCGAGATCTACACGTACTGACACACTCTTTCCCTACACGACGCT D508 
Barcode rev 1 CAAGCAGAAGACGGCATACGAGATCGAGTAATGTGACTGGAGTTCAGACGTGTGCT D701 
Barcode rev 2 CAAGCAGAAGACGGCATACGAGATTCTCCGGAGTGACTGGAGTTCAGACGTGTGCT D702 
Barcode rev 3 CAAGCAGAAGACGGCATACGAGATAATGAGCGGTGACTGGAGTTCAGACGTGTGCT D703 
Barcode rev 4 CAAGCAGAAGACGGCATACGAGATGGAATCTCGTGACTGGAGTTCAGACGTGTGCT D704 
Barcode rev 5 CAAGCAGAAGACGGCATACGAGATTTCTGAATGTGACTGGAGTTCAGACGTGTGCT D705 
Barcode rev 6 CAAGCAGAAGACGGCATACGAGATACGAATTCGTGACTGGAGTTCAGACGTGTGCT D706 
Barcode rev 7 CAAGCAGAAGACGGCATACGAGATAGCTTCAGGTGACTGGAGTTCAGACGTGTGCT D707 
Barcode rev 8 CAAGCAGAAGACGGCATACGAGATGCGCATTAGTGACTGGAGTTCAGACGTGTGCT D708 
Barcode rev 9 CAAGCAGAAGACGGCATACGAGATCATAGCCGGTGACTGGAGTTCAGACGTGTGCT D709 
Barcode rev 10 CAAGCAGAAGACGGCATACGAGATTTCGCGGAGTGACTGGAGTTCAGACGTGTGCT D710 
Barcode rev 11 CAAGCAGAAGACGGCATACGAGATGCGCGAGAGTGACTGGAGTTCAGACGTGTGCT D711 
Barcode rev 12 CAAGCAGAAGACGGCATACGAGATCTATCGCTGTGACTGGAGTTCAGACGTGTGCT D712 
 
 
4.1.6 Plasmids 
 
Designation Insert Application Source 
plentiCRISPRv2ccdB CRISPR gRNA 
targeted CRISPR knock outs, carries Cas0, 
gRNA and Puromycin selection cassette Addgene 
155 
pMD.2G - Envelope plasmid for production of lentiviral particles 
Kindly provided by 
Achim Kramer, Charité 
Berlin, Germany 
 
psPAX2 - Packaging plasmid for production of lentiviral particles 
Kindly provided by 
Achim Kramer, Charité 
Berlin, Germany 
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4.1.7 Enzymes and buffers 
Enzyme Company Catalog# 
BsmBI New England Biolabs R0580L 
DNAse1 New England Biolabs M0303S 
DNAse1 reaction buffer New England Biolabs B0303S 
Horseradish peroxidase Sigma-Aldrich 77332 
Proteinase K New England Biolabs P8107S 
T4 DNA Ligase Promega M180 
T4 DNA ligase buffer Promega C126 
 
4.1.8 Kits 
ELISAs 
Kit Target Company Catalog# 
Interferon α All Subtype ELISA Kit human IFN α PBL Assay Science 41115-1 
Human CXCL10/IP-10 DuoSet ELISA human CXCL10 R&D Systems DY266 
VeriKine Mouse Interferon β ELISA Kit murine IFN β PBL Assay Science 42400-1 
Cell Death Detection ELISAPLUS nucleosomes Sigma-Aldrich 11774425001 
Human Complement C1q ELISA Kit Human C1q Abcam ab170246 
Human Anti-Nuclear Antibodies (ANA) ELISA Kit ANA Autoantibodies Alpha Diagnostics 3205 
 
Other Kits 
Kit Company Catalog# 
A&B Fast SYBR Green Master mix Thermo Fisher Scientific 4385612 
AlamarBlue™ Cell Viability Reagent Thermo Fisher Scientific DAL1025 
Bright-Glo™ Luciferase Assay System Promega E2610 
CD14 MicroBeads Miltenyi Biotec 130-050-201 
Giemsa Stain Kit Abcam ab150670 
High-Capacity cDNA reverse transcription Kit Thermo Fisher Scientific 4368814 
Low input Quick-Amp Labeling Kit, one color Agilent Technologies 5190-2305 
Mitochondria Isolation Kit for Mammalial cells Thermo Fisher Scientific 89874 
Phusion® High-Fidelity PCR Kit New England Biolabs E0553L 
Plasmacytoid Dendritic Cell Isolation Kit II Miltenyi Biotec 130-097-415 
Quant-iT™ PicoGreen ® dsDNA Kit Thermo Fisher Scientific P11496 
Whole mouse genome 4x44K microarray kit Agilent Technologies G4122F 
Zymoclean Gel DNA recovery Kit Zymo Research D4007 
Zyppy Plasmid Miniprep Kit Zymo Research D4020 
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4.1.9 Buffers 
Buffer/Solution Ingredients 
FACS buffer (mouse samples) PBS, 2,5 % /v/v) FCS, 0,1 % (w/v) NaN3 
MACS buffer PBS, 0,2 % (w/v) HSA, 5 mM EDTA 
IFA buffer PBS, 3 % (v/v) serum (depending on primary antibody), 3 % 
(v/v) cold water fish gelatine, 1 % (w/v) BSA , 0,5 % Tween 
20 (v/v) 
ELISA dilution buffer PBS-T, 1 % (w/v) BSA 
PBS/HSA PBS, 0,02 % (w/v) HSA 
RBC lysis buffer dH2O, 15,4 mM NH4Cl, 1 mM KHCO3, 127,3 µM EDTA 
Outknocker lysis buffer dH2O, 0,2 mg/ml Proteinase K, 1 mM CaCl2, 3 mM MgCl2, 1 mM 
EDTA, 1 % Triton X100, 10 mM Tris (ph7.5) 
PBS-T PBS, 0,05 % Tween 20 
PBS Dulbecco's PBS (Gibco Cat.# 14190094) 
dH2O UltraPureTM Distilled Water (Invitrogen Cat.# 10977-035) 
TE dH2O, 10 mM Tris (pH 8.0), 1 mM EDTA 
Lavage solution PBS, 0,02 % (v/v) EDTA 
Casein solution PBS, 7 % (w/v) Casein 
 
4.1.10 Antibodies and Dyes 
FACS antibodies  
Antigen target-species Fluorochrome Company Dilution Catalog# 
CD115 mouse PE BD 1:100 562249 
CD3 mouse FITC BD 1:100 561798 
CD4 mouse Pe-Cy7 BD 1:100 552775 
CD45 mouse V500 BD 1:100 561487 
CD8a mouse APC BD 1:100 561093 
Gr1 mouse PerCP-Cy5.5 Biolegend 1:100 108428 
CD14 human PE Miltenyi Biotec 1:100 170-078-013 
CD15 human FITC Miltenyi Biotec 1:40 170-078-051 
CD66b human APC-Vio770 Miltenyi Biotec 1:40 130-104-399 
 
Antibodies for other applications 
Name Target Application Company Catalog# 
MPO-Biotin murine MPO NET ELISA Hycult Biotech HM1051BT 
pIRF3 human phosphorylated IRF3 FACS Cell Signaling D601M 
1A8 Ly6G neutrophil depletion BioXcell BP0075-1 
2A3 isotype control isotype control BioXcell BP0089 
PL23 chromatin Immunofluorescence made in house - 
NE human NE Immunofluorescence Calbiochem 481001 
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Secondary antibodies 
Name Reactivity Origin Fluorochrome Company Catalog# 
anti-mouse Alexa568 mouse goat Alexa Fluor 568 Thermo Fisher Scientific A-21124 
anti-rabbit Alexa488 rabbit goat Alexa Fluor 488 Thermo Fisher Scientific A-11008 
 
Dyes and Probes 
Name Company Catalog# 
4',6-diamidino-2-phenylindole (DAPI) Thermo Fisher Scientific 62247 
Cell trackerTM Deep Red Dye Thermo Fisher Scientific C34565 
Hoechst 33342 Thermo Fisher Scientific 62249 
Lyso TrackerTM Red DND-99 Thermo Fisher Scientific L7528 
SytoTM Green Nucleic Acid Stain Thermo Fisher Scientific S7578 
SytoxTM Orange Nucleic Acid Stain Thermo Fisher Scientific S11368 
 
4.1.11 Chemicals 
Chemical Company Catalog# 
Agarose Biozym 840004 
Albutein (HSA) Grifols G4AFB05201 
Amlexanox Invivogen inh-amx 
Bafilomycin Invivogen tlrl-baf1 
BSA Carl Roth 8076.3 
Calf-Thymus DNA Thermo Fisher Scientific 15633019 
Carbenecillin Sigma-Aldrich C1613 
Casein Sodium salt Sigma-Aldrich C8654 
CCCP MedChemExpress HY-100941 
Chloroform Honeywell 602-006-00-4 
ConA Sigma-Aldrich C5275-5MG 
Cytochalasin B Sigma-Aldrich C6762 
DL-Dithiothreitol Sigma-Aldrich 43815 
DMSO Sigma-Aldrich D8418 
DOTAP Carl Roth L787.2 
EDTA Sigma-Aldrich E6758 
Elastase inhibitor (NEi) Biomol AG-CR1-3632-M001 
Ethanol Merck 1.009.832.511 
Ethidiumbromide Thermo Fisher Scientific 15585011 
FcR blocking reagent, human Miltenyi Biotec 130-059-901 
FCS Merck S0115 
fMLP Sigma-Aldrich F3506 
Gelatin from cold water fish skin Sigma-Aldrich G7765 
Glycogen Thermo Fisher Scientific R0561 
hIFNγ Sigma-Aldrich SRP3058 
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hIFNα universal PBL Assay Science 11200-1 
hIFNβ PBL Assay Science 11415-1 
Histopaque 1119 Sigma-Aldrich 11191-100ML 
hMCSF Miltenyi Biotec 130-096-485 
Isopropanol Fisher Chemical P/7500/17 
K777 Adipogen AG-CR1-0158-M001 
L-Glutamine Gibco 25030-024 
Lipofectamine 2000 Thermo Fisher Scientific 11668027 
LPS Enzo Life Science ALX-581-011-L001 
Luminol AAT Bioquest 11050 
MeOH Merck 1.060.092.500 
mGCSF Peprotech 250-05 
Nigericin Sigma-Aldrich N7143 
Nystatin Sigma-Aldrich N6261 
Paraformaldehyde Sigma-Aldrich P6148 
pdAdT Invivogen tlrl-patn 
Penicillin/Streptomycin Gibco 15140-122 
Percoll GE Healthcare 17-0891-02 
PMA Sigma-Aldrich P8139 
Puromycin Sigma-Aldrich P8633 
Quanti-Blue solution Invivogen rep-qb1 
RU.521 Invivogen inh-ru521 
Sivelestat Sigma-Aldrich S7198 
Sodiumacetate Sigma-Aldrich S2889 
TRIS Carl Roth 9090.3 
TritonX 100 Sigma-Aldrich X100 
TRIZOL Thermo Fisher Scientific 15596026 
Trypsin Promega V5111 
Tween 20 Sigma-Aldrich P1379 
zVAD-FMK Invivogen tlrl-vad 
 
4.1.12 Material 
Name Company Catalog# 
12-well plate Sarstedt 83.3921 
15µ-Slide 8-well IBIDI 80827 
24-well plate Sarstedt 83.3922 
6-well plate Sarstedt 83.3920 
96-well plate Sarstedt 83.3924 
Cellscraper Sarstedt 83.1832 
Cover glasses 13mm Thermo Fisher Scientific 0864 
Eppendorf Tubes Eppendorf 0030120086 
FACS tubes BD 352054 
Falcon tubes 15 ml Corning 430791 
Falcon tubes 50 ml Corning 430829 
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LS columns Miltenyi Biotec 130-042-401 
MicroAMP Fast Optical96-well Reaction plate Applied Biosystems 4346906 
MicroAMP 8-tube-Strip 200 µl Applied Biosystems N8010838 
Microscope slide Marienfeld 1010612 
MidiMACS Separator Miltenyi Biotec 130-042-302 
Plastipak 1 ml Sub-Q syringe BD 305501 
S-Monovette K3E Sarstedt 02.1066.001 
S-Monovette Serum Sarstedt 02.1063.100 
Sterican needle 18 G x 1,5" Braun 4658313 
Steril filter system 500 ml Corning 430758 
Stuffed tips 10 µl Thermo Fisher Scientific 2139 
Stuffed tips 1000 µl Corning 4140 
Stuffed tips 200 µl Corning 4136 
Tissue culture Bottle T175 Sarstedt 83.3912.002 
Tissue culture Bottle T25 Sarstedt 83.3910.002 
Tissue culture Bottle T75 Sarstedt 83.3911.002 
 
4.1.13 Machines 
Machine Company 
Agilent 2100 Bioanalyzer Agilent Technologies 
Casy Cell Counter OMNI Life Science 
Centrifuge 5415D Eppendorf 
Compact Thermomixer Eppendorf 
EVOS FL Auto2  Thermo Fisher Scientific 
Fluoroskan Ascent Thermo Fisher Scientific 
G2565CA High-resolution Laser Microarray Scanner Agilent Technologies 
Gel Doc XR+ BioRad  
Innova 44R Bacterial shaker New Brunswick Scientific 
MACS Quant Miltenyi Biotec 
Microconcentrator 5301 Eppendorf 
Multifuge 3S-R Thermo Fisher Scientific 
NanoDrop2000 Thermo Fisher Scientific 
Optima L-90K Ultra Centrifuge Beckmann Coulter 
Orbitrap LC-MS Thermo Fisher Scientific 
QuantStudio 3 Thermo Fisher Scientific 
Sonopuls Sonicator Bandelin 
TCS SP8 Confocal Microscope Leica Microsystems 
Thermo Cycler S1000 BioRad  
Thermo Forma Cell Culture Incubator Thermo Fisher Scientific 
Versa Max microplate reader Molecular devices 
Victor X Light Luminescence Reader Perkin Elmer 
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4.1.14 Software 
Name Version Company  
GraphPad PRISM 7.03 GraphPad Software 
MACS Quantify 2.11 Miltenyi Biotec 
FlowJo 10.2 FlowJo 
ImageJ 1.52c National Institute of Health, USA 
Quant Studio Design & Analysis 1.4.1 Thermo Fisher Scientific 
Perkin Elmer 2030 Workstation 4.0 Perkin Elmer 
Rosetta Resolver Biosoftware 7.2.2 Rosetta Biosoftware 
 
4.2 Methods 
4.2.1 Human primary immune cells 
Isolation of human neutrophils 
The ethics council of the Charité Berlin (Germany) approved blood sampling and all donors gave 
informed consent according to the Declaration of Helsinki.  
Human neutrophils were isolated by a two-step density separation as described before 35. Heparinized 
blood (5 U/ml) was layered on an equal volume of histopaque 1119 and centrifuged at 800 g for 20 
min. PBMCs and neutrophil layers were collected separately, washed with PBS 0,2 % HSA and pelleted 
at 300 g 10 min. The neutrophil pellet was resuspended in PBS 0,2 % HSA, layered on a discontinuous 
Percoll gradient (85 %-65 % in 2ml layers) and centrifuged at 800 g for 20 min. The neutrophil 
containing band was collected, washed in PBS 0,2 % HSA and pelleted for 10 min at 300 g. The cell 
number was determined using a CASY cell counter (OMNI Life Science).  
Isolation of human monocytes and differentiation in macrophages 
Monocytes were isolated by positive selection. The PBMC fraction generated during neutrophil 
isolation was washed again in MACS buffer and pelleted 10 min at 300 g. The cells were resuspended 
in MACS buffer and counted using the CASY cell counter (OMNI Life Science). After subsequent 
pelleting, 80 µl MACS buffer and 20 µl magnetic CD14-beads were added per 107 cells and the mixture 
was incubated for 15 min at 8°C. After another washing step, the cells were passed through a magnetic 
LS MACS column (Miltenyi) by gravity flow. The column was washed with 8 ml of MACS buffer and 
bound monocytes were subsequently eluted with 5 ml MACS buffer, washed and counted. The purity 
of the preparation was determined by FACS staining with an anti-CD14 antibody. Monocytes were 
cultivated in RPMI basic medium at 37°C, 7 % CO2. 
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To generate monocyte-derived macrophages (MDM), monocytes were taken up in RPMI basic medium 
supplemented with 5 ng/ml hMCSF and incubated at 37°C and 7 % CO2 for a total of 7 days, including 
a medium change after three days. 
Isolation of human pDCs 
pDCs were isolated by negative selection. The PBMC fraction was washed and counted as described 
above and incubated for 10 min with 100 µl non-pDC biotin-antibody cocktail II and 400 µl MACS buffer 
per 108 PBMCs. After subsequent washing, non-pDC microbead cocktail II was added at the same ratio 
and incubated for 15 min at 8°C. The cell suspension was added to a LS MACS column (Miltenyi) and 
allowed to pass by gravity flow. After washing the column with 8 ml of MACS buffer, the flow through 
was collected, pelleted and the cells were counted by CASY cell counter (OMNI Life Science). pDCs 
were cultivated in RPMI basic medium at 37°C, 7 % CO2. 
4.2.2 Murine primary immune cells 
Isolation of murine neutrophils 
Mice were injected i.p. with 1 ml of 7 % Casein solution in the evening and again after 12 h at the next 
morning. Three hours after the second injection, mice were sacrificed by rapid cervical dislocation. The 
peritoneal cavity was flushed with a total of 10 ml of lavage solution and the exiting liquid with the 
cells was collected. The cells were pelleted by centrifugation at 200 g for 10 min and washed three 
times with PBS. After washing the cells were resuspended in 1 ml of PBS and mixed with 9 ml Percoll 
gradient. Neutrophils were separated by continuous density centrifugation for 20 min at 60000 g and 
the upper band containing the neutrophils was collected. Subsequently neutrophils were washed and 
counted in the CASY cell counter (OMNI Life Science). To assess cell purity, a cytospin with 1x105 cells 
was stained with Gimsa and analyzed by microscopy. Neutrophils were identified by their nuclear 
morphology.  
Generation of bone-marrow derived macrophages (BMM) 
The mice were sacrificed by rapid cervical dislocation and the femurs of their hind legs were collected. 
The bones were rinsed with 70 % EtOH and washed in PBS. The bone-marrow was flushed out with 
PBS. The cells were pelleted at 300 g for 10 min and red blood cells were lysed using 3 ml RBC lysis 
buffer for 3 min on ice. The cells were resuspended in DMEM with 10 % FCS, Q, P/S and 20 % L-cell 
supernatant containing mMCSF. Cells differentiated for 7 days at 37°C, 5 % CO2. 
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4.2.3 Generation of gene specific CRISPR knockouts in human and murine cell lines 
Cultivation of cell lines 
For generation of CRISPR knockouts a human and a murine cell line were chosen. The human 
monocyte-like cell line THP1 was cultured in RPMI basic medium at 37°C, 7 % CO2. Murine immortalized 
Balb/C macrophages were cultured in DMEM basic medium at 37°C, 5 % CO2. 
gRNA design 
gRNA sequences targeting all possible transcript variants were obtained from ChopChop 
(https://chopchop.rc.fas.harvard.edu) and tested for sequence specificity using NCBI Nucleotide Basic 
local alignment search tool (BLAST, https://blast.ncbi.nlm.nih.gov/Blast.cgi). Oligonucleotides 
consisting of the gRNA (20 bp, without PAM-sequence) flanked by adapter sequences were generated 
that had the following structure: 
5’-GT CGTCTC C CACC G – 20 bp-gRNA – GTTT C GAGACG TG-3’ 
The reverse complement oligonucleotide was generated using an online tool (http://reverse-
complement.com/). The oligonucleotides were synthetized by Sigma-Aldrich (Darmstadt, Germany). 
Oligo-annealing, ligation into plentiCRISPRv2ccdB and transformation into chemo-competent E.Coli 
The oligonucleotides were resuspended in 1 µl dH2O (100 µM) of forward and reverse oligonucleotide 
were combined with 98 µl TE buffer, heated to 99°C for 5 min and allowed to cool down to room 
temperature (RT). Using a Golden gate cloning strategy, the annealed oligonucleotides were ligated 
into the plentiCRISPRv2ccdB target vector. 
Cloning mix     Cloning reaction    
component amount   temperature time  
plentiCRISPRv2ccdB 50 ng   37°C 5 min 
10x 
T4 ligase buffer 2 µl   16°C 10 min 
T4 ligase 1 µl   55°C 5 min  
BsmBI 1 µl (10 U/µl)   80°C 5 min  
Annealed oligonucleotides 1 µl   4°C ∞  
dH2O Ad 20 µl        
 
10 µl of the ligation mix were added to recA-deficient E. coli DH5α and incubated for 10 min on ice. 
After a 45 sec heat shock to 42°C, bacteria were stored for 1 min on ice. 1 ml LB medium was added 
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and the bacteria were incubated for 1 h rotating at 37°C. The cells were pelleted for 5 min at 1000 g 
and plated on selective agar plates containing Carbenicilin (100 µg/ml).  
Isolation of plasmid DNA from bacteria 
5 ml LB were inoculated with a single colony and incubated shaking o.n. at 37°C under selective 
conditions. Bacteria were pelleted and plasmid DNA was isolated using the Zyppy Plasmid Miniprep Kit 
(Zymo research) according to manufacturers instructions. The DNA concentration was determined 
with the NanoDrop2000 (Thermo Fisher Scientific). The plasmids were sent for sequencing (Eurofins 
Genomics, Anzinger Str. 7a, 85560 Ebersberg, Germany) using the hU6-F primer (5'-GAGGGCCTATTTCC 
CATGATT-3').  
Lentivirus production 
8x105 HEK 293T cells were seeded in a 6-well plate the day before transfection. On the day of 
transfection, the medium was replaced with 1 ml OptiMEM medium. 2 µg plentiCRISPRv2ccdB, 0,5 µg 
psPAX, 1,5 µg pMD2.G and 7 µl Lipofectamine were combined in 500 µl OptiMEM and incubated for 
15 min at RT. The transfection mix was added carefully to the HEK 293T cells and cells were incubated 
at 37°C and 5 % CO2. The medium was replaced with DMEM basic medium after 24 h, virus was 
harvested after 72 h and 96 h and stored at -80°C. 
Transduction and selection of target cells 
1x106 target cells were seeded in 1 ml of their respective medium in a 6-well plate. 1 ml of viral 
supernatant was added and cells were incubated for 4 h at 37°C, then 3 ml fresh medium were added. 
After 48 h, the medium was replaced and cells were kept under selective conditions with 5 µg/ml 
Puromycin for 72 h.  
Generation of single clones by limited dilution cloning 
The cells were counted by CASY cell counter (OMNI Life Science). For each construct 500 wells with 0,8 
cells/well in 200 µl medium were seeded. The cells were cultivated for approx. two weeks until colonies 
appeared. 32 clones of each constructs were transferred into a new plate and cultivated for another 
two days. The cells were split in two plates; one was frozen in mammalian cell freezing medium and 
the other further processed for DNA isolation. 
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Verification of target gene mutation by Outknocker 
The verification of the knockouts was performed as described before 156. In brief, the cells were lysed 
in 30 µl Outknocker lysis buffer for 10 min at 65°C and subsequently inactivated for 15 min at 95°C. 
The isolated genomic DNA was used as template for two consecutive PCR reactions. In the first PCR, 
the target locus of the gRNA was amplified using site-specific primers (N23) with attached adapter 
sequences: 
Fwd: ACACTCTTTCCCTACACGACGctcttccgatct-N23 
Rev: TGACTGGAGTTCAGACGTGTGctcttccgatct-N23 
In the second PCR the samples of the first PCR were labeled with barcodes in an arrayed fashion and 
sequencing adapters were attached. The second PCR used the same reaction conditions as the first 
PCR. 
PCR components  PCR programm  
      
DNA 1 µl  98°C 30 sec  
Phusion pol. 0,0625 µl  98°C 10 sec  
dNTPs 0,125 µl  60°C 30 sec 19x 
primer fwd 0,3125 µl  72°C 30 sec  
primer rev. 0,3125 µl  72°C 3 min  
5x buffer 1,25 µl  12°C ∞  
DMSO 0,1875 µl     
dH2O 3 µl     
 
After the PCRs were finished, 3 µl of the 2nd PCR step were collected and pooled. The samples were 
separated on a 1,5 % agarose gel at 100 V and bands between 300 to 450 bp were collected. They were 
eluted from the gel using the Zymoclean Gel DNA Recovery kit (Zymo Research) according to 
manufacturers specifications and DNA was precipitated using 0,1 volume 3 M NaOAc (pH 5.2) and 1,1 
volume isopropanol. After 15 min centrifugation at full speed, the pellet was washed with 70 % EtOH, 
air dried and resuspended in 30 µl H2O. The concentration was determined by NanoDrop2000 (Thermo 
Fisher Scientific). 
Illumina MiSeq 250bp single-end sequencing was performed by ATLAS Biolabs GmbH (Friedrichstraße 
147, 20117 Berlin, Germany). The received FASTA-files were analyzed with the Outknocker web tool 
(http://www.outknocker.org/). Outknocker provided an alignment of the sequencing results with the 
target locus of the gRNA, showing if there was a mutation, how many sequencing reads span the area 
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of interest and how many indels were detected. For further experiments, we selected clones with a 
sufficient number of reads and a clear out-of-frame mutation.  
4.2.4 Induction, isolation and quantification of human and murine NETs 
Induction, visualization and quantification of human NETs 
1x105 neutrophils were seeded in a 24-well plate in RPMI neutrophil medium on a glass coverslip. The 
cells were stimulated with 100 nM PMA for 4 h at 37°C, 7 % CO2. The cells were fixed 2 % para-
formaldehyde (PFA) (w/v) for 15 min at RT, subsequently washed twice with PBS and stored at 4°C. 
For NET staining, the samples were permeabilized for 5 min with 0,1 % TritonX100 in PBS at RT and 
subsequently blocked for 20 min with IFA blocking buffer. Afterwards the samples were incubated with 
the primary antibodies mouse α-human chromatin (PL2.3, 1 µg/ml) and rabbit α-human NE (10 µg/ml) 
for 1 h at RT. After three subsequent washes with PBS, the according secondary antibodies (10 µg/ml) 
and Hoechst (100 ng/ml) were added for 30 min. Finally, the samples were washed twice with PBS and 
once with water and then mounted on glass slides.  
Five random images of the separate channels were taken with the 10x objective, using the EVOS FL 
Auto2 imaging system (Thermo Fisher Scientific). The images were analyzed as described before using 
ImageJ 241. In brief, the number of cells was determined using the Hoechst images with the Bernsen 
automatic local threshold function with diameter set to 15 and the threshold to 35. Particles larger 
than 20 pixels were counted. For NET-positive cells the PL23 channel was used. The threshold was set 
interactively, controlling both unstimulated and stimulated samples, and objects larger than 75 pixels 
were counted. Percentage of NET formation was calculated by the following formula: 
% 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 = 𝑐𝑐𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐 𝑃𝑃𝑃𝑃23+ 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑁𝑁
𝑐𝑐𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐 𝐻𝐻𝑁𝑁𝑐𝑐𝑐𝑐ℎ𝑁𝑁𝑐𝑐+𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑁𝑁 ∗ 100 
Isolation and quantification of human NETs  
For NET isolation 3x106 neutrophils were seeded in a 6-well plate and stimulated for 4 h with 100 nM 
PMA in RPMI neutrophil medium. After 4 h the medium was removed, the NETs were washed three 
times with PBS and 300 µl PBS were added. The NETs were scraped off the plate and transferred into 
an Eppendorf tube. The NETs were either directly frozen or sonicated with the Bandelin Sonopuls stick-
sonicator with three pulses (70 % power) of three seconds each.  
For the stimulation of recombinant cGAS, samples were further processed. NETs were digested with 
either DNAse1 (10 U/ml) for 2 h a 37°C or with Proteinase K (10 U/ml) for 2h at 56°C. To stop the 
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enzymatic reactions, the mix was inactivated for 10 min at 85°C. Furthermore, NETs were separated 
into DNA and protein components using phenol-chloroform extraction.  
To quantify NETs the Quant-iT™ PicoGreen ® dsDNA Kit was used according to manufacturers 
specification. Calf thymus DNA was used as a standard, starting from 1 mg/ml following a 1:1 serial 
dilution. 
Induction, visualization and quantification of murine NETs 
105 neutrophils were seeded in a 24-well plate in 500 µl RPMI with 1 % serum of DNAse1-/- mice and 
recombinant mGCSF (100 ng/ml) and stimulated for 12 h with 100 nM PMA. Sytox orange (50 µM) and 
syto green (12,5 µM) were added 1:100 to the samples and incubate for 15 min at 37°C. Three images 
per sample were taken at a 20x magnification and analyzed by manual counting. The cell number was 
determined by sytox orange positive cells, whereas the NET number was determined by large syto 
green particles. Percentage of NET formation was calculated by the following formula: 
% 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 = 𝑐𝑐𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐 𝑁𝑁𝑠𝑠𝑐𝑐𝑁𝑁𝑠𝑠 𝑁𝑁𝑟𝑟𝑟𝑟𝑐𝑐𝑟𝑟𝑐𝑐+𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑁𝑁
𝑐𝑐𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐 𝑁𝑁𝑠𝑠𝑐𝑐𝑁𝑁 𝑟𝑟𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐+𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑁𝑁 ∗ 100 
Analysis of the NET proteome by mass spectrometry 
NETs were generated and harvested as described above in the absence of HSA. NETs were finally 
resuspended in 200 µl PBS and sonicated. 90 µl sample were reduced with 15 µl 45 mM Dithiothreitol 
(DTT) for 15 min at 60°C and subsequently alkylated with 15 µl 100 mM Iodoacetamide (IAA) for 15 
min at RT. The sample was further diluted with 4 volumes of 50 mM Ammonium bicarbonate / 5 % 
Acetonitrile (ACN) and digested o.n. at 37°C with 0,5 µg trypsin (Promega). The digestion was stopped 
by adding 12 µl of 20 % trifluoroacetic acid (TFA). The sample was desalted with a ZipTip C18 (Millipore, 
0,6 µl bed volume) that was wetted with 50 µl 100 % ACN and equilibrated with 50 µl 0,1 % TFA. After 
the sample ran through the tip, it was washed twice with 50 µl 0,1 % TFA. Peptides were eluted in two 
consecutive steps with 5 µl of 60 and 80 % ACN 0,1 % TFA. Eluted peptides were combined and dried 
at 45°C using a microconcentrator (Eppendorf). For LC-MS/MS analysis the peptides were analyzed 
using a QExactive Plus mass spectrometer (Thermo Fisher Scientific) coupled on line to a Dionex 
UltiMate 3000 RSLC nano system (Thermo Fisher Scientific). After solubilization in 23 μl 2 % ACN /0,1 
% TFA, 10 µl of the sample was loaded on a C18 PepMap 100 trap column (300 μm x 5mm; 5 μm particle 
size 100 Å pore size; Thermo Fisher Scientific) at a flow rate of 20 µl/min 2 % ACN /0,1 % TFA for pre-
concentration and desalting. Separation was performed using a PicoChip (H354 Reprosil-Pur C18-AQ3; 
75 µm i.d. x 105 mm; 120 Å pore size; TipSize 15 µm; New Objective) at a flow rate of 300 nl/min. HPLC 
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solvent A was 0,1 % formic acid (FA) and peptides were eluted from the column using HPLC solvent B 
80 % ACN / 0,1 % FA starting from 3 %, increasing to 40 % in 45 minutes, and to 98 % in 5 minutes. The 
peptides were analyzed in data-dependent acquisition mode that alternated between one MS scan 
and 10 MS/MS scans for the most abundant precursor ions. MS scans were acquired over a mass range 
of m/z 350–1600 and resolution was set to 70000. Peptides were fragmented using HCD at 27 % 
normalized collision energy and measured in the Orbitrap at a resolution of 17500. 
Proteins were identified using an in-house version of Mascot (version 2.6). Peak lists were searched 
against the SwissProt_human data base (20,214 sequences; 11,330,251 residues) Mass accuracy was 
set to 5 ppm for MS mode and to 0,03 Da for MS/MS mode and two missed tryptic cleavage sites were 
allowed. Methionine oxidation, acetylation at protein N-terminus, pyroglutamate formation of N-
terminal glutamine and carbamidomethylation of cysteines were allowed as variable modifications. 
The false discovery rate was set to 1 %. 
Isolation of mitochondrial DNA 
HEK 293 T cells were harvested and mitochondria were isolated using the Mitochondria Isolation Kit 
(Thermo Fisher Scientific) according to manufacturers instructions. DNA was isolated with the Zyppy 
Plasmid Miniprep Kit (Zymo Research) and quantified using the Nanodrop 2000. 
 4.2.5 Stimulation of target cells with isolated NETs  
Generation human serum from SLE patients 
Blood was collected in S-Monovette serum tubes and stored rolling for 30 min at RT. The tubes were 
centrifuged at 2000 g for 10 min and the serum was collected, aliquoted and shock frozen in liquid 
nitrogen. 
Stimulation human and murine cells  
105 cells/well were seeded 100 µl in 96-well plate in their according medium. NETs were added at a 
final concentration of 100 µg/ml, either with or without DOTAP (5 µl/well). As a positive control for 
interferon induction pdAdT (2 µg /ml) was transfected using DOTAP. Human serum was applied at a 
final concentration of 10 %. The cells were incubated for 15 h at 37°C and supernatants were collected 
and frozen at -80°C. The inhibitors NEi (20 µM) and Sivelestat (1 µM), K777 (10 µM) and zVAD-FMK (20 
µM) were added in 50 µl at 4x concentration before the NETs were added. 
For inflammasome stimulation, 105 murine BMM were seeded per well 100 µl in 96-well plate in BMM 
medium. If required, cells were primed with 500 ng/ml LPS for 3 h at 37°C. For Activation of the NLRP3 
Material and Methods 
73 
 
inflammasome, the cells were treated for 1h with 15 µM Nigericin. For activation of the AIM2 
inflammasome cells were stimulated with pdAdT (2 µg/ml) or NETs (100 µg/ml) in the presence of 
lipofectamine or DOTAP for 4 h. 
If different CRISPR clones or primary cells of different genotype were seeded for comparison, the cell 
number was compared using the Alamar Blue assay according to manufacturers specifications. In brief, 
10 µl Alamar Blue solution were added to 100 µl cell solution and incubated for 30 min at 37°C. 
Subsequently, the fluorescence was measured using a fluorescent plate-reader at 514/590 (ex/em). 
The cell count data was used for normalization of the interferon data.  
4.2.6 Cocultivation 
3x106 target cells (PBMCs, monocytes or pDCs) were combined with neutrophils at a 1:1 ratio in 1 ml 
RPMI basic medium. They were either left untreated or stimulated with PMA (final concentration 100 
nM) or ConA (final concentration 50 µg/ml) in a final volume of 1,5 ml. The inhibitors NEi (20 µM), 
RU.521 (10 µM), Amlexanox (10 µg/ml), CCCP (10 µM), Nystatin (10 µg/ml), Cyto B (5 µg/ml) or DNAse1 
(5 U/ml) were added before PMA stimulation. The cells were cocultivated rotating for at 37°C at 5 % 
CO2. After 15 h, the cells were pelleted at 1000 g for 5 min on 4°C. The supernatant was collected and 
frozen at -80°C and the cells were resuspended in 1 ml TRIZOL and frozen as well. 
4.2.7 RNA isolation and reverse transcription 
The TRIZOL samples were defrosted at RT and 200 µl chloroform were added. The samples were mixed 
by inverting the tubes and incubated for 5 min at RT. After 15 min centrifugation at 10000 g at 4°C the 
aqueous phase was collected in RNAse free tubes and mixed with 1 µl glycogen (20 mg/ml) and 500 µl 
isopropanol. The mix was incubated for at least 1 h at -20°C, in most of the cases over night to allow 
optimal precipitation. The mix was centrifuged at 16100 g for 10 min at 4°C, the supernatant was 
discarded and the pellet was washed twice with 500 µl cold 70 % EtOH. Finally, the pellet was air dried 
and resuspended in 30 µl dH2O and stored at -80°C. The RNA concentration was measured with the 
NanoDrop2000 (Thermo Fisher Scientific).  
2 µg of RNA were reverse transcribed using the High-Capacity cDNA reverse Transcription Kit (Thermo 
Fisher Scientific) according to manufacturers instructions.  
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reaction mix     PCR program 
RNA 2 µg     
25x dNTPs 0,8 µl   25°C 10 min 
10x RT buffer 2 µl   37°C  120 min 
10x random primers 2 µl   85°C  5 min 
Reverse transcriptase 1 µl   12°C ∞ 
dH2O ad 20 µl     
 
4.2.8 Detection of TIIFN 
Expression analysis by quantitative polymerase chain reaction (qPCR) 
Primers for qPCR were chosen from selected publications and checked for their specificity using the 
NCBI primer designing tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer functionality 
was tested by serial dilution of the cDNA and by melt curve analysis of the qPCR products. qPCR was 
performed using the Quant Studio 3 qPCR system with the following specifications: 
qPCR reaction     qPCR programm 
10 µl A&B Fast SYBR Green Master mix    
1 µl primer fwd (20 µM)    95°C  
1 µl primer rev (20 µM)    95°C 50 cycles 
1 µl cDNA     60°C  
7 µl dH2O       
 
The cycle of threshold (Ct) values were analyzed using Quant Studio Design & Analysis software, at an 
normalized reporter value (ΔRn) of 0,1. Human β2-microglobulin (B2M, Gene ID 567) and murine 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Gene ID 14433) were used as references genes 
for sample loading control.  
For human cocultivation experiments, the data were analyzed using the ΔΔCt method. The Ct value of 
the reference gene was substracted from the Ct value of the gene of interest to normalize for equal 
loading. The resulting ΔCt value was substracted from the ΔCt value of the unstimulated control. The 
fold change was calculated using the formula 𝐹𝐹𝐹𝐹 = 2(−ΔΔCt). In cases where inhibitors were used, 
samples were normalized to cocultivations of PBMCs with neutrophils stimulated with PMA without 
inhibitor.  
In murine ConA in vivo experiments the ΔCt value was calculated the same way as described for human 
samples. To make the different mice comparable, the relative expression was calculated by using the 
formula 𝑅𝑅𝑁𝑁 = 2−ΔCt . 
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Reporter cell assay for human TIIFN 
For the detection of human TIIFN HEK Blue reporter cells were used. 0,8x105 cells were seeded in 100 
µl DMEM basic medium in 96-well plates and combined with 100 µl undiluted supernatant of 
stimulated cells and incubated for 24 h at 37°C. After 24 h, 100 µl of the HEK Blue cell supernatant 
were transferred into a new plate, combined with 100 µl Quanti-Blue solution and incubated at 37°C 
until a color change from pink to blue was visible that correlated with the presence of TIIFN. The color 
change was measured at OD655nm using a spectrophotometer. 
Reporter cell assay for murine TIIFN 
0,5x105 L929 ISRE Luc cells were seeded in 100 µl DMEM in white 96-well plates and incubated o.n. at 
37°C. The next day, 100 µl undiluted culture supernatant was added and incubated for 6 h at 37°C. 
Subsequently, the supernatant was aspirated and replaced with 100 µl Bright-Glo luciferase substrate 
(Promega). After 2 min incubation at RT, luciferase activity was quantified with the Victor X Light reader 
(Perkin Elmer). 
ELISAs 
ELISAs for human universal IFNα, humane CXCL10, ANCA antibodies, human C1q, nucleosomes, and 
murine IFNβ were conducted according to the instructions of the manufacturers. The supernatants of 
stimulated cells were used undiluted. For blocking of plates and dilution of standard curves, ELISA 
dilution buffer was used, unless it was specified differently in the instructions. ELISA plate were washed 
with PBS-T. 
4.2.10 Uptake of NETs by human macrophages 
Cocultivation of macrophages and neutrophils undergoing NETosis 
Human monocytes were isolated and differentiated into macrophages in 8-well IBIDI chambers as 
described above. At day seven, the supernatant was removed and replaced with 150 µl fresh medium. 
In case of live cell imaging, neutrophils were pre-stained with cell-tracker according to manufacturers 
instructions. Neutrophils were added to the macrophages at a ratio of 1:1 in the presence of Hoechst 
and stimulated with 100 nM PMA. For live cell imaging cell were recorded for 6 h at 20x magnification. 
Alternatively, cells were incubated for 4 h at 37°C and subsequently treated with 20 U DNAse1 for 15 
min to remove extracellular NETs. Afterwards the samples were fixed for 15 min at RT with 2 % PFA. 
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Staining of uptake samples 
Cells were permeabilized with 0,5 % Triton X100 in PBS for 5 min at RT and subsequently blocked for 
20 min at RT with IFA-blocking buffer. The samples were incubated with the primary antibodies for 1 
h at RT and washed three times with PBS. The corresponding secondary antibodies and Hoechst (100 
ng/ml) were added for 30 min at RT. After three subsequent washes with PBS, the samples were stored 
in PBS at 4°C and imaged as soon as possible. The samples were imaged using the SP8 confocal (Leica) 
microscope with the 63x objective.  
4.2.11 FACS staining 
FACS human neutrophils 
Human cells were resuspended in PBS and incubated with FcR-blocking solution (Miltenyi) for 5 min at 
RT. Subsequently fluorochrome-labeled antibodies were added and the samples were incubated for 
30 min on ice. The cells were washed three times with PBS and analyzed using the MACS Quant system. 
To test viability DAPI (500 ng/ml) was added directly before acquisition. The data was analyzed by 
FlowJoX. 
 
FACS murine immune cells 
100 µl of full blood were transferred into a FACS tube and mixed with 100 µl FACS buffer containing 
the fluorochrome-labeled antibodies in 2x concentration. The samples were vortexed gently and 
incubated for 1 h in the dark at RT. Subsequently 3 ml of 1x one step lyse/fix solution (Invitrogen) was 
added and incubate for 30 min in the dark at RT. The cells were pelleted at 500 g for 5 min and washed 
three times with FACS buffer. Finally, the cells were resuspended in 300 µl PBS and 50 µl were 
measured using the MACS Quant system. 
 
FACS for phosphorylation of IRF3 
Monocytes were stimulated for 6 h with 100 µg/ml NETs and 25 µl DOTAP. Subsequently the cells were 
fixed with 4 % PFA (w/v) for 10 min at RT. After centrifugation for 5 min at 300g and 4°C, cells were 
stored o.n in 90 % MeOH at -20°C. At the next day, the cells were harvested by centrifugation, 
resuspended in 100 µl 0,5 % (w/v) BSA in PBS and incubated with the primary antibody (1:50, 
concentration not specified by company) for 1 h at RT. The cells were centrifuged and washed three 
times in 500 µl 0,5 % BSA in PBS. Subsequently the cells were incubated for 30 min with the secondary 
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antibody (10 µg/ml) at RT. After three additional washing steps the cells were resuspended in 200 µl 
PBS and analyzed with the flow cytometer. 
4.2.12 Murine in vivo experiments 
All animal experiments were officially approved by Landesamt für Gesundheit und Soziales (Berlin, 
Germany) and are conducted in compliance with the German animal protection law. 
Concanavalin A injection 
Mice of different genotypes were injected i.v. with ConA (15 mg/kg bodyweight). After 12 h, mice were 
anesthetized with isoflurane and bled by cardiac puncture, resulting in painless death due to blood 
loss. The blood was collected in syringes with EDTA (final concentration 50 µM) to prevent coagulation 
and immediately stored on ice. To generate plasma the blood was centrifuged 10 min at 4°C at 10000 
g. The plasma was collected and shock frozen in liquid nitrogen. The cells were resuspended in 1 ml 
RBC lysis buffer and incubated for 3 min on ice. The cells were pelleted at 500 g for 5 min at 4°C, 
resuspended in 1 ml TRIZOL and stored for RNA isolation at -80°C. 
ALT/AST measurement 
The hepatocyte specific enzymes alanine-aminotransferase (ALT) and asparatate-aminotransferase 
(AST) that were used as markers for liver damage were quantified by the routine veterinarian service 
laboratory SYNLAB.vet GmbH (Turmstraße 21, 10559 Berlin, Germany). 
NET ELISA 
Biotin-coated ELISA plates were labeled with 50 µl MPO-streptavidin (1 µg/ml) o.n. at 4°C. At the next 
day, the plates were washed in PBS-T and blocked for 2 h at RT with 5 % BSA in PBS. 50 µl sample or 
50 µl standard were added to the wells and incubated 2h at RT under constant shaking. Murine NETs 
were used as a standard, starting with 1 µg/ml as a highest concentration being diluted 1:1. The serum 
samples were used undiluted. Subsequently, the plate was washed three times with PBS-T and the 
anti-DNA antibody (1:50) coupled to a peroxidase of the ROCHE cell death ELISA Kit was added for 2 h. 
Finally, the plate was washed, 100 µl TMB substrate were added and the reaction was stopped using 
50 µl 2N H2SO4 when the desired color change was visible. The signal was quantified at OD405nm using 
a spectrophotometer. 
Material and Methods 
78 
 
Neutrophil depletion 
Wildtype mice were injected i.p. with the neutrophil-depleting Ly6G antibody or an isotype control (20 
mg/kg bodyweight). After 24 h mice were treated with PBS or ConA as described before. To verify the 
successful depletion, neutrophils were quantified in full blood as described above. 
Chemiluminescence assay for detection of ROS production 
105 neutrophils were seeded in 100 µl medium in a white 96-well plate. HRP (1200 U/ml) and luminol 
(50 mM) were diluted 1:200 in medium and 11 µl of the mix were added to the cells. The cells were 
incubated for 15 min at 37°C and subsequently stimulated with PMA (100 nM) or left untreated. 
Chemiluminscence was recorded using the Victor X Light reader (Perkin Elmer) for a total of 3 h in 2,5 
minute intervals. 
4.2.13 Microarray for ConA injected mice 
Total RNA quality and quantity was analyzed using an Agilent 2100 Bioanalyzer (Agilent Technologies) 
and a NanoDrop 1000 UV-Vis spectrophotometer (Thermo Fisher Scientific). Microarray experiments 
were performed as single-color hybridization. Total RNA was amplified and labeled with the low input 
Quick-Amp Labeling Kit (Agilent Technologies). In brief, mRNA was reverse transcribed and amplified 
using an oligo-dT-T7 promoter primer and labeled with cyanine 3-CTP. After precipitation, purification, 
and quantification, 1,25 μg of each labeled cRNA was fragmented and hybridized to whole genome 
mouse 4 × 44k multipack microarrays (Agilent-014868, whole mouse genome 4x44K microarray kit) 
according to the supplier’s protocol (Agilent Technologies). Scanning of microarrays was performed 
with 5 μm resolution using a G2565CA high-resolution laser microarray scanner (Agilent Technologies) 
with extended dynamic range (XDR). Microarray image data were processed with the Image 
Analysis/Feature Extraction software G2567AA v. A.11.5.1.1 (Agilent Technologies) using default 
settings and the GE1_1105_Oct12 extraction protocol. The extracted MAGE-ML files were analyzed 
further with the Rosetta Resolver Biosoftware, Build 7.2.2 SP1.31 (Rosetta Biosoftware) and the 
extracted txt files were further analyzed with R scripts and the associated BioConductor limma package 
242. 
To generate the scatter plot, fold changes detected by microarray after ConA stimulations were plotted 
from Wildtype versus cGAS-/- mice. Genes were colored by significance of their different regulation in 
Wildtype compared to cGAS-/- mice. Labeled genes are significant genes that are contained in either 
GO-term „cytokine activity“ (GO:005125) or „response to type I interferon“ (GO:0034340). 
Select GO-terms from microarray were plotted using the R tmod package 243. 
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4.2.14 In vitro stimulation of recombinant cGAS 
Constructs and cloning 
The plasmids encoding catalytic domains of human (h) and mouse (m) cGAS (aa 155–522 and aa 141–
507, respectively) for an N-terminal His6–MBP (maltose-binding protein) fusion protein expression 
were described before244. 
Protein expression and purification 
Proteins were expressed and purified as described before 227. Proteins were flash-frozen in liquid 
nitrogen and stored at −80 °C. 
Radio-labelled cGAS activity assays 
Radiolabelled cGAS activity assays were performed analogously to previously described 244. Briefly, 10 
ng/µl sonified NETs (defined by absorption at 260nm) were mixed with 4 µM mcGAS. The reaction was 
started by adding 100 µM ATP and 100 µM GTP in buffer containing 40 mM Tris pH 7.5, 100 mM NaCl, 
10 mM MgCl2, and 1:600 [α32P]ATP (3,000 Ci/mmol, Hartman Analytic). Following the incubation at 
35°C for indicated time the reactions were stopped by plotting on PEI-Cellulose F plates (Merck) and 
analysed by thin-layer chromatography with 1 M (NH4)2SO4/1,5 M KH2PO4 as running buffer. The 
radiolabelled products were visualized with a Typhoon FLA 9000 phosphor imaging system.  
For DNaseI-treated NETs 6 ng/µl NETs and 6 µM hcGAS were used. NETs components and proteinase-
treated NETs were prepared as described above and tested by using 8 ng/µl NETs and 4 µM hcGAS. In 
all control experiments pET28M–SUMO1–GFP vector (EMBL) (6,2 kbp, plasmid) was used in 
corresponding concentrations. 
NET Electrophoresis 
300 ng of DNAseI-treated NETs were analysed in 1,5 % agarose gel prepared with Ethidiumbromide (1 
µg/ml), in running buffer containing 40 mM Tris, 20 mM acetic acid and 1 mM EDTA, pH 8,3. For 
analysis of the separate NETs components and proteinase-treated NETs 170 ng of material were used. 
The gel images were obtained with Gel Doc XR+ Imager (BioRad). 
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4.2.15 Statistical analysis 
The number of replicates for each experiment is indicated below the figures. The compiled data was 
analyzed by GraphPad PRISM, using the indicated test. To assess if a parametric or non-paramatric test 
has to be used, the data sets were tested using the Shapiro-Wilk-Test, α=0,05. The statistical 
significance is indicated in the figures as follows: *p<0,05, **p<0,01, ***p<0,001, ****p<0,0001, 
values indicate exact p-values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
X 
 
 
5 References 
1. Buchmann, K. Evolution of Innate Immunity: Clues from Invertebrates via Fish to Mammals. 
Front. Immunol. 5, 459 (2014). 
2. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428–435 (2008). 
3. Schett, G. & Neurath, M. F. Resolution of chronic inflammatory disease: universal and tissue-
specific concepts. Nat. Commun. 9, 3261 (2018). 
4. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 
81, 1–5 (2007). 
5. Pisetsky, D. S. The origin and properties of extracellular DNA: From PAMP to DAMP. Clin. 
Immunol. 144, 32–40 (2012). 
6. Gallucci, S. & Maffei, M. E. DNA Sensing across the Tree of Life. Trends Immunol. 38, 719–732 
(2017). 
7. Motta, V., Soares, F., Sun, T. & Philpott, D. J. NOD-Like Receptors: Versatile Cytosolic Sentinels. 
Physiol. Rev. 95, 149–178 (2015). 
8. Kawai, T. & Akira, S. Toll-like Receptors and Their Crosstalk with Other Innate Receptors in 
Infection and Immunity. Immunity 34, 637–650 (2011). 
9. Hoving, J. C., Wilson, G. J. & Brown, G. D. Signalling C-Type lectin receptors, microbial 
recognition and immunity. Cell. Microbiol. 16, 185–194 (2014). 
10. Sharma, S., Fitzgerald, K. A., Cancro, M. P. & Marshak-Rothstein, A. Nucleic Acid-Sensing 
Receptors: Rheostats of Autoimmunity and Autoinflammation. J. Immunol. 195, 3507–12 
(2015). 
11. Brubaker, S. W., Bonham, K. S., Zanoni, I. & Kagan, J. C. Innate Immune Pattern Recognition: A 
Cell Biological Perspective. Annu. Rev. Immunol. 33, 257–290 (2015). 
12. Ortega-Gómez, A., Perretti, M. & Soehnlein, O. Resolution of inflammation: an integrated view. 
EMBO Mol. Med. 5, 661–74 (2013). 
13. Newburger, P. E. & Dale, D. C. Evaluation and management of patients with isolated 
neutropenia. Semin. Hematol. 50, 198–206 (2013). 
14. Borregaard, N. Neutrophils, from Marrow to Microbes. Immunity 33, 657–670 (2010). 
15. McCracken, J. M. & Allen, L.-A. H. Regulation of human neutrophil apoptosis and lifespan in 
health and disease. J. Cell Death 7, 15–23 (2014). 
16. Strydom, N. & Rankin, S. M. Regulation of circulating neutrophil numbers under homeostasis 
and in disease. J. Innate Immun. 5, 304–14 (2013). 
References 
XI 
 
17. Thomas, C. J. & Schroder, K. Pattern recognition receptor function in neutrophils. Trends 
Immunol. 34, 317–328 (2013). 
18. Scapini, P., Lapinet-Vera, J. A. & Cassatella, M. A. The neutrophil as a cellular source of 
chemokines. Immunol. Rev. 195–203 (2000). 
19. Wozniak, A., Betts, W. H., Murphy, G. A. & Rokicinski, M. Interleukin-8 primes human 
neutrophils for enhanced superoxide anion production. Immunology 79, 608–15 (1993). 
20. Tecchio, C., Micheletti, A. & Cassatella, M. A. Neutrophil-derived cytokines: facts beyond 
expression. Front. Immunol. 5, 508 (2014). 
21. Dinarello, C. A. Proinflammatory Cytokines. Chest 118, 503–508 (2000). 
22. DeCoursey, T. E. & Ligeti, E. Regulation and termination of NADPH oxidase activity. Cell. Mol. 
Life Sci. 62, 2173–2193 (2005). 
23. Winterbourn, C. C., Kettle, A. J. & Hampton, M. B. Reactive Oxygen Species and Neutrophil 
Function. Annu. Rev. Biochem. 85, 765–792 (2016). 
24. Nguyen, G. T., Green, E. R. & Mecsas, J. Neutrophils to the ROScue: Mechanisms of NADPH 
Oxidase Activation and Bacterial Resistance. Front. Cell. Infect. Microbiol. 7, 373 (2017). 
25. Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P. & Malik, A. B. Reactive oxygen species in 
inflammation and tissue injury. Antioxid. Redox Signal. 20, 1126–67 (2014). 
26. Marciano, B. E. et al. Common severe infections in chronic granulomatous disease. Clin. Infect. 
Dis. 60, 1176–83 (2015). 
27. Amulic, B., Cazalet, C., Hayes, G. L., Metzler, K. D. & Zychlinsky, A. Neutrophil function: from 
mechanisms to disease. Annu. Rev. Immunol. 30, 459–489 (2012). 
28. Faurschou, M. & Borregaard, N. Neutrophil granules and secretory vesicles in inflammation. 
Microbes Infect. 5, 1317–1327 (2003). 
29. Borregaard, N., Sørensen, O. E. & Theilgaard-Mönch, K. Neutrophil granules: a library of innate 
immunity proteins. Trends Immunol. 28, 340–345 (2007). 
30. Nordenfelt, P. & Tapper, H. Phagosome dynamics during phagocytosis by neutrophils. J. Leukoc. 
Biol. 90, 271–284 (2011). 
31. Pauwels, A.-M., Trost, M., Beyaert, R. & Hoffmann, E. Patterns, Receptors, and Signals: 
Regulation of Phagosome Maturation. Trends Immunol. 38, 407–422 (2017). 
32. Richards, D. M. & Endres, R. G. The mechanism of phagocytosis: Two stages of engulfment. 
Biophys. J. 107, 1542–1553 (2014). 
33. Brinkmann, V. et al. Neutrophil Extracellular Traps Kill Bacteria Brinkmann Science 2004.pdf. 
Science 303, 1532–5 (2004). 
34. Urban, C. F. et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein 
References 
XII 
 
complex involved in host defense against Candida albicans. PLoS Pathog. 5, (2009). 
35. Fuchs, T. A. et al. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 
176, 231–241 (2007). 
36. Wen, F., White, G. J., VanEtten, H. D., Xiong, Z. & Hawes, M. C. Extracellular DNA is required for 
root tip resistance to fungal infection. Plant Physiol. 151, 820–9 (2009). 
37. Sousa-Rocha, D. et al. Trypanosoma cruzi and Its Soluble Antigens Induce NET Release by 
Stimulating Toll-Like Receptors. PLoS One 10, e0139569 (2015). 
38. Kenny, E. F. et al. Diverse stimuli engage different neutrophil extracellular trap pathways. Elife 
6, (2017). 
39. Papayannopoulos, V., Metzler, K. D., Hakkim, A. & Zychlinsky, A. Neutrophil elastase and 
myeloperoxidase regulate the formation of neutrophil extracellular traps. J. Cell Biol. 191, 677–
91 (2010). 
40. Munafo, D. B. et al. DNase I Inhibits a Late Phase of Reactive Oxygen Species Production in 
Neutrophils. J. Innate Immun. 1, 527–542 (2009). 
41. Ramos-Kichik, V. et al. Neutrophil extracellular traps are induced by Mycobacterium 
tuberculosis. Tuberculosis 89, 29–37 (2009). 
42. Urban, C. F., Reichard, U., Brinkmann, V. & Zychlinsky, A. Neutrophil extracellular traps capture 
and kill Candida albicans yeast and hyphal forms. Cell. Microbiol. 8, 668–676 (2006). 
43. Schönrich, G. & Raftery, M. J. Neutrophil Extracellular Traps Go Viral. Front. Immunol. 7, 366 
(2016). 
44. Branzk, N. et al. Neutrophils sense microbe size and selectively release neutrophil extracellular 
traps in response to large pathogens. Nat. Immunol. 15, 1017–1025 (2014). 
45. Clark, S. R. et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in 
septic blood. Nat. Med. 13, 463–469 (2007). 
46. Yousefi, S., Mihalache, C., Kozlowski, E., Schmid, I. & Simon, H. U. Viable neutrophils release 
mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ. 16, 1438–44 (2009). 
47. Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 
623–625 (2009). 
48. Mitroulis, I. et al. Neutrophil Extracellular Trap Formation Is Associated with IL-1β and 
Autophagy-Related Signaling in Gout. PLoS One 6, e29318 (2011). 
49. Amulic, B. et al. Cell-Cycle Proteins Control Production of Neutrophil Extracellular Traps. Dev. 
Cell 43, 449–462.e5 (2017). 
50. Bianchi, M. et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. 
Blood 114, 2619–2622 (2009). 
References 
XIII 
 
51. Hakkim, A. et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular 
trap formation. Nat. Chem. Biol. 7, 75–77 (2011). 
52. Metzler, K. D., Goosmann, C., Lubojemska, A., Zychlinsky, A. & Papayannopoulos, V. A 
Myeloperoxidase-Containing Complex Regulates Neutrophil Elastase Release and Actin 
Dynamics during NETosis. Cell Rep. 8, 883–896 (2014). 
53. Sollberger, G. et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular 
traps. Sci. Immunol. 3, eaar6689 (2018). 
54. Pilsczek, F. H. et al. A Novel Mechanism of Rapid Nuclear Neutrophil Extracellular Trap 
Formation in Response to Staphylococcus aureus. J. Immunol. 185, 7413–7425 (2010). 
55. Beiter, K. et al. An Endonuclease Allows Streptococcus pneumoniae to Escape from Neutrophil 
Extracellular Traps. Curr. Biol. 16, 401–407 (2006). 
56. Halverson, T. W. R., Wilton, M., Poon, K. K. H., Petri, B. B. & Lewenza, S. DNA is an antimicrobial 
component of neutrophil extracellular traps. PLoS Pathog. 11, e1004593 (2015). 
57. Guimaraes-Costa, A. B. et al. Leishmania amazonensis promastigotes induce and are killed by 
neutrophil extracellular traps. Proc. Natl. Acad. Sci. 106, 6748–6753 (2009). 
58. Juneau, R. A., Pang, B., Weimer, K. E. D., Armbruster, C. E. & Swords, W. E. Nontypeable 
Haemophilus influenzae Initiates Formation of Neutrophil Extracellular Traps. Infect. Immun. 
79, 431–438 (2011). 
59. Bhattacharya, M. et al. Staphylococcus aureus biofilms release leukocidins to elicit extracellular 
trap formation and evade neutrophil-mediated killing. Proc. Natl. Acad. Sci. 115, 7416–7421 
(2018). 
60. Park, J. et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci. 
Transl. Med. 8, 361ra138 (2016). 
61. Wong, S. L. et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound 
healing. Nat. Med. 21, 815–819 (2015). 
62. Camicia, G., Pozner, R. & de Larrañaga, G. Neutrophil Extracellular Traps in Sepsis. Shock 42, 
286–294 (2014). 
63. Martinod, K. & Wagner, D. D. Thrombosis: tangled up in NETs. Blood 123, 2768–2776 (2013). 
64. Warnatsch, A., Ioannou, M., Wang, Q. & Papayannopoulos, V. Neutrophil extracellular traps 
license macrophages for cytokine production in atherosclerosis. Science (80-. ). 349, 316–320 
(2015). 
65. Gupta, S. & Kaplan, M. J. The role of neutrophils and NETosis in autoimmune and renal diseases. 
Nat Rev Nephrol 12, 402–413 (2016). 
66. Momohara, S., Kashiwazaki, S., Inoue, K., Saito, S. & Nakagawa, T. Elastase from 
References 
XIV 
 
polymorphonuclear leukocyte in articular cartilage and synovial fluids of patients with 
rheumatoid arthritis. Clin. Rheumatol. 16, 133–40 (1997). 
67. Denny, M. F. et al. A distinct subset of proinflammatory neutrophils isolated from patients with 
systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 
184, 3284–3297 (2010). 
68. Rees, F., Doherty, M., Grainge, M. J., Lanyon, P. & Zhang, W. The worldwide incidence and 
prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. 
Rheumatology 56, 1945–1961 (2017). 
69. Al-Mayouf, S. M. et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic 
lupus erythematosus. Nat. Genet. 43, 1186–1188 (2011). 
70. Yasutomo, K. et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. 
Genet. 28, 313–4 (2001). 
71. Cojocaru, M., Cojocaru, I. M., Silosi, I. & Vrabie, C. D. Manifestations of systemic lupus 
erythematosus. Maedica (Buchar). 6, 330–6 (2011). 
72. Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N Engl J Med 358, 929–939 (2008). 
73. Stojan, G. & Petri, M. Atherosclerosis in systemic lupus erythematosus. J. Cardiovasc. 
Pharmacol. 62, 255–62 (2013). 
74. Midgley, A. & Beresford, M. W. Cellular localization of nuclear antigen during neutrophil 
apoptosis: mechanism for autoantigen exposure? Lupus 20, 641–6 (2011). 
75. Friou, G. Clinical application of lupus serum-nucleoprotein reaction using fluorescent antibody 
technique. J Clin Invest 8, 224–229 (1958). 
76. Cervera, R. et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker 
for lupus nephropathy. Ann. Rheum. Dis. 62, 431–4 (2003). 
77. Nässberger, L., Jonsson, H., Sjöholm, A. G., Sturfelt, G. & Heubner, A. Circulating anti-elastase 
in systemic lupus erythematosus. Lancet (London, England) 1, 509 (1989). 
78. Fritzler, M. J. & Tan, E. M. Antibodies to histones in drug-induced and idiopathic lupus 
erythematosus. J. Clin. Invest. 62, 560–7 (1978). 
79. Spronk, P. E. et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br. 
J. Rheumatol. 35, 625–31 (1996). 
80. Carmona-Rivera, C., Zhao, W., Yalavarthi, S. & Kaplan, M. J. Neutrophil extracellular traps induce 
endothelial dysfunction in systemic lupus erythematosus through the activation of matrix 
metalloproteinase-2. Ann Rheum Dis 74, 1417–1424 (2015). 
81. Lande, R. et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide 
complexes in systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra19 (2011). 
References 
XV 
 
82. Hirose, O., Itabashi, M., Takei, T., Honda, K. & Nitta, K. Antineutrophil cytoplasmic antibody-
associated glomerulonephritis with immunoglobulin deposition. Clin. Exp. Nephrol. 21, 643–
650 (2017). 
83. Waldman, M. & Madaio, M. P. Pathogenic autoantibodies in lupus nephritis. Lupus 14, 19–24 
(2005). 
84. Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in 
pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20 (2011). 
85. Lood, C. et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are 
interferogenic and contribute to lupus-like disease. Nat Med 22, 146–153 (2016). 
86. Blanco, P., Palucka, A. K., Gill, M., Pascual, V. & Banchereau, J. Induction of dendritic cell 
differentiation by IFN-alpha in systemic lupus erythematosus. Science (80-. ). 294, 1540–1543 
(2001). 
87. Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. 
Nature 449, 564–569 (2007). 
88. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I interferons in infectious 
disease. Nat. Rev. Immunol. 15, 87–103 (2015). 
89. Crow, M. K. Type I interferon in the pathogenesis of lupus. J Immunol 192, 5459–5468 (2014). 
90. Banchereau, J. & Pascual, V. Type I Interferon in Systemic Lupus Erythematosus and Other 
Autoimmune Diseases. Immunity 25, 383–392 (2006). 
91. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus 
blood. J Exp Med 197, 711–723 (2003). 
92. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of 
patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 100, 2610–5 (2003). 
93. Amoura, Z. et al. Circulating plasma levels of nucleosomes in patients with systemic lupus 
erythematosus: correlation with serum antinucleosome antibody titers and absence of clear 
association with disease activity. Arthritis Rheum. 40, 2217–25 (1997). 
94. Telles, R. W., Ferreira, G. A., Silva, N. P. da & Sato, E. I. Increased plasma myeloperoxidase levels 
in systemic lupus erythematosus. Rheumatol. Int. 30, 779–784 (2010). 
95. Atamaniuk, J. et al. Analysing cell-free plasma DNA and SLE disease activity. Eur. J. Clin. Invest. 
41, 579–583 (2011). 
96. Carli, L., Tani, C., Vagnani, S., Signorini, V. & Mosca, M. Leukopenia, lymphopenia, and 
neutropenia in systemic lupus erythematosus: Prevalence and clinical impact—A systematic 
literature review. Semin. Arthritis Rheum. 45, 190–194 (2015). 
97. Ren, Y. et al. Increased Apoptotic Neutrophils and Macrophages and Impaired Macrophage 
References 
XVI 
 
Phagocytic Clearance of Apoptotic Neutrophils in Systemic Lupus Erythematosus. Arthritis 
Rheum. 48, 2888–2897 (2003). 
98. Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and 
expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538–
552 (2011). 
99. Hacbarth, E. & Kajdacsy-Balla, A. Low density neutrophils in patients with systemic lupus 
erythematosus, rheumatoid arthritis, and acute rheumatic fever. Arthritis Rheum 29, 1334–
1342 (1986). 
100. Midgley, A. & Beresford, M. Increased expression of low density granulocytes in juvenile-onset 
systemic lupus erythematosus patients correlates with disease activity. Lupus 25, 407–411 
(2016). 
101. Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with 
lupus nephritis. Proc Natl Acad Sci U S A 107, 9813–9818 (2010). 
102. Wang, H., Li, T., Chen, S., Gu, Y. & Ye, S. Neutrophil extracellular trap mitochondrial DNA and its 
autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. 
Arthritis Rheumatol. 67, 3190–3200 (2015). 
103. Farrera, C. & Fadeel, B. Macrophage Clearance of Neutrophil Extracellular Traps Is a Silent 
Process. J. Immunol. 191, 2647–2656 (2013). 
104. Shao, W.-H. & Cohen, P. L. Disturbances of apoptotic cell clearance in systemic lupus 
erythematosus. Arthritis Res. Ther. 13, 202 (2011). 
105. Jacob, M., Napirei, M., Ricken,  a, Dixkens, C. & Mannherz, H. Histopathology of lupus-like 
nephritis in Dnase1-deficient mice in comparison to NZB/W F1 mice. Lupus 11, 514–527 (2002). 
106. Sisirak, V. et al. Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. 
Cell 166, 88–101 (2016). 
107. Leffler, J. et al. Degradation of neutrophil extracellular traps co-varies with disease activity in 
patients with systemic lupus erythematosus. Arthritis Res. Ther. 15, R84 (2013). 
108. Lee-Kirsch, M. A. et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are 
associated with systemic lupus erythematosus. Nat. Genet. 39, 1065–1067 (2007). 
109. Fye, J. M., Orebaugh, C. D., Coffin, S. R., Hollis, T. & Perrino, F. W. Dominant Mutations of the 
TREX1 Exonuclease Gene in Lupus and Aicardi-Goutières Syndrome. J. Biol. Chem. 286, 32373–
32382 (2011). 
110. Hu, Z. et al. Neutrophil extracellular traps induce IL-1?? production by macrophages in 
combination with lipopolysaccharide. Int. J. Mol. Med. 39, 549–558 (2017). 
111. Kahlenberg, J. M., Carmona-Rivera, C., Smith, C. K. & Kaplan, M. J. Neutrophil extracellular trap-
References 
XVII 
 
associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. 
J. Immunol. 190, 1217–1226 (2013). 
112. Mankan, A. K., Dau, T., Jenne, D. & Hornung, V. The NLRP3/ASC/Caspase-1 axis regulates IL-
1beta processing in neutrophils. Eur. J. Immunol. 42, 710–715 (2012). 
113. Sabbione, F. et al. Neutrophil Extracellular Traps Stimulate Proinflammatory Responses in 
Human Airway Epithelial Cells. J. Innate Immun. 9, 387–402 (2017). 
114. Chamilos, G. et al. Cytosolic sensing of extracellular self-DNA transported into monocytes by 
the antimicrobial peptide LL37. Blood 120, 3699–3707 (2012). 
115. Caielli, S. et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon 
production in human lupus. J Exp Med 213, 697–713 (2016). 
116. Nickerson, K. M., Cullen, J. L., Kashgarian, M. & Shlomchik, M. J. Exacerbated autoimmunity in 
the absence of TLR9 in MRL.Fas(lpr) mice depends on Ifnar1. J. Immunol. 190, 3889–94 (2013). 
117. Lartigue, A. et al. Role of TLR9 in Anti-Nucleosome and Anti-DNA Antibody Production in lpr 
Mutation-Induced Murine Lupus. J. Immunol. 177, 1349–1354 (2006). 
118. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor 
That Activates the Type I Interferon Pathway. Science (80-. ). 339, 786–791 (2013). 
119. Lio, C.-W. J. et al. cGAS-STING Signaling Regulates Initial Innate Control of Cytomegalovirus 
Infection. J. Virol. 90, 7789–7797 (2016). 
120. Schoggins, J. W. et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in 
innate immunity. Nature 505, 691–695 (2014). 
121. Wu, J. J. et al. Inhibition of cGAS DNA Sensing by a Herpesvirus Virion Protein. Cell Host Microbe 
18, 333–344 (2015). 
122. Ma, Z. et al. Modulation of the cGAS-STING DNA sensing pathway by gammaherpesviruses. Proc 
Natl Acad Sci U S A 112, E4306-15 (2015). 
123. Dansako, H. et al. The cyclic GMP-AMP synthetase-STING signaling pathway is required for both 
the innate immune response against HBV and the suppression of HBV assembly. FEBS J. 283, 
144–156 (2016). 
124. Dai, P. et al. Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine 
Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway. PLoS 
Pathog. 10, e1003989 (2014). 
125. Lam, E., Stein, S. & Falck-Pedersen, E. Adenovirus Detection by the cGAS/STING/TBK1 DNA 
Sensing Cascade. J. Virol. 88, 974–981 (2014). 
126. Gao, D. et al. Cyclic GMP-AMP Synthase Is an Innate Immune Sensor of HIV and Other 
Retroviruses. Science (80-. ). 341, 903–906 (2013). 
References 
XVIII 
 
127. Watson, R. O. et al. The Cytosolic Sensor cGAS Detects Mycobacterium tuberculosis DNA to 
Induce Type I Interferons and Activate Autophagy. Cell Host Microbe 17, 811–819 (2015). 
128. Storek, K. M., Gertsvolf, N. A., Ohlson, M. B. & Monack, D. M. cGAS and Ifi204 cooperate to 
produce type I IFNs in response to Francisella infection. J Immunol 194, 3236–3245 (2015). 
129. Hartlova, A. et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor 
STING to promote anti-microbial innate immunity. Immunity 42, 332–343 (2015). 
130. Glück, S. et al. Innate immune sensing of cytosolic chromatin fragments through cGAS promotes 
senescence. Nat. Cell Biol. 19, 1061–1070 (2017). 
131. West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 
520, 553–557 (2015). 
132. Ablasser, A. et al. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA 
polymerase III–transcribed RNA intermediate. Nat. Immunol. 10, 1065–1072 (2009). 
133. Unterholzner, L. et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 11, 
997–1004 (2010). 
134. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor 
that activates the type I interferon pathway. Science (80-. ). 339, 786–791 (2013). 
135. Lee, A., Park, E.-B., Lee, J., Choi, B.-S. & Kang, S.-J. The N terminus of cGAS de-oligomerizes the 
cGAS:DNA complex and lifts the DNA size restriction of core-cGAS activity. FEBS Lett. 591, 954–
961 (2017). 
136. Zhang, X. et al. The Cytosolic DNA Sensor cGAS Forms an Oligomeric Complex with DNA and 
Undergoes Switch-like Conformational Changes in the Activation Loop. Cell Rep. 6, 421–430 
(2014). 
137. Gao, P. et al. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-
activated cyclic GMP-AMP synthase. Cell 153, 1094–1107 (2013). 
138. Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling 
by cytosolic DNA. Science (80-. ). 826, 826–830 (2014). 
139. Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous 
high-affinity ligand for STING. Mol Cell 51, 226–235 (2013). 
140. Tanaka, Y. & Chen, Z. J. STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA 
Signaling Pathway. Sci. Signal. 5, ra20-ra20 (2012). 
141. Hiscott, J. Triggering the Innate Antiviral Response through IRF-3 Activation. J. Biol. Chem. 282, 
15325–15329 (2007). 
142. West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 
520, 553–557 (2015). 
References 
XIX 
 
143. Stetson, D. B., Ko, J. S., Heidmann, T. & Medzhitov, R. Trex1 Prevents Cell-Intrinsic Initiation of 
Autoimmunity. Cell 134, 587–598 (2008). 
144. Ablasser, A. et al. TREX1 Deficiency Triggers Cell-Autonomous Immunity in a cGAS-Dependent 
Manner. J. Immunol. 192, 5993–5997 (2014). 
145. Gao, D. et al. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. 
Proc. Natl. Acad. Sci. 112, (2015). 
146. Yoshida, H., Okabe, Y., Kawane, K., Fukuyama, H. & Nagata, S. Lethal anemia caused by 
interferon-beta produced in mouse embryos carrying undigested DNA. Nat Immunol 6, 49–56 
(2005). 
147. Lan, Y. Y., Londono, D., Bouley, R., Rooney, M. S. & Hacohen, N. Dnase2a deficiency uncovers 
lysosomal clearance of damaged nuclear DNA via autophagy. Cell Rep 9, 180–192 (2015). 
148. Crow, Y. J. et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-
Goutières syndrome at the AGS1 locus. Nat. Genet. 38, 917–920 (2006). 
149. Kawane, K., Tanaka, H., Kitahara, Y., Shimaoka, S. & Nagata, S. Cytokine-dependent but acquired 
immunity-independent arthritis caused by DNA escaped from degradation. Proc. Natl. Acad. 
Sci. 107, 19432–19437 (2010). 
150. Kawane, K. et al. Chronic polyarthritis caused by mammalian DNA that escapes from 
degradation in macrophages. Nature 443, 998–1002 (2006). 
151. Jeremiah, N. et al. Inherited STING-activating mutation underlies a familial inflammatory 
syndrome with lupus-like manifestations. J Clin Invest 124, 5516–5520 (2014). 
152. Ablasser, A. et al. cGAS produces a 2’-5’-linked cyclic dinucleotide second messenger that 
activates STING. Nature 498, 380–384 (2013). 
153. Diner, E. J. et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic 
dinucleotide that activates human STING. Cell Rep 3, 1355–1361 (2013). 
154. Mali, P. et al. RNA-Guided Human Genome Engineering via Cas9. 823, 823–827 (2013). 
155. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR 
screening. Nat. Methods 11, 783–784 (2014). 
156. Schmid-Burgk, J. L. et al. OutKnocker : a web tool for rapid and simple genotyping of designer 
nuclease edited cell lines. 1719–1723 (2014). doi:10.1101/gr.176701.114 
157. Peng, K., Broz, P., Jones, J., Joubert, L.-M. & Monack, D. Elevated AIM2-mediated pyroptosis 
triggered by hypercytotoxic Francisella mutant strains is attributed to increased intracellular 
bacteriolysis. Cell. Microbiol. 13, 1586–1600 (2011). 
158. Prame Kumar, K., Nicholls, A. J. & Wong, C. H. Y. Partners in crime: neutrophils and 
monocytes/macrophages in inflammation and disease. Cell Tissue Res. 371, 551–565 (2018). 
References 
XX 
 
159. Takaoka, A. et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune 
response. Nature 448, 501–505 (2007). 
160. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745 (2000). 
161. Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes 
is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487–496 (2007). 
162. Leffler, J. et al. Neutrophil extracellular traps that are not degraded in systemic lupus 
erythematosus activate complement exacerbating the disease. J Immunol 188, 3522–3531 
(2012). 
163. Ahn, J., Gutman, D., Saijo, S. & Barber, G. N. STING manifests self DNA-dependent inflammatory 
disease. Proc. Natl. Acad. Sci. U. S. A. 109, 19386–91 (2012). 
164. Kerur, N. et al. CGAS drives noncanonical-inflammasome activation in age-related macular 
degeneration. Nat. Med. 24, 50–61 (2018). 
165. Gaidt, M. M. et al. The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell 
Death Program Upstream of NLRP3. Cell 171, 1110–1124.e18 (2017). 
166. Corkum, C. P. et al. Immune cell subsets and their gene expression profiles from human PBMC 
isolated by Vacutainer Cell Preparation Tube (CPTTM) and standard density gradient. BMC 
Immunol. 16, 48 (2015). 
167. Connelly, K. L. et al. Longitudinal association of type 1 interferon-induced chemokines with 
disease activity in systemic lupus erythematosus. Sci. Rep. 8, 3268 (2018). 
168. Vincent, J. et al. Small molecule inhibition of cGAS reduces interferon expression in primary 
macrophages from autoimmune mice. Nat. Commun. 8, 750 (2017). 
169. Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and 
imidazoquinolines. J Immunol 186, 4794–4804 (2011). 
170. Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M. & Tashiro, Y. Bafilomycin A1, a specific 
inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in 
lysosomes of cultured cells. J. Biol. Chem. 266, 17707–12 (1991). 
171. Jiménez-Alcázar, M. et al. Host DNases prevent vascular occlusion by neutrophil extracellular 
traps. Science (80-. ). 358, (2017). 
172. Glennon-Alty, L., Hackett, A. P., Chapman, E. A. & Wright, H. L. Neutrophils and redox stress in 
the pathogenesis of autoimmune disease. Free Radic. Biol. Med. 0–1 (2018). 
doi:10.1016/j.freeradbiomed.2018.03.049 
173. Tanaka, K. et al. In vivo characterization of neutrophil extracellular traps in various organs of a 
murine sepsis model. PLoS One 9, e111888 (2014). 
174. Amulic, B. et al. Cell-Cycle Proteins Control Production of Neutrophil Extracellular Traps. Dev. 
References 
XXI 
 
Cell 43, 449–462.e5 (2017). 
175. Heymann, F., Hamesch, K., Weiskirchen, R. & Tacke, F. The concanavalin A model of acute 
hepatitis in mice. Lab. Anim. 49, 12–20 (2015). 
176. Daley, J. M., Thomay, A. A., Connolly, M. D., Reichner, J. S. & Albina, J. E. Use of Ly6G-specific 
monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83, 64–70 (2007). 
177. Orlowski, G. M. et al. Multiple Cathepsins Promote Pro–IL-1β Synthesis and NLRP3-Mediated 
IL-1β Activation. J. Immunol. 195, 1685–1697 (2015). 
178. Bangalore, N., Travis, J., Onunka, V. C., Pohl, J. & Shafer, W. M. Identification of the primary 
antimicrobial domains in human neutrophil cathepsin G. J. Biol. Chem. 265, 13584–8 (1990). 
179. Chen, Y. T. et al. In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against 
Trypanosoma cruzi. PLoS Negl. Trop. Dis. 4, e825 (2010). 
180. West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 
520, 553–557 (2015). 
181. Härtlova, A. et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor 
STING to promote anti-microbial innate immunity. Immunity 42, 332–343 (2015). 
182. Du, M. & Chen, Z. J. DNA-induced liquid phase condensation of cGAS activates innate immune 
signaling. 1022, 1–10 (2018). 
183. Almine, J. F. et al. IFI16 and cGAS cooperate in the activation of STING during DNA sensing in 
human keratinocytes. Nat. Commun. 8, 14392 (2017). 
184. Marsman, G., Zeerleder, S. & Luken, B. M. Extracellular histones, cell-free DNA, or nucleosomes: 
differences in immunostimulation. Cell Death Dis. 7, e2518 (2016). 
185. Lee-Kirsch, M. A. et al. Familial Chilblain Lupus, a Monogenic Form of Cutaneous Lupus 
Erythematosus, Maps to Chromosome 3p. Am. J. Hum. Genet. 79, 731–737 (2006). 
186. Kolaczkowska, E. et al. Molecular mechanisms of NET formation and degradation revealed by 
intravital imaging in the liver vasculature. Nat. Commun. 6, 6673 (2015). 
187. Mitsios, A., Arampatzioglou, A., Arelaki, S., Mitroulis, I. & Ritis, K. NETopathies? Unraveling the 
dark side of old diseases through neutrophils. Frontiers in Immunology (2017). 
doi:10.3389/fimmu.2016.00678 
188. Rodríguez-Carrio, J., Alperi-López, M., López, P., Ballina-García, F. J. & Suárez, A. Heterogeneity 
of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As 
a Clinical Biomarker. Front. Immunol. 8, 2007 (2017). 
189. Oestreicher, J. L. et al. Molecular classification of psoriasis disease-associated genes through 
pharmacogenomic expression profiling. Pharmacogenomics J. 1, 272–287 (2001). 
190. Zhou, X. et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of 
References 
XXII 
 
psoriasis on the 63,100-element oligonucleotide array. Physiol. Genomics 13, 69–78 (2003). 
191. Rönnblom, L. E., Alm, G. V. & Öberg, K. Autoimmune Phenomena in Patients with Malignant 
Carcinoid Tumors During Interferon-α Treatment. Acta Oncol. (Madr). 30, 537–540 (1991). 
192. Kiefer, K., Oropallo, M. A., Cancro, M. P. & Marshak-Rothstein, A. Role of type I interferons in 
the activation of autoreactive B cells. Immunol. Cell Biol. 90, 498–504 (2012). 
193. Hervas-Stubbs, S. et al. Direct effects of type I interferons on cells of the immune system. Clin. 
Cancer Res. 17, 2619–27 (2011). 
194. Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 
36–49 (2014). 
195. Bossaller, L. et al. TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage 
Abnormalities in Pristane-Induced Murine Lupus. J. Immunol. 197, 1044–1053 (2016). 
196. Patole, P. S. et al. G-Rich DNA Suppresses Systemic Lupus. J. Am. Soc. Nephrol. 16, 3273–3280 
(2005). 
197. Summers, S. A. et al. TLR9 and TLR4 are required for the development of autoimmunity and 
lupus nephritis in pristane nephropathy. J. Autoimmun. 35, 291–298 (2010). 
198. An, J. et al. Expression of Cyclic GMP-AMP Synthase in Patients With Systemic Lupus 
Erythematosus. Arthritis Rheumatol. 69, 800–807 (2017). 
199. Khamashta, M. et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to 
severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. 
Ann. Rheum. Dis. 75, 1909–1916 (2016). 
200. Kalunian, K. C. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb 
interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. 75, 196–
202 (2016). 
201. Furie, R. et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-
to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 69, 376–386 (2017). 
202. Riggs, J. M. et al. Characterisation of anifrolumab, a fully human anti-interferon receptor 
antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci. Med. 5, 
e000261 (2018). 
203. Morimoto, A. M. et al. Association of endogenous anti-interferon-α autoantibodies with 
decreased interferon-pathway and disease activity in patients with systemic lupus 
erythematosus. Arthritis Rheum. 63, 2407–2415 (2011). 
204. Hall, J. et al. Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel 
fluorescence polarization assay. PLoS One 12, e0184843 (2017). 
205. Rosenbaum, J. T., Mount, G. R., Youssef, J. & Lin, P. New Perspectives in Rheumatology: 
References 
XXIII 
 
Avoiding Antimalarial Toxicity. Arthritis Rheumatol. 68, 1805–1809 (2016). 
206. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. & Khamashta, M. A. Clinical efficacy and 
side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. 
Dis. 69, 20–8 (2010). 
207. Ponticelli, C. & Moroni, G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert 
Opin. Drug Saf. 16, 411–419 (2017). 
208. Jang, C.-H., Choi, J.-H., Byun, M.-S. & Jue, D.-M. Chloroquine inhibits production of TNF-α, IL-1β 
and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different 
modes. Rheumatology 45, 703–710 (2006). 
209. Kuznik, A. et al. Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and 
Imidazoquinolines. J. Immunol. 186, 4794–4804 (2011). 
210. An, J. et al. A novel anti-malarial drug derivative inhibits cyclic GMP-AMP synthase in Trex1 
deficient mice. Arthritis Rheumatol. (2018). doi:10.1002/art.40559 
211. An, J., Woodward, J. J., Sasaki, T., Minie, M. & Elkon, K. B. Cutting Edge: Antimalarial Drugs 
Inhibit IFN-β Production through Blockade of Cyclic GMP-AMP Synthase–DNA Interaction. J. 
Immunol. 194, 4089–4093 (2015). 
212. Piscianz, E. et al. Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old 
Drugs. Curr. Med. Chem. 25, 1–14 (2017). 
213. Wang, Y., Su, G.-H., Zhang, F., Chu, J.-X. & Wang, Y.-S. Cyclic GMP-AMP Synthase Is Required for 
Cell Proliferation and Inflammatory Responses in Rheumatoid Arthritis Synoviocytes. Mediators 
Inflamm. 2015, 192329 (2015). 
214. Clark, I. A., Budd, A. C., Alleva, L. M. & Cowden, W. B. Human malarial disease: a consequence 
of inflammatory cytokine release. Malar. J. 5, 85 (2006). 
215. Sebina, I. & Haque, A. Effects of type I interferons in malaria. Immunology (2018). 
doi:10.1111/imm.12971 
216. Gallego-Marin, C. et al. Cyclic GMP–AMP Synthase Is the Cytosolic Sensor of Plasmodium 
falciparum Genomic DNA and Activates Type I IFN in Malaria. J. Immunol. 200, 768–774 (2018). 
217. Feintuch, C. M. et al. Activated Neutrophils Are Associated with Pediatric Cerebral Malaria 
Vasculopathy in Malawian Children. MBio 7, e01300-15 (2016). 
218. Baker, V. S. et al. Cytokine-associated neutrophil extracellular traps and antinuclear antibodies 
in Plasmodium falciparum infected children under six years of age. Malar. J. 7, 41 (2008). 
219. Rocha, B. C. et al. Type I Interferon Transcriptional Signature in Neutrophils and Low-Density 
Granulocytes Are Associated with Tissue Damage in Malaria. Cell Rep. 13, 2829–2841 (2015). 
220. Abrams, S. T. et al. Circulating Histones Are Mediators of Trauma-associated Lung Injury. Am. J. 
References 
XXIV 
 
Respir. Crit. Care Med. 187, 160–169 (2013). 
221. Pereira, L. F. et al. Histones interact with anionic phospholipids with high avidity; its relevance 
for the binding of histone-antihistone immune complexes. Clin. Exp. Immunol. 97, 175–80 
(1994). 
222. Lee, C.-C., Sun, Y., Qian, S. & Huang, H. W. Transmembrane pores formed by human 
antimicrobial peptide LL-37. Biophys. J. 100, 1688–96 (2011). 
223. Andersson, U., Yang, H. & Harris, H. High-mobility group box 1 protein (HMGB1) operates as an 
alarmin outside as well as inside cells. Semin. Immunol. 0–1 (2018). 
doi:10.1016/j.smim.2018.02.011 
224. Xu, J. et al. Macrophage endocytosis of high-mobility group box 1 triggers pyroptosis. Cell Death 
Differ. 21, 1229–1239 (2014). 
225. Yanai, H. et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate 
immune responses. Nature 462, 99–103 (2009). 
226. Sirois, C. M. et al. RAGE is a nucleic acid receptor that promotes inflammatory responses to 
DNA. J. Exp. Med. 210, 2447–2463 (2013). 
227. Andreeva, L. et al. cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein–
DNA ladders. Nature 549, 394–398 (2017). 
228. Nguyen, T. A. et al. SIDT2 Transports Extracellular dsRNA into the Cytoplasm for Innate Immune 
Recognition. Immunity 47, 498–509.e6 (2017). 
229. Aizawa, S. et al. Lysosomal membrane protein SIDT2 mediates the direct uptake of DNA by 
lysosomes. Autophagy 13, 218–222 (2017). 
230. Kovacsovics-Bankowski, M. & Rock, K. L. A phagosome-to-cytosol pathway for exogenous 
antigens presented on MHC class I molecules. Science 267, 243–6 (1995). 
231. Ackerman, A. L., Giodini, A. & Cresswell, P. A Role for the Endoplasmic Reticulum Protein 
Retrotranslocation Machinery during Crosspresentation by Dendritic Cells. Immunity 25, 607–
617 (2006). 
232. Manz, M. G. & Boettcher, S. Emergency granulopoiesis. Nat. Rev. Immunol. 14, 302–314 (2014). 
233. Harris, D. P., Bandyopadhyay, S., Maxwell, T. J., Willard, B. & DiCorleto, P. E. Tumor Necrosis 
Factor (TNF)-α Induction of CXCL10 in Endothelial Cells Requires Protein Arginine 
Methyltransferase 5 (PRMT5)-mediated Nuclear Factor (NF)-κB p65 Methylation. J. Biol. Chem. 
289, 15328–15339 (2014). 
234. Unterholzner, L. The interferon response to intracellular DNA: why so many receptors? 
Immunobiology 218, 1312–1321 (2013). 
235. Jønsson, K. L. et al. IFI16 is required for DNA sensing in human macrophages by promoting 
References 
XXV 
 
production and function of cGAMP. Nat. Commun. 8, 14391 (2017). 
236. Gray, E. E. et al. The AIM2-like Receptors Are Dispensable for the Interferon Response to 
Intracellular DNA. Immunity 45, 255–66 (2016). 
237. Banerjee, I. et al. Gasdermin D Restrains Type I Interferon Response to Cytosolic DNA by 
Disrupting Ionic Homeostasis. Immunity 1–14 (2018). doi:10.1016/j.immuni.2018.07.006 
238. Yan, S. et al. Deficiency of the AIM2–ASC Signal Uncovers the STING-Driven Overreactive 
Response of Type I IFN and Reciprocal Depression of Protective IFN-γ Immunity in 
Mycobacterial Infection. J. Immunol. 200, 1016–1026 (2018). 
239. Wang, Y. et al. Inflammasome Activation Triggers Caspase-1-Mediated Cleavage of cGAS to 
Regulate Responses to DNA Virus Infection. Immunity 46, 393–404 (2017). 
240. Swanson, K. V. et al. A noncanonical function of cGAMP in inflammasome priming and 
activation. J. Exp. Med. 214, 3611–3626 (2017). 
241. Brinkmann, V., Goosmann, C., Kuhn, L. I. & Zychlinsky, A. Automatic quantification of in vitro 
NET formation. Front Immunol 3, 413 (2012). 
242. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and 
microarray studies. Nucleic Acids Res. 43, e47–e47 (2015). 
243. Weiner, J. & Domaszewska, T. tmod: an R package for general and multivariate enrichment 
analysis. (2016). doi:10.7287/peerj.preprints.2420v1 
244. Civril, F. et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498, 332–7 
(2013). 
 
 
 
 
 
 
 
 
 
Appendix 
XXVI 
 
6 Appendix 
Appendix A NET-associated proteins identified by mass spectrometry. 
The table lists proteins that were identified on NETs by mass spectrometry. Proteins were included, if 
more than two unique significant peptides were identified, using a false discovery rate of 1 %. 
# Accession Protein names 
Num. of 
significant 
sequences 
Num. of 
significant 
unique 
sequences 
1 1433Z_HUMAN 14-3-3 protein zeta/delta 14 9 
2 6PGD_HUMAN 6-phosphogluconate dehydrogenase 17 17 
3 ACTB_HUMAN Actin, cytoplasmic 1 (Beta-actin) 84 3 
4 ACTBL_HUMAN Beta-actin-like protein 2 (Kappa-actin) 28 3 
5 ACTC_HUMAN Actin, alpha cardiac muscle 1 (Alpha-cardiac actin) 38 3 
6 ACTG_HUMAN Actin, cytoplasmic 2 (Gamma-actin) 86 5 
7 ACTN1_HUMAN Alpha-actinin-1  6 4 
8 ACTN4_HUMAN Alpha-actinin-4 11 3 
9 AL5AP_HUMAN Arachidonate 5-lipoxygenase-activating protein 3 3 
10 ALBU_HUMAN Serum albumin 29 29 
11 ALDOA_HUMAN Fructose-bisphosphate aldolase A 4 4 
12 AN32B_HUMAN Acidic leucine-rich nuclear phosphoprotein 32 family member B 3 3 
13 ANX11_HUMAN Annexin A11 9 8 
14 ANXA1_HUMAN Annexin A1 32 32 
15 ANXA3_HUMAN Annexin A3 9 9 
16 ANXA4_HUMAN Annexin A4 8 7 
17 ANXA5_HUMAN Annexin A5 6 6 
18 ANXA6_HUMAN Annexin A6 26 25 
19 APMAP_HUMAN Adipocyte plasma membrane-associated protein 10 10 
20 APOBR_HUMAN Apolipoprotein B receptor 3 3 
21 ARC1B_HUMAN Actin-related protein 2/3 complex subunit 1B 4 4 
22 ARGI1_HUMAN Arginase-1 3 3 
23 ARP2_HUMAN Actin-related protein 2 3 3 
24 ARP3_HUMAN Actin-related protein 3 7 7 
25 ARPC2_HUMAN Actin-related protein 2/3 complex subunit 2 3 3 
26 ARPC3_HUMAN Actin-related protein 2/3 complex subunit 3 3 3 
27 ARPC4_HUMAN Actin-related protein 2/3 complex subunit 4 4 4 
28 AT2A3_HUMAN Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 3 3 
29 ATPA_HUMAN ATP synthase subunit alpha, mitochondrial 6 6 
30 ATPB_HUMAN ATP synthase subunit beta, mitochondrial 7 7 
31 B3AT_HUMAN Band 3 anion transport protein 5 5 
32 BAP31_HUMAN B-cell receptor-associated protein 31 3 3 
33 BASP1_HUMAN Brain acid soluble protein 1 12 12 
34 BLVRB_HUMAN Flavin reductase 4 4 
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35 BPI_HUMAN Bactericidal permeability-increasing protein 8 8 
36 CAH1_HUMAN Carbonic anhydrase 1 5 5 
37 CAH2_HUMAN Carbonic anhydrase 2 9 9 
38 CALM1_HUMAN Calmodulin-1 4 4 
39 CALR_HUMAN Calreticulin  12 12 
40 CALX_HUMAN Calnexin 13 13 
41 CAMP_HUMAN Cathelicidin antimicrobial peptide 3 3 
42 CAP1_HUMAN Adenylyl cyclase-associated protein 1  6 6 
43 CAP7_HUMAN Azurocidin 7 7 
44 CAPG_HUMAN Macrophage-capping protein 4 4 
45 CAPZB_HUMAN F-actin-capping protein subunit beta 7 7 
46 CATA_HUMAN Catalase 11 11 
47 CATG_HUMAN Cathepsin G 9 9 
48 CAZA1_HUMAN F-actin-capping protein subunit alpha-1 3 3 
49 CD59_HUMAN CD59 glycoprotein 3 3 
50 CDC42_HUMAN Cell division control protein 42 homolog 5 3 
51 CDD_HUMAN Cytidine deaminase 3 3 
52 CEAM8_HUMAN Carcinoembryonic antigen-related cell adhesion molecule 8 4 3 
53 CH60_HUMAN 60 kDa heat shock protein, mitochondrial 4 4 
54 CISY_HUMAN Citrate synthase, mitochondrial 3 3 
55 CLIC1_HUMAN Chloride intracellular channel protein 1 3 3 
56 COF1_HUMAN Cofilin-1 3 3 
57 COR1A_HUMAN Coronin-1A 8 8 
58 COX5A_HUMAN Cytochrome c oxidase subunit 5A, mitochondrial 3 3 
59 CP4F3_HUMAN Docosahexaenoic acid omega-hydroxylase  7 7 
60 CPNE3_HUMAN Copine-3 4 4 
61 CPZIP_HUMAN CapZ-interacting protein 3 3 
62 CY24A_HUMAN Cytochrome b-245 light chain 4 4 
63 CY24B_HUMAN Cytochrome b-245 heavy chain 3 3 
64 DEF3_HUMAN Neutrophil defensin 3 4 4 
65 DYSF_HUMAN Dysferlin 7 7 
66 ECP_HUMAN Eosinophil cationic protein 6 6 
67 EF1A1_HUMAN Elongation factor 1-alpha 1 5 5 
68 ELNE_HUMAN Neutrophil elastase 34 34 
69 ENOA_HUMAN Alpha-enolase 10 10 
70 ENPL_HUMAN Endoplasmin 5 5 
71 FA49B_HUMAN FAM49B  3 3 
72 FLNA_HUMAN Filamin-A 4 4 
73 FLOT1_HUMAN Flotillin-1 3 3 
74 G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase  15 15 
75 G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase 12 12 
77 G6PI_HUMAN Glucose-6-phosphate isomerase 24 24 
78 GANAB_HUMAN Neutral alpha-glucosidase AB 4 4 
79 GBB2_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 9 3 
80 GDIB_HUMAN Rab GDP dissociation inhibitor beta  3 3 
81 GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 5 5 
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82 GDIR2_HUMAN Rho GDP-dissociation inhibitor 2 23 23 
83 GELS_HUMAN Gelsolin  33 33 
84 GLU2B_HUMAN Glucosidase 2 subunit beta 5 5 
85 GLYG_HUMAN Glycogenin-1 5 5 
86 GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit alpha-2 13 9 
87 GRAN_HUMAN Grancalcin 6 6 
88 GRN_HUMAN Granulins 9 9 
89 GRP78_HUMAN Endoplasmic reticulum chaperone BiP 9 9 
90 GSTO1_HUMAN Glutathione S-transferase omega 1 4 4 
91 GSTP1_HUMAN Glutathione S-transferase P 5 5 
92 GTR3_HUMAN Solute carrier family 2 4 4 
93 H12_HUMAN Histone H1.2 13 5 
94 H15_HUMAN Histone H1.5 10 8 
95 H2A1C_HUMAN Histone H2A type 1-C 20 3 
96 H2A1D_HUMAN Histone H2A type 1-D 16 6 
97 H2A1H_HUMAN Histone H2A type 1-H 16 5 
98 H2A2B_HUMAN Histone H2A type 2-B 13 3 
99 H2AV_HUMAN Histone H2A.V 5 4 
100 H2AX_HUMAN Histone H2AX 18 3 
101 H2AY_HUMAN Core histone macro-H2A.1 11 5 
102 H2B1B_HUMAN Histone H2B type 1-B 21 4 
103 H2B1D_HUMAN Histone H2B type 1-D 19 19 
104 H4_HUMAN Histone H4 18 18 
105 HBA_HUMAN Hemoglobin subunit alpha (Alpha-globin) 46 46 
106 HBB_HUMAN Hemoglobin subunit beta (Beta-globin) 47 20 
107 HBD_HUMAN Hemoglobin subunit delta (Delta-globin) 31 4 
108 HBG1_HUMAN Hemoglobin subunit gamma-1 (Gamma-1-globin) 7 3 
109 HCLS1_HUMAN Hematopoietic lineage cell-specific protein 5 5 
110 HMGB1_HUMAN High mobility group protein B1 3 3 
111 HMGB2_HUMAN High mobility group protein B2 6 6 
112 HMGN1_HUMAN Non-histone chromosomal protein HMG-14 3 3 
113 HMGN2_HUMAN Non-histone chromosomal protein HMG-17 4 4 
115 HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U  3 3 
116 HORN_HUMAN Hornerin 3 3 
117 HS71A_HUMAN Heat shock 70 kDa protein 1A 3 3 
118 HS90A_HUMAN Heat shock protein HSP 90-alpha  3 3 
119 HSP7C_HUMAN Heat shock cognate 71 kDa protein 11 5 
120 HXK3_HUMAN Hexokinase-3 5 5 
121 ITAM_HUMAN Integrin alpha-M 10 10 
122 ITB2_HUMAN Integrin beta-2 11 11 
123 K1C10_HUMAN Keratin, type I cytoskeletal 10 11 10 
124 K1C9_HUMAN Keratin, type I cytoskeletal 9 9 9 
125 K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal 13 9 
126 K2C1_HUMAN Keratin, type II cytoskeletal 1 7 5 
127 KPYM_HUMAN Pyruvate kinase PKM  5 5 
128 LASP1_HUMAN LIM and SH3 domain protein 1 3 3 
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129 LDHA_HUMAN L-lactate dehydrogenase A chain 8 8 
130 LDHB_HUMAN L-lactate dehydrogenase B chain 4 3 
131 LEG10_HUMAN Galectin-10 3 3 
132 LKHA4_HUMAN Leukotriene A-4 hydrolase 9 9 
134 LOX5_HUMAN Arachidonate 5-lipoxygenase 9 9 
135 LSP1_HUMAN Lymphocyte-specific protein 1 11 11 
136 LYSC_HUMAN Lysozyme C 4 4 
137 MDHC_HUMAN Malate dehydrogenase, cytoplasmic 4 4 
138 MDHM_HUMAN Malate dehydrogenase, mitochondrial 4 4 
139 ML12A_HUMAN Myosin regulatory light chain 12A 4 4 
140 MMP9_HUMAN Matrix metalloproteinase-9 4 4 
141 MNDA_HUMAN Myeloid cell nuclear differentiation antigen 6 6 
142 MOES_HUMAN Moesin 5 5 
143 MYH9_HUMAN Myosin-9 9 9 
144 MYL6_HUMAN Myosin light polypeptide 6 8 8 
145 MYO1F_HUMAN Unconventional myosin-If 3 3 
146 NAMPT_HUMAN Nicotinamide phosphoribosyltransferase 3 3 
147 NGAL_HUMAN Neutrophil gelatinase-associated lipocalin 4 4 
148 PADI4_HUMAN Protein-arginine deiminase type-4 8 8 
149 PARK7_HUMAN Protein/nucleic acid deglycase DJ-1 5 5 
150 PDIA1_HUMAN Protein disulfide-isomerase  5 5 
151 PDIA3_HUMAN Protein disulfide-isomerase A3 14 14 
152 PDIA6_HUMAN Protein disulfide-isomerase A6 3 3 
153 PERE_HUMAN Eosinophil peroxidase 27 22 
154 PERM_HUMAN Myeloperoxidase 45 45 
155 PGAM1_HUMAN Phosphoglycerate mutase 1 11 11 
156 PGK1_HUMAN Phosphoglycerate kinase 1 9 9 
157 PHB2_HUMAN Prohibitin-2 3 3 
158 PLBL1_HUMAN Phospholipase B-like 1 8 8 
159 PLSL_HUMAN Plastin-2 4 4 
160 PNPH_HUMAN Purine nucleoside phosphorylase 4 4 
161 PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A 4 4 
162 PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B 4 4 
163 PRDX2_HUMAN Peroxiredoxin-2 11 11 
164 PRDX3_HUMAN Thioredoxin-dependent peroxide reductase, mitochondrial 5 3 
165 PRG2_HUMAN Bone marrow proteoglycan 4 4 
166 PROF1_HUMAN Profilin-1 16 16 
167 PRTN3_HUMAN Myeloblastin 5 5 
168 PTMA_HUMAN Prothymosin alpha 4 4 
169 PTPRC_HUMAN Receptor-type tyrosine-protein phosphatase C 5 5 
170 PYGL_HUMAN Glycogen phosphorylase, liver form 5 5 
171 RAB1B_HUMAN Ras-related protein Rab-1B 5 3 
172 RAC1_HUMAN Ras-related C3 botulinum toxin substrate 1 6 3 
173 RAN_HUMAN GTP-binding nuclear protein Ran 3 3 
174 RETN_HUMAN Resistin 3 3 
175 RHOA_HUMAN Transforming protein RhoA 6 4 
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176 RHOG_HUMAN Rho-related GTP-binding protein  4 3 
177 RNAS2_HUMAN Non-secretory ribonuclease  4 4 
178 RS27A_HUMAN Ubiquitin-40S ribosomal protein S27a 3 3 
179 RTN4_HUMAN Reticulon-4 4 4 
180 S100P_HUMAN Protein S100-P 3 3 
181 S10A4_HUMAN Protein S100-A4 3 3 
182 S10A6_HUMAN Protein S100-A6 3 3 
183 S10A8_HUMAN Protein S100-A8 9 9 
184 S10A9_HUMAN Protein S100-A9 16 16 
185 S10AB_HUMAN Protein S100-A11 3 3 
186 S10AC_HUMAN Protein S100-A12 6 6 
187 SFPQ_HUMAN Splicing factor, proline- and glutamine-rich 3 3 
188 SH3L1_HUMAN SH3 domain-binding glutamic acid-rich-like protein 3 3 
189 SODC_HUMAN Superoxide dismutase 4 4 
190 SODM_HUMAN Superoxide dismutase 7 7 
191 SPB10_HUMAN Serpin B10 3 3 
192 SQOR_HUMAN Sulfide:quinone oxidoreductase 3 3 
193 STMN1_HUMAN Stathmin 4 4 
194 STOM_HUMAN Erythrocyte band 7 integral membrane protein 10 10 
195 SUN2_HUMAN SUN domain-containing protein 2 3 3 
196 TALDO_HUMAN Transaldolase 6 6 
197 TBA1A_HUMAN Tubulin alpha-1A chain 5 5 
198 TBB2A_HUMAN Tubulin beta-2A chain 7 7 
199 TBB4A_HUMAN Tubulin beta-4A chain 13 13 
200 TERA_HUMAN Transitional endoplasmic reticulum ATPase 5 5 
201 THIO_HUMAN Thioredoxin  4 4 
202 TKT_HUMAN Transketolase 34 34 
203 TLN1_HUMAN Talin-1 3 3 
204 TPIS_HUMAN Triosephosphate isomerase 11 11 
205 TPM3_HUMAN Tropomyosin alpha-3 chain 7 7 
206 TPM4_HUMAN Tropomyosin alpha-4 chain 6 6 
207 TRFL_HUMAN Lactotransferrin 81 81 
208 TYB4_HUMAN Thymosin beta-4 5 5 
209 UGPA_HUMAN UTP--glucose-1-phosphate uridylyltransferase 3 3 
210 VASP_HUMAN Vasodilator-stimulated phosphoprotein 5 5 
211 VAT1_HUMAN Synaptic vesicle membrane protein VAT-1 homolog  7 7 
212 VIME_HUMAN Vimentin 3 3 
213 VINC_HUMAN Vinculin  3 3 
214 WDR1_HUMAN WD repeat-containing protein 1  8 8 
215 ZYX_HUMAN Zyxin 3 3 
 
 
 
Selbstständigkeitserklärung 
XXXI 
 
7 Selbstständigkeitserklärung 
Hiermit erkläre ich, dass ich die vorliegende Arbeit selbstständig verfasst und keine anderen als die 
angegebenen Quellen und Hilfsmittel verwendet habe. Ich versichere, dass diese Arbeit in dieser oder 
anderer Form noch keiner anderen Prüfungsbehörde vorgelegt wurde. Der Inhalt der 
Promotionsordnung der Mathematisch-Naturwissenschaftlichen Fakultät I der Humboldt Universität 
zu Berlin vom 27. Juni 2012 ist mir bekannt. 
 
Berlin, 1. Oktober 2018 
 
 
Falko Apel 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
XXXII 
 
8 Acknowledgements 
Science, and a PhD in particular, is a journey that cannot be finished alone. I want to use these last 
lines of my thesis to thank all the people that helped me on this long way to reach this moment. 
Arturo, thank you for being a great mentor. Your scientific spirit has always inspired and motivated me 
and without your constructive guidance, the project wouldn’t have ended so well. Also I would like 
express my deep gratitude for your support with all the little stumbling rocks that I had to deal with 
outside of the lab. 
It was a pleasure and privilege to work with a group of people that is so enthusiastic about science. 
Thank you to all the members of the Zychlinsky lab for creating such a great working environment; you 
are a fantastic and colorful pile of extraordinary people. 
Gabriel, although never officially my supervisor, you always were a great support. Thank you for all 
your time and help, may it be with the little details or the big picture. 
Lorenz, thank you everything, not only for being my butcher when I was not skilled enough, but also 
for your motivating, enthusiastic nature and being a friend. Long live the DOSENBIER! 
Garth, Gerben and Borko, thank you for proof reading my thesis and for all the discussion and 
comments in countless lab meetings, from which my work benefited so much. 
Bärbel, thank you for writing the Mausantrag “with” me, without you I would have never done an in 
vivo experiment. 
Yvonne, thank you for being my third and fourth hand and my second brain. Without you, my PhD 
would have taken another five years.  
Thank you to my Gang, not only for cooking amazing food, but especially for being this kind of great 
friends everyone needs to live a happy and fulfilled life. 
Eike, thank you for all the years of patience and support, for always covering my back, being a partner 
in crime and especially being a great mother for our Möpschen. You two are my true motivation and 
love. 
Lastly, I would also thank my parents for being a save harbor whenever one is needed and for never 
asking when my PhD is finally over. 
 
It is now. 
